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A recent surge in emergence of drug resistant strains of Mycobacterium tuberculosis, 
the etiological agent of tuberculosis has highlighted the importance of developing new 
therapeutics and devising novel strategies for effective management of this disease. 
The cell wall of M. tuberculosis is a major determinant of high level drug resistance 
demonstrated by this pathogen. Therefore pathways for the synthesis of its components 
and their regulation have remained an attractive drug target. In this study, the pathway 
for decaprenyl phosphate recycling emerges as a new target and illustrates a possible 
mechanism of resistance to the recently discovered anti-tubercular compounds, 
Benzothiazinones. Additionally, the newly identified Lac-I type transcriptional 
regulator IpsA, sheds light on an intricate regulatory network for the synthesis of cell 
wall components, such as the phosphatidyl inositol based lipoglycans. Since the 
pathway is critical for growth in members of Corynebacterineae, it provides for an 
untapped resource for designing novel inhibitors against the pathogenic species M. 
tuberculosis and Corynebacterium diphtheriae. This work also explores new 
approaches for the design of anti-tubercular compounds against cell wall 
glycosyltransferases, such as ‘co-targeting’ of interacting transferases as revealed by 
protein-protein interaction studies and utilising the concept of ‘polar hydrophobicity’ in 
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1.1 Mycobacteria and related species 
In 1882, Robert Koch isolated Mycobacterium tuberculosis (MTB), the etiologic agent 
of tuberculosis (TB) from the lungs of infected animals using methylene blue based 
dye and described it as a rod shaped Gram positive bacteria classified under the genus 
Mycobacterium. The members of the genus Mycobacterium are aerobic 
Actinomycetales that are rod shaped, acid-alcohol fast, non-capsular, non-endosporous, 
and non-motile with the exception of Mycobacterium marnium that exhibits motility in 
macrophages (Stamm et al., 2003). Mycobacterium forms a part of the 
Corynebacterium-Mycobacterium-Nocardia (CMN) branch in the sub-order 
Corynebacterineae of the actinomycete group. The genus Rhodococcus is designated 
as the fourth member of this sub-order. The organisms under this branch have a 
characteristic type IV cell wall with distinctive structures such as meso-diaminopimelic 
acid, N-acetyl glucosamine and N-glycolated muramic acid. In addition, the cell wall 
contains a unique polysaccharide, arabinoglactan (AG), substituted with long chain 
fatty acids, termed mycolic acids (Dobson, 1985; Minnikin, 1982; Minnikin, 1980). 
The classification of organisms in the Corynebacterineae sub-order is based on the 
composition of their cell envelope. The mycolates in Corynebacterium are the smallest 
in size with 22-38 carbons, whilst those in Nocardia and Rhodococcus are intermediate 
in size with 40-60 carbon atoms. The largest and the most complex mycolates are 
synthesised in Mycobacterium and contain 60-90 carbon atoms (Brennan and Nikaido, 
1995; Iain C. Sutcliffe, 2010). 
The species in the Mycobacterium group have been divided into two sub-groups based 
on their growth rate. The first group of slow-growing species of mycobacteria with a 
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generation time of 15-20 hours include; MTB, Mycobacterium bovis BCG, 
Mycobacterium avium, Mycobacterium canetti, Mycobacterium kansasii, and the non-
culturable Mycobacterium leprae. The second group comprises of fast-growing species 
of mycobacteria with a generation time of 3-4 hours with Mycobacterim smegmatis and 
Mycobacterium chelonae being the most significant. The fast growers are also 
characterised by the presence of αꞌ-mycolates in their cell walls (Brennan and Nikaido, 
1995).  
 
MTB is a part of the M. tuberculosis complex (MTBC) that includes four other TB-
causing mycobacteria; M. africanum, M. bovis, M. microti and M. canetti. While M. 
africanum and M. canetti are causative agents of TB in parts of Africa, infection with 
M. microti is considered to be opportunistic and prevalent in immuno-compromised 
individuals, M. bovis is common in cattle and can cause TB in humans if unpasteurised 
milk is routinely consumed. Other virulent strains of mycobacteria include M. leprae 
and the opportunistic pathogens, M. marinum, M. avium and M. kansasii. The virulent 
strains of M. tuberculosis also occur in chains and forms unique serpentine cords. 
These characteristic structures are attributed to presence of ‘cord factor’ i.e. trehalose 





1.2  Tuberculosis 
 
1.2.1 Origins of Tuberculosis 
TB is considered to be an ancient scourge. Evidence for its occurrence have been 
reported in prehistoric literary works, including Deuteronomy and Leviticus, using the 
ancient Hebrew word ‘schachepheth’ (Daniel and Daniel, 1999). In 400 BC 
Hippocrates described TB as the condition associated with fever, cough and loss of 
appetite and termed it as “phthisis”. It has also been referred to as “Consumption”, 
“King’s Evil”, “Pott’s disease”, “Scofula” and “The White Plague” in various literary 
records.  
 
The evolution and phylogeny of the MTB complex remains poorly understood. The 
most popular hypothesis on TB evolution was suggested by Aidan Cockburn in 1963 
who proposed M. bovis as the ancestor of MTB. Cockburn argued that the pathogen 
had transmitted from cattle to humans as a consequence of domestication and evolved 
into its present respiratory form due to urbanisation of human settlements (A. R. Zink, 
2007). This classical theory of TB evolution has been challenged by (Brosch et al., 
2002)) who recently proposed MTB to be the common ancestor for the entire MTB 
complex. The genus Mycobacterium is hypothesised to have originated 150 million 
years ago and the modern strains of MTB appear to have diversified 20,000- 15,000 
years ago from a common ancestor as a result of a genetic evolutionary bottleneck 
(Hayman, 1984). M. bovis is therefore a derivative of the parent MTB strain that 
branched off later during development of other pathogenic mycobacteria. Brosch’s 
hypothesis is based on modern techniques for genotyping and are supported by ancient 
DNA studies. Genetic and molecular evidence from the skeletal remains of Egyptian 
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mummies have established the presence of pathogen in Egypt over 5000 years ago 
(Crubezy et al., 1998; Helen D. Donoghue, 2010; Nerlich et al., 1997) and designated 
East Africa as the birth place of TB. The disease was well established in this region by 
the 19
th
 century and later spread to other parts of the world with inter-continental 
movement (Wirth et al., 2008). 
 
1.2.2 Clinical manifestations 
TB is a dreadful communicative infectious disease that spreads through small airborne 
droplets generated by sneezing, coughing or talking with an infected individual. 
Although the bacteria mainly colonises the lung tissue and causes pulmonary TB, it is 
also capable of infecting other parts of the body, such as lymph nodes, bones/joints or 
meninges and results in extra-pulmonary TB. The etiologic agent of TB in cattle is M. 
bovis that also causes extra-pulmonary TB in humans. Not all individuals exposed to 
TB develop an active form of the disease, as the immune system successfully wards off 
the infection in healthy individuals. However, persons a with weak immune system, 
such as HIV patients, are more susceptible to TB and can develop latent or active TB 
upon exposure to the bacteria. 
 
An encounter with MTB sets off an immune response in the lungs and marcophages 
are recruited for phagocytosis. Although the macrophages are able to engulf the 
bacteria, its digestion is prevented due to the waxy cell wall. The bacteria continues to 
divide inside the macrophage. Once the macrophage bursts open, the bacteria gets 
engulfed by other macrophages and forms a scar tissue. This stage of TB infection is 
called primary TB and is usually asymptomatic and the individual is non-infectious. 
The scar tissue and lymph nodes may eventually harden as Ca
2+
 is recruited from the 
Chapter 1 
6 
blood stream to the infected area. This process of calcification of scar tissue results in 
formation of a quarantined area within the lung and is called a tubercle or a granuloma. 
These calcified scars can easily be detected using radiology. MTB can remain in this 
state of latent or dormant infection for many years in a healthy individual. 
 
If the immune system is weakened or suppressed, the bacteria can rupture the scar 
tissue and cause active TB referred to as secondary TB or reactivation of TB. A rare 
form of TB is called disseminated TB, that occurs when infected macrophages moving 
through the circulatory system transport the bacteria to other sites in the body. The 
symptoms of disseminated TB depend on the location infected.  
 
1.2.3 Epidemiology 
TB is one of the most fatal diseases to have affected mankind since the ancient times. 
Nearly one third of the world’s population is estimated to be suffering from one or the 
other form of the disease (Murray and Salomon, 1998). According to WHO Global TB 
report of 2012, 8.7 million people had contracted TB in 2011 of which 1.1 million 
reported cases were of individuals with HIV co-infection. Of the total number of 
infected individuals reported, 12% of the infected population, including 430,000 cases 
of those co-infected with HIV had died from the disease. Geographically, the highest 
numbers of TB incidences are reported from Asia and Africa, with India and China 
alone accounting for 40% of the total TB cases (Fig 1.1). Africa accounts for 24% of 
the cases and suffers from highest number of deaths per capita. The remaining numbers 
of cases are reported from South-East Asia and Western Pacific regions. Although the 
mortality rate from TB infection has reduced to 41% since 1990, TB still continues to 




These drug resistant strains are classified as  multidrug resistant (MDR), which 
includes organisms that are resistant to the most effective anti-TB drugs – isoniazid and 
rifampicin, and extensively drug resistant (XDR), which refers to MDR strains resistant 
to second line drugs, such as amikacin, kanamycin, capreomycin and fluoroquinolone. 
Recently, a new class of drug resistant TB, termed totally drug resistant TB (TDR-TB) 
has been reported in Iran, Italy, India and South Africa (Klopper et al., 2013; 
Loewenberg, 2012). These strains are reported to be resistant to all first and second line 
drugs currently used for the treatment of TB. 
 
It is now estimated that 3.7% of new TB patients in the world i.e. 310,000 have MDR-
TB, with Brazil, India, China, Russia and South Africa accounting for 60% of the total 
cases. Approximately 9% of the MDR cases are also reported to be XDR with at least 
one case of XDR in 84 countries. In case of HIV positive individuals, TB is the most 
Figure 1.1: Estimated number of TB cases worldwide accoding to Global 




common and deadliest of all opportunistic infections and puts them at the highest risk. 
The severity of infection increases several folds in such individuals due to their weak 
immune system and renders them difficult to treat (Aids Control and Prevention 
(Aidscap) Project of Family Health Internal, 1996). According to WHO nearly one 
third of the HIV infected patients in the world suffer from latent TB of which 80% of 
infected individuals reside in Africa. The increase in number of patients being affected 
by drug resistant strains of TB, has prompted the need for new drugs and better 
vaccines. Clinical trials are underway for many new potential drug and vaccine 
candidates for effective treatment in future.  
 
1.2.4 Treatment  
In the late eighteenth century, TB that was commonly referred to as “consumption” 
resulted in the death of one in every four individuals in England. The major factors that 
attributed to this high mortality rate was the lack of hygiene and sanitation, poor 
nutrition and absence of adequate medical care (Davis, 2000). However, during the 
nineteenth century, with improvements in the socio-economic conditions and a grave 
realisation that TB is an infectious disease; a downward trend in the death rate was 
observed. The treatment of TB during this time was based on a regimen of nutritious 
diet, bed-rest and fresh air provided in a “sanatorium”. Since antibiotics had not been 
discovered yet, sanatorium was the sole way for helping patients cope with the disease. 
Robert Koch’s discovery of the TB bacteria in 1882 not only won him the Nobel Prize 
in Medicine but also paved the way for the identification of antibiotics targeted to 
pulmonary lesions and cavitation, a characteristic of TB infection that revolutionised 
the treatment of TB. After isolating MTB, Koch made several attempts to find a cure 
for the disease. One such attempt was the use of “tuberculin”, a glycerine extract from 
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MTB which Koch reported could inhibit the growth of the pathogen (Koch, 1891). 
Tuberculin was immediately adopted as a cure for TB but the treatment suffered a 
major setback when its administration resulted in several critical reactions in TB 
patients (Gradmann, 2006). Subsequently, Tuberculin was determined to be non-
therapeutic but had significant diagnostic value as it could be utilised for detecting 
“latent TB”. It is still used today and is known as “Mantoux Test” (Daniel, 2006). 
The first breakthrough in the treatment of TB was achieved in 1908 when the avirulent 
form of M. bovis, known as M. bovis BCG (Bacillus Calmette Guerin) was isolated by 
Albert Calmette and Camille Guerin. This BCG strain lost its virulence after its 39
th
 
passage and paved the way for the first vaccine against TB. At present, BCG is widely 
used as a vaccine to prevent extra-pulmonary infection in children under the age of 5 
with maximum efficiency (Bloom and Murray, 1992). 
 
The idea of treatment of TB with chemotherapeutics originated in 1946 and 
streptomycin (SM) was the first antibiotic to be tested. The results of early clinical 
trials showed that SM could effectively reduce mortality rates. However, M. 
tuberculosis developed resistance by modifying the ribosome protein S12 and 16S 
rRNA within five years of drug trials (Musser, 1992). In 1948, p-aminosalicylic acid 
(PAS), a folic acid inhibitor was introduced for the treatment of TB. However, owing 
to its low efficacy, PAS was used in combination with SM and resulted in a decrease in 
incidences of resistance. The effective three drug combination regimen was adopted in 
1952 with the addition of isoniazid (INH) to the existing therapy consisting of SM and 
PAS. Later in 1966, rifampicin (RIF) and pyrazinamide (PZA) were added to the six-
month regimen of standard TB treatment which was introduced in the 1970s (Saltini, 
2006). The current therapy for TB treatment known as Directly Observed Therapy-
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Short course (DOTS) comprises of five elements. These include a (i) political 
commitment from the governments for designing and implementation of adequate 
disease management strategies and financial help, (ii) case detection through sputum 
smear test and drug susceptibility testing (DST), (iii) standardised treatment under 
supervision with adequate patient support, (iv) a system for ensuring regular supply of 
quality anti-TB drugs, (v) a system for regular monitoring and assessment of the 
treatment received on a case by case basis. The element of chemotherapy in DOTS 
follows a tiered approach, where attempts are made to cure infection with the first line 
drugs: INH, RIF, Ethambutol (EMB), SM and PZA. Referred to as the initial phase, it 
makes use of three or more drugs for two months to kill actively dividing bacteria. 
Post-treatment with the first-line drugs in the initiation phase, the patient now enters 
into the second-phase, the ‘continuation phase’ that makes use of fewer drugs, mostly 
RIF and INH for four to seven months in order to kill the remaining or dormant 
bacteria and prevent relapse. The patient is considered cured at six months. INH alone 
is administered for six-nine months to a patient suffering from latent TB. If resistance 
is found for any one of the above drugs or side effects are observed in the patient, less 
effective second line drugs that include quinolones, cycloserine, amikacin, SM, 
kanamycin, ethinonamide and PAS are then administered. The third line of 
therapeutics, include amoxicillin-clavulanate, clofazamine, clarithromycin, imipenem, 
thioacetazone, and high-doses of INH that are prescribed in the case of MDR and XDR 




1.3  Drugs for treatment of TB 
The emergence of MDR and XDR strains that are tough to control with present 
chemotherapeutics, calls for the hastening of efforts for generating new delivery 
systems, different regimes and novel drugs with effective anti-mycobacterial activity, 
for improved treatment. Drug resistance is not just limited to MDR and XDR-TB. 
Recently reported in four countries across the world, TDR-TB has attracted the 
attention of many researchers and health organisations to its potential threat. However, 
despite the rise in number of incidences of TDR-TB being reported each year, WHO 
doesn’t acknowledge it as a new class and instead includes them under the category of 
XDR-TB, as currently there are no defined and internationally accepted methods 
available to test the drug susceptibility in such cases. Moreover, the new drugs being 
developed are yet to be tested on these TDR-TB strains. Therefore, on grounds of 
insufficient data to support the status, WHO recommends not using the term TDR-TB 
in practice, even though the concept is clearly understandable in theory. 
 
The present TB treatment comprises of INH, RIF, PZA and EMB as the major drugs, 
with each having a unique mode of action. The course of therapy consists of a mix of 
four drugs to help in combating the problem of increase of drug resistance. No new 
drug has been included in this standard regimen, since its introduction in 1970. 
Recently two new drugs, bedaquiline and delamanid were proposed to be included in 
this short course regimen to treat MDR-TB. However, by early 2013, only bedaquiline 
was approved by the American and European Regulatory Authorities and was 
incorporated as a novel second-line drug, the first in 40 years since the treatment came 
into effect (Osborne, 2013). Delamanid was initially declined by the Committee for 
Medicinal Products for Human Use (CHMP), the European Medical Agency on 
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grounds of insufficient evidence to prove effectiveness and accurate dosage of the drug 
in the treatment of MDR-TB. In addition, clinical trials conducted to test the potency of 
delamanid only tested the drug for a short duration of two months and could not 
demonstrate its efficacy over the course of 6 months, a requirement of the standard 
DOTS regimen. However, in a revised statement issued by European Regulatory 
Authorities later in 2013, Otsuka Pharmaceutical Co., Ltd. (Otsuka) was granted a 
marketing authorization for Deltyba(TM) (delamanid) for treatment of MDR-TB in 
adults. Although, the initial failure of delamanid was a huge set back for a new 
chemotherapeutic, hopes are being pinned on the REMoxTB therapy that is currently in 
Phase III clinical trials. REMoxTB therapy is a global venture between Bayer 
Healthcare AG, the Medical Research Council and University College London to 
evaluate the response of a moxifloxacin containing TB regime in TB patients in 9 
countries across the world. The therapy tests moxifloxacin as a replacement of INH 
and EMB, and is to be used in conjunction with other current first line drugs for TB 
treatment. The preliminary results are promising and suggest that the inclusion of 
moxifloxacin in the present regimen can reduce the course of therapy from 6 to 4 
months. The new drug pipeline (Fig 1.2) comprises of several new candidates and 
regimens being evaluated for their potential as future TB drugs and therapies. The new 
therapeutic agents developed for TB treatment have to fulfill a well defined criterion 
that includes, validated safety reporting, greater potency than existing drugs, a novel 
target and mechanism of action, no harmful drug-drug interactions with existing TB 
drugs, and high compatibility with anti-retroviral therapies to treat HIV co-infection 




Several new options are currently being explored for the treatment of TB. These 
include re-purposing of drugs such as rifamycin, fluoroquinolones, riminophenazines, 
oxazolidinones that are currently used to treat other infections. In addition, the use of 
adjunct immunotherapies, such as either cytokines or their inhibitors and other 
immunomodulatory compounds that increase the immune response to the pathogen. 
Finally, novel anti-mycobacterial agents such as bedaquiline, benzothiazinones 
nitroimidazoles, dipiperidine, SQ109, capuramycin, and the caparazene nucleoside 
(Figure 1.2) are being developed. The mechanism of action of main TB drugs that are 
in clinical use has been studied in detail while that of several novel candidates in pre-




















1.3.1 Drugs in DOTS  
 
1.3.1.1  Isoniazid  
 
Isoniazid (INH: isonicotinic acid hydrazide, Figure 1.3) is one of the most powerful 
drugs against TB and forms the core of anti-TB therapy. Administered as a pro-drug, it 
gets activated by a catalase-peroxidase katG (Zhang et al., 1992). INH inhibits the 
biosynthesis of the cell wall by targeting mycolic acids (Banerjee et al., 1994; Mdluli 
et al., 1998), and shows bactericidal activity. However, it exhibits bacteriostatic 
activity against resting bacilli. INH was first used in anti-TB treatment in 1952 (Saltini, 
2006), and it possesses very low minimum inhibitory concentration (MIC) values of ≤ 
0.02 µg/mL (Zhang et al., 1992) against M. tuberculosis H37Rv. Use of INH as an 
anti-TB drug initiated a global search for its target in MTB. The first contribution was 
made by Middlebrook in 1954 who observed that INH resistant MTB strains had a 
decreased catalase activity (Middlebrook and Dressler, 1954). Several years later, 
analysis of clinical isolates of MTB strains sensitive to INH revealed peroxidase KatG 
as the activator of INH (Zhang et al., 1992). In the same study, 3ʹ-deletion mutants of 
MTB katG in shuttle vectors when expressed in E. coli could confer susceptibility to 
inherently INH resistant E. coli that varied with the level of enzyme expressed. There 
are three possible targets of INH reported using independent studies. Firstly, mycolic 
acid biosynthesis, secondly, NAD
+
 (nicotinamide dinucleotide) metabolism through 
 
 
Figure 1.3: Structure of Isoniazid 
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interference of NADH dehydrogenase II (Ndh II), and thirdly, pyridoxal phosphate 
metabolism (Lee et al., 2001). Mycolic acid biosynthesis is widely accepted as the 
primary target (Banerjee et al., 1994; Kremer et al., 2003; Winder and Collins, 1970). 
Resistance to INH is observed in M. smegmatis when the enoyl-ACP reductase, InhA is 
over-expressed (Marrakchi et al., 2000). Similar effects are observed in clinical isolates 
of M. tuberculosis with a Ser94Ala mutation in InhA (Morlock et al., 2003). In normal 
metabolism, mycolic acids are reduced by InhA using NADH as a co-factor. However 
in the presence of INH, NAD complexes with INH, to form an isonicotinic acyl radical 
and generates an INH-NAD adduct that interacts with InhA and impedes the reduction 
of mycolic acids (Broussy et al., 2003; Rozwarski et al., 1998). This inhibitory effect is 
hindered in the protein with a Ser94Ala mutation, and results in resistance to INH 
(Pantano et al., 2002). Another set of mutations that contribute to INH resistance have 
been isolated in the β-ketoacyl-ACP synthase KasA, that elongates the meromycolate 
chain (Kremer et al., 2000). Mutations that confer resistance to INH due to over-
expression of KasA have been isolated (Mdluli et al., 1996), however, in vitro studies 
on the other hand have demonstrated that activated INH does not inhibit KasA and its 
over-expression has no effect on the MIC of INH (Choi et al., 2000; Kremer et al., 






Rifampicin or rifampin (RIF, Fig 1.4 A) targets the β-subunit of RNA polymerase 
(RpoB) thereby inhibiting transcription. This antibiotic has effective bactericidal 
activity against actively dividing and non-dividing bacilli. Mutations occurring in the 
81 bp region of the target gene rpoB results in resistance to RIF (Taniguchi et al., 
1996). The most suitable dose of RIF has never been determined and currently 600 mg 
per day is prescribed for TB treatment (Steingart et al., 2011; Van Ingen et al., 2011). 
A HIGHRIF trial is an initiative to establish the optimum concentration of RIF, both in 
terms of efficacy against the bacilli and tolerance by the host. An improvement over 
RIF is rifapentine (Fig 1.4 B) that has a similar mechanism of inhibition as RIF but a 
longer half-life. This characteristic gives a significant advantage to rifapentine, as its 
inclusion in TB therapy as a replacement for RIF could aid in shortening therapy 
(Udwadia, 2012). 
  
Figure 1.4: Structure of A. Rifampicin and B. Rifapentine 
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Pyrazinamide (PZA: pyrazinoic acid amide, Fig 1.5) is highly specific to mycobacteria 
and displays activity against both latent and persistent bacilli. Introduction of PZA to 
the DOTS regimen was a turning point in TB chemotherapy as the duration of therapy 
was then reduced from nine to six months. The mechanism of action of PZA is still 
unclear. Earlier hypothesis suggested by Scorpio and Zhang et. al. illustrate PZA as a 
prodrug that is activated by mycobacterial pyrazinamidase PncA (Scorpio and Zhang, 
1996). PZA is easily diffusible through the cell wall and gets converted into its non-
diffusible active form pyrazinoic acid (POA) in the cytosol. The weakly acidic non 
diffusible POA accumulates in cytosol and supplements enough protons to create an 
imbalance in the proton gradient across the membrane (Zhang and Mitchison, 2003; 
Zhang et al., 2003b). This imbalance disrupts the membrane energetics which proves 
lethal for mycobacteria. However, an alternative mechanism was recently proposed by 
(Shi et al., 2011)) that purported PZA to inhibit trans-translation by bindng to RpsA. 
RpsA-PZA complex prevents the binding of RpsA to tmRNA and impedes the core 
mechanism responsible for tagging damaged proteins for proteolysis and rescuing 
stalled ribosomes. Inhibition of this process by PZA renders the ribosomes unavailable 
for cellular function and is particularly detrimental for latent TB bacilli where 
 
Figure 1.5: Structure of Pyrazinamide 
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ribosomes are already in short supply (Shi et al., 2011). These findings have 
questioned PZA’s status as a prodrug and have revealed RpsA and the trans-translation 
machinery as an appealing target for developing novel therapeutics against TB.  
 
1.3.1.4  Ethambutol 
 
 
Figure 1.6: Structure of Ethambutol 
 
Ethambutol (EMB: (2,2(ethylenediimino)di-1-butanol, Figure 1.6) is a bacteriostatic 
agent that targets the synthesis of the arabinan component of arabinogalactan (AG) in 
the mycobacterial cell wall. The anti-mycobacterial activity of EMB was first reported 
in 1961 (Thomas et al., 1961) which led to its inclusion in the DOTS regimen. Since 
the drug forms the most vulnerable component of DOTS, several of its analogues and 
replacements are currently being tested (Protopopova et al., 2005). The mode of action 
and mechanisms of resistance to EMB are only partially understood. EMB targets AG 
biosynthesis by inhibiting the glycosyltransferases encoded by embCAB operon 
(Belanger et al., 1996; Telenti et al., 1997), in particular EmbB (Alcaide et al., 1997; 
Mikusova et al., 1995; Sreevatsan et al., 1997).  
 
Genome sequence analysis of EMB resistant clinical isolates illustrated an EMB 
resistance determining region (ERDR) in the gene embB (Alcaide et al., 1997; Telenti 
et al., 1997) to harbor missense mutations in codon 306 that resulted in Met306Leu, 
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Met306Val or Met306Ile substitutions in 68-70% of the EMB resistant clinical isolates 
(Ramaswamy et al., 2000; Sreevatsan et al., 1997). These findings branded codon 306 
as a molecular marker for EMB resistance. However, it is also implicated that 
mutations in codon 306 could alter the drug-enzyme interaction and mediate resistance 
against the drug (Sreevatsan et al., 1997). 
Treatment of mycobacteria with EMB causes accumulation of decaprenyl-phospho-
arabinose (DPA), the sole arabinose donor employed for production of the arabinan 
component of AG and lipoarabinomannan (LAM). The drug causes bacteria to 
synthesise modified LAMs with decreased arabinose content and AG is completely 
devoid of the arabinan component (Mikusova et al., 1995). Consequently, 
accumulation of mycolates, such as trehalose mono- and dimycolates is observed as 
these mycolic acid esters that are otherwise attached to terminal arabinose (Ara) 
residues of AG are unable to be deposited into the defective AG polymer that is 
synthesised in presence of EMB (Wolucka et al., 1994). Lack of mycolates in the cell 
wall reduces its impermeability and makes the bacteria more susceptible to drugs. 
Therefore, EMB when administered along with other drugs of the DOTS therapy 







Figure 1.7: Structure of Streptomycin 
 
Streptomycin (SM, Figure 1.7) an aminoglycoside obtained from Streptomyces griseus, 
inhibits translation by binding to 16S rRNA of the 30S subunit of the bacterial 
ribosome, therefore preventing the binding of formyl-methionine tRNA to the 30S 
subunit. The drug has bactericidal activity when consumed in large doses and shows 
bacteriostatic effects when a low dosage is given. SM was the first antibiotic proven to 
have anti-mycobacterial activity and was introduced for TB treatment over 70 years 
ago. The effectiveness of SM lasts for up to the first three months of therapy and 
reduces thereafter as the bacteria starts to develop resistance to the antibiotic (Marshall, 
1949). The development of resistance to the antibiotic in a short duration led to a 
realisation that the problem of TB can only be tackled with use of a cocktail of drugs. 
SM is included as a second line anti-TB drug and administered only in cases of failure 




1.3.1.6  Ethionamide  
 
 
Figure 1.8: Structure of Ethionamide 
 
Ethionamide (ETH, 2-ethylthioisonicotinamide, Figure 1.8) is a bacteriostatic anti-
mycobacterial agent that was discovered in 1956 and employed in the treatment of TB 
in 1961. ETH is a structural analogue of INH and inhibits mycolic acid biosynthesis 
(Winder et al., 1971) with a different mode of action to INH. Mutations that confer 
resistance to ETH have been associated with gene loci ethA and inhA (Banerjee et al., 
1994; Morlock et al., 2003). Lack of cross-resistance between INH and ETH in clinical 
isolates of mycobacteria, especially ones with mutations in katG led to the idea of ETH 
being a pro-drug requiring an alternative enzyme to KatG for its activation (Baulard et 
al., 2000; Debarber et al., 2000). The mode of action of ETH became clearer when 
isolates of MTB with mutations in EthA, a flavin monooxygenase encoded by Rv3854c 
(ethA or etaA) were found to be resistant to ETH (Debarber et al., 2000; Morlock et al., 
2003). Based on over-expression studies, EthA was designated as the activator of the 
pro-drug ETH (Banerjee et al., 1994; Debarber et al., 2000). The enzyme EthR (EtaR, 
etaR or ethR) encoded by Rv3855 downstream of ethA, was hypothesised to be 
responsible for the negative regulation of EthA synthesis as its over-expression led to 
an increase in resistance to ETH (Baulard et al., 2000; Debarber et al., 2000). Genetic 
knockout experiments in M. bovis BCG confirmed EthR as the transcriptional repressor 
of EthA (Baulard et al., 2000), as its inactivation resulted in hypersensitivity to the 
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drug. Sequence analysis of EthR highlighted its high similarity to members of the TetR 
family of transcriptional repressors (Baulard et al., 2000; Debarber et al., 2000). ETH 
is oxidised at the sulphide group by EthA to generate the corresponding S-oxide. This 
S-oxide is further oxidised by EthA to yield 2-ethyl-4-aminopyridine. The intermediary 
S-oxide is highly toxic to mycobacteria, but the final product 2-ethyl-4-aminopyridine 
is devoid of any anti-mycobacterial properties (Vannelli et al., 2002). Studies 
conducted in various species of mycobacteria have also reported that ETH targets InhA 
similar to INH and inhibits biosynthesis of mycolic acids in mycobacteria (Banerjee et 
al., 1994; Baulard et al., 2000) 
 
1.3.1.7 Para-aminosalicylic acid 
 
 
Figure 1.9: p-aminosalicylic acid 
 
Para-aminosalicylic acid (PAS, Figure 1.9) is a bacteriostatic agent that was 
introduced for the treatment of TB alongside SM and INH as a first-line drug in the 
earliest of all regimens practiced. However, due to harmful side-effects and the 
inclusion of more potent drugs, such as RIF, PAS was removed as a first-line agent 
and incorporated into second-line drug regimens. PAS is now used for treatment of 
MDR-TB and XDR-TB (Rengarajan et al., 2004). The mechanism of action of PAS 
has not been elucidated yet and the target is still unknown. However, recently 
analysed isolates of MTB and transposon mutagenesis of genes in M. bovis BCG 
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revealed mutations in the thymidylate synthase (thyA) an enzyme responsible for 
regulating intracellular folate levels, that either result in reduced levels of ThyA or a 
decrease in activity of the enzyme play a crucial role in imparting resistance to the 
drug (Rengarajan et al., 2004). Interestingly, mutations in ThyA also account for 
resistance to other drugs that inhibit folate synthesis. PAS is hypothesised to work as 
an inhibitor of enzyme dihydropteroate synthase due to its close structural similarity to 
the actual substrate, para-amino benzoic acid (Iwainsky, 1988). However, in vitro 
studies that evaluated the inhibitory effect of PAS, were unable to deduce notable PAS 
activity implying that PAS may function as a pro-drug and gets activated inside the 
cell (Chakraborty et al., 2013). The use of PAS is limited to MDR-TB and XDR-TB, 
due to its harmful side effects mainly in the gastro-intestinal tract.  
 
1.3.1.8  Fluoroquinolones  
 
Figure 1.10: Structure of fluoroquinolones A. Moxifloxacin B. Gatifloxacin 
 
Antimicrobials, such as ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and 
ofloxacin belong to a single group of broad-spectrum antibiotics referred to as 
fluoroquinolones (FQs). FQs are routinely prescribed in case of infections and are 
administered as second-line drugs for MDR-TB treatment. This group of anti-
microbials target DNA gyrase, a type II topoisomerase consisting of two subunits that 
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are encoded by gyrA and gyrB (Takiff et al., 1994). Mutations occur frequently in the 
quniolone resistance determining region (QRDR) of gyrA, mainly in codons 90, 91 
and 94, and less frequently in the gyrB (Alangaden et al., 1995; Ginsburg et al., 2005; 
Takiff et al., 1994). Recently, studies in mouse models employing FQs as part of a 
first-line regimen have demonstrated that these anti-microbials can effectively reduce 
the duration of chemotherapy by two months (Nuermberger et al., 2004), thus 
highlighting their potential usefulness as first-line agents. Efforts are currently 
underway to test new regimens with moxifloxacin (Fig 1.10 A) as a replacement of 
EMB or INH, and gatifloxacin (Fig 1.10 B) as a substitute for EMB (Skovierova et al., 
2010). In addition, new inhibitors that target either the DNA gyrase and/or are based 
on FQs are currently being developed.  
 
1.3.1.9  Aminoglycosides 
Alongside SM, other aminoglycosides, such as capreomycin, kanamycin and amikacin 
are second-line drugs prescribed for the treatment of drug-resistant TB. These 
antibiotics are verified inhibitors of protein translation and are not used as first-line 
agents due to a problem of cross-resistance (Alangaden et al., 1998; Maus et al., 
2005a). The resistance to all aminoglycosides can occur due to mutations in 16S 
rRNA (rrs), however mutations in tlyA, a rRNA methyltransferase are also 
accountable for capreomycin resistance (Alangaden et al., 1998; Johansen et al., 2006; 
Maus et al., 2005b; Via et al., 2010). Methylation by TlyA enhances the effect of 
capreomycin, whereas mutations in TlyA that prevent methylation of rRNA render 
capreomycin ineffective. Methylation of rRNA is a mechanism used by 
aminoglycoside producing bacteria to become resistant to their own metabolites. 
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However, in case of capreomycin the effect is reversed as methylation assists in its 
action. 
 
1.3.2 New TB Drugs 
The problem of emerging drug resistance in MTB has highlighted the need of new 
drugs, vaccines and treatment regimens. Recently, a multitude of compounds with 
anti-tubercular activity have been generated with combined efforts of industry and 
academia, and several of these compounds have emerged as promising drug 
candidates. These efforts have led to the formulation of a drug pipeline (Fig 1.2), 
depicting the state of development for each of compound with potential to be an anti-
TB drug in the near future.  
The drug pipeline holds immense promise in terms of new compounds with a prospect 
of future anti-TB drugs. However, there is an extensive lag between the pre-clinical 
and clinical stages, as most of the new compounds are either being evaluated for safe 
use or are rejected owing to toxic effects. This is a grave problem that requires 
immediate attention and considerable efforts to bridge the existing gap and increasing 




1.3.2.1  Clofazimine 
 
 
Figure 1.11: Structure of Clofazimine 
 
Clofazimine (Figure 1.11) is a hydrophobic riminophenazine antibiotic discovered in 
1957 (Barry et al., 1957) and employed for the treatment of leprosy in 1962. The 
hydrophobic and anti-inflammatory properties of clofazimine makes it ideal for the 
treatment of leprosy as it accumulates in the nerves and skin, which are the main sites 
of M. leprae infection, and also prevents adverse immune reactions, thereby evading 
the complications that may arise in chemotherapy (Anderson, 1983; Dutta, 1980; 
Imkamp, 1981). Clofazimine is currently a part of a three-drug regimen along with 
RIF and dapsone for the treatment of leprosy as advised by WHO. Although 
clofazimine is inactive against pulmonary TB, its lipophilicity and anti-inflammatory 
properties have found their use in formulation of new riminophenazine based 
compounds with a novel mechanism of action. Clofazimine and drugs based on 
clofazimine may prove useful in the treatment of HIV individuals with suppressed 
immune system, especially in tackling immune reconstitution inflammatory syndrome 




1.3.2.2  Oxazolindinones 
 
Figure 1.12: Structure of oxazolindinones A. Linezolid B. Sutezolid C. AZD5847 
 
Oxazolindinones are a class of drugs that inhibit protein synthesis by binding to the 
23S subunit of the ribosome. Linezolid (Figure 1.12 A) is a drug from this class with 
bacteriostatic activity against TB bacilli and also shows activity against MDR-TB 
(Fortun et al., 2005; Lee et al., 2012b). Resistance to linezolid could develop if 
mutations arise either in rplC or in 23S rRNA (Lee et al., 2012b), that disturb the van 
der waal forces of interaction responsible for arrangement of a functional ribosome. 
The drawback of linezolid is its ability to damage nerves and cause bone marrow 
suppression when administered to patients (Sotgiu et al., 2012). Linezolid is 
recommended for patients suffering from MDR-TB and should be prescribed with 
caution. The toxic effects of linezolid have led to development of structural analogues 
that are currently being examined for their anti-mycobacterial activity. Sutezolid 
(PNU-100480, Figure 1.12 B) is a more potent analogue of linezolid that is currently 
in Phase II clinical trials and has been tested for its effectiveness in conjuction with 
TMC207/SQ109 and PA824 (Wallis et al., 2012; Wallis et al., 2010). Trials with 
sutezolid and SQ109/TMC207 combination produced additive effects, whereas 
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deleterious or not significantly beneficial effects were observed with PA824 rendering 
it unsuitable for use with PA824 (Wallis et al., 2010). AZD5847 (Figure 1.12 C) is not 
an analogue of linezolid, but has similar mode of action to linezolid. The drug-drug 
interaction studies with AZD5847 have yielded no interference and the compound has 
progressed to Phase II clinical trials (Zumla et al., 2013).  
1.3.2.3  Nitroimidazoles 
 
Figure 1.13: Structure of nitroimidazoles A. Delamanid B. PA-824 
 
Nitroimidazoles are a class of antibiotics used for the treatment of anaerobic 
infections. This property of nitroimidazoles has implicated their use in treatment of 
latent TB infections (Migliori et al., 2013). Delamanid (OPC67683, Fig 1.13 A) and 
PA824 (Fig 1.13 B) are leading nitroimidazoles, with Delamanid being the most 
recently licensed drug to be used for treatment of MDR-TB. Both, delamanid and 
PA824 are pro-drugs that require intracellular activation (Manjunatha et al., 2006a). 
Delamanid (nitrodihydroimidazooxazole) is an inhibitor of mycolic acid biosynthesis 
in mycobacteria (Matsumoto et al., 2006). Delamanid is activated by the enzyme Ddn, 
a nitroreductase that utilises deazaflavin as a coenzyme. This enzyme is specific for 
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MTB and is absent in M. leprae  (Manjunatha et al., 2006b). Mutations in ddn or in 
genes for deazaflavin synthesis can lead to the development of resistance in bacteria 
against delamanid (Arora et al., 2011; Manjunatha et al., 2006a; Manjunatha et al., 
2006b). In addition to inhibition of mycolic acid biosynthesis, delamanid is proposed 
to kill mycobacteria by overproduction of DNA damaging free radicals (Hurdle et al., 
2008; Singh et al., 2008). The chemical nature of these free radicals has not been 
determined but their production is attributed to des‑nitro‑imidazooxazole that is 
generated as a result of the reduction process. PA824 is similar to delamanid as it also 
requires activation by Ddn. The active form of PA824 is a reactive nitrogen species, 
including nitric oxide. These harmful radicals lead to cellular toxicity that ultimately 
kills the bacteria. Resistance to PA824 can develop if synthesis of the Coenzyme is 
inhibited as it inactivates Ddn (Lin et al., 2012). PA824 also inhibits mycolic acid 
biosynthesis in mycobacteria but in aerobic conditions. In the absence of oxygen, 
cellular toxicity is mediated by inhibition of Cytochrome C oxidase by nitric oxide 
(Manjunatha et al., 2006a). 






Figure 1.14: Structure of Bedaquiline 
 
Bedaquiline or sirturo (TMC207, Figure 1.14) a diarylquinolone, is a new inclusion in 
DOTS therapy, the first in 40 years. Whole genome sequencing of bedaquiline 
resistant mutants revealed that missense mutations in atpE resulted in Asp32Val and 
Ala63Pro substitutions in the ε-subunit of the ATP synthase (Andries et al., 2005; 
Huitric et al., 2010). Bedaquiline inhibits the synthesis of ATP as it binds the ε-
subunit, thus disturbing the association between the ε-subunit and the C-ring of the 
ATP synthase (Koul et al., 2007). This leads to energy deficiency in cells and disturbs 
the proton gradient across the membrane. The target ATP synthase is common to both 
mycobacteria and humans but differ in terms of sensitivity to bedaquiline, as the 
human ATP synthase is 20,000-fold less sensitive to the drug (Haagsma et al., 2009). 
Bedaquiline has several advantages including action against both active and latent 
forms of TB infection, a very long half-life and significantly low levels of MIC in 
comparison to INH and RIF when used for the treatment of MDR-TB strains (Huitric 











Figure 1.15 Structure of SQ109 
 
One of the major candidates that could be introduced for therapy against TB in the 
near future includes EMB analogues. EMB, is among the foremost chemotherapeutic 
that targets proteins in AG biosynthesis (Takayama and Kilburn, 1989). Using 
combinatorial chemistry, EMB derivatives have been synthesised, of which NIH241 
and SQ109 are the most promising. SQ109,[N-(2-adamantyl)-N-[(2E)-3,7-
dimethylocta-2,6-dienyl]ethane-1,2-diamine] (Figure 1.15), has low cytotoxicity and 
better in vivo efficacy against MTB than EMB (Protopopova et al., 2005). The EMB-
like diaminated compound SQ109, possess very efficient anti-mycobacterial activity 
and is effective against MDR-TB strains. SQ109 accumulates in the lungs, at the site 
of TB infection. The mechanism of action of SQ109 is considered to be different to 
EMB, as neither the EMB resistant nor MDR strains of MTB show any cross-
resistance to SQ109 (Sacksteder et al., 2012). Recently, it has been reported that 
SQ109 acts by preventing the incorporation of mycolic acids into the cell wall by 
inhibiting a trehalose monomycolate (TMM) transporter MmpL3, without altering the 
total cellular mycolic acid levels (Tahlan et al., 2012). The total mycolate levels are 
maintained in the cell since the reduction in trehalose dimycolate (TDM) levels leads 
to a corresponding increase in TMM levels, once TMM transport is stalled in presence 
of the drug. However, since the study did not use any direct spontaneous mutants 
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against the drug, it is likely that the compound has secondary targets or inhibits the 
protein by binding to essential residues critical for function and survival.  
 
The safety profile of SQ109 has been established and it is a well-tolerated drug with a 
long plasma half-life. SQ109 has progressed to Phase II clinical trials (Ginsberg). 
Strong synergistic activity with bedaquiline, INH and RIF renders SQ109 a promising 
new drug to reduce the duration of TB treatment (Nikonenko et al., 2007). The highly 
synergistic effects of SQ109 and bedaquiline can be attributed to the function of 
SQ109 to weaken the cell wall by inhibiting the deposition of mycolates thereby 
allowing easy access to the ATP synthase for bedaquiline. This combination therapy is 
currently being investigated in Phase II clinical trials. SQ109 has a narrow spectrum, 
being active against M. tuberculosis, M. bovis, M. smegmatis and M. avium. 
 





Figure 1.16: Structure of A. Benzothiazinone lead compound BTZ043 and B. 
Dinitrobenzamide lead compound DNB1 
 
Discovered under the “New Medicines for TB”, European consortium project, the 
sulphur-containing heterocycles benzothiazinones (BTZ or 1,4 dioxa-8-
azaspiro[4.5]dec-8-yl-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one) is a 
novel and highly potent anti-mycobacterial agent. The lead compound of the series is 
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BTZ043 (Fig 1.16 A) (Makarov et al., 2006). BTZ targets the enzyme decaprenyl-
phosphoryl-β-D-ribose epimerase, encoded by dprE1 (Rv3790) and dprE2 (Rv3791), 
responsible for epimerisation of DPR to DPA (Christophe et al., 2009; Makarov et al., 
2009; Mikusova et al., 2005). The lipid based sugar donor, DPA is a precursor 
molecule supplying arabinofuranose residues to AG and LAM (Mikusova et al., 2005; 
Wolucka, 2008). Rv3790 is highly conserved in orthologous genes from various 
actinomycetales, including NCgl0187 in C. glutamicum (Meniche et al., 2008) 
BTZs are bactericidal and reduce bacterial activity by more than 1000-fold in less than 
72 hours (Makarov et al., 2009). The compound targets active cellular metabolism and 
causes the bacteria to swell before lysis. The compounds display very low MICs for the 
MTB complex (1-30 ng/mL) and for fast-growing Mycobacterium species (0.1-80 
ng/mL) (Makarov et al., 2009). They are relatively non-toxic (Makarov et al., 2009) 
and have high potency for MDR-TB and XDR-TB strains (Pasca et al., 2010).  
 
The target of BTZ was determined through analysis of spontaneous resistant mutants of 
M. smegmatis and M. tuberculosis to BTZ. The resistant strains were found to harbor a 
mis-sense mutation in MSMEG_6382 and Rv3790. These mutants showed a Cys387 
conversion to either Ser/Gly and the MICs increased by 250-10,000 fold, respectively 
(Makarov et al., 2009). Interestingly, M. avium and M. aurum are naturally resistant to 
BTZs, as Cys387 residue is naturally substituted by Ser/Ala. These findings suggest 
that BTZs target DprE1 at the Cys387 residue, which abolishes the oxidase activity of 
the enzyme (Makarov et al., 2009). The nitro-group of BTZ is proposed to be reduced 
to a nitroso-group by the action of DprE1. The nitroso-group forms a semi-mercaptal 
linkage to the conserved cystine residue (Cys387) in the active site of the enzyme, thus 
rendering it non-functional (Trefzer et al., 2010; Trefzer et al., 2012). Therefore, BTZs 
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are also classified as suicide substrates for the FAD dependant DprE1 enzyme (Trefzer 
et al., 2012). 
 
Dinitrobenzamides (DNBs, Figure 1.16 B) are nitro-compounds that target 
decaprenylphosphoryl-β-D-ribose 2ꞌ epimerase similar to BTZs (Christophe et al., 
2009; Makarov et al., 2009). They were identified as potent anti-TB compounds from a 
library of compounds screened using fluorescence microscopy (Christophe et al., 
2009). DNBs exhibit a similar mechanism of action to BTZ as it undergoes reduction 
by DprE1 (Trefzer et al., 2010; Trefzer et al., 2012). Recent studies have demonstrated 
that mis-sense mutations in Cys387 can confer resistance to both drugs (Christophe et 
al., 2009; Makarov et al., 2009). BTZs and DNBs can also be inactivated by the 
nitroreductase NfnB in M. smegmatis (Manina et al., 2010). While orthologues of nfnB 
are absent in MTB, its presence in eukaryotes questions the efficacy of BTZ and DNB 
as anti-TB drugs (Manina et al., 2010). The lead compound BTZ043 is in late stages of 
pre-clinical trials and has successfully demonstrated high bactericidal activity against 
MDR-TB strains, thus paving way for the clinical trials (Pasca et al., 2010). The 
vulnerability of DprE1 to antimycobacterial agents, such as DNBs and BTZs and its 
essentiality in various mycobacterial species, highlights its potential as a suitable target 





1.4  The mycobacterial cell wall 
The cell envelope of mycobacteria is critical as it imparts high resistance and tolerance 
to several anti-mycobacterial agents and also contributes towards the patho-
physiological properties of the bacteria. Electron microscopic studies revealed that the 
cell envelope of mycobacteria consists of four components: an innermost layer of 
plasma membrane, consecutively three distinct layers of peptidoglycan (PG), a third 
layer of low electron density comprising AG and an outermost asymmetric layer of 
mycolic acids, phospholipids and glycolipids. Of these four components, PG, AG, 
mycolic acids and other lipids form the core of the mycobacterial cell wall. The classic 
chemotype IV cell wall of MTB comprises of PG; an insoluble matrix of alternating N-
glycolated muramic acid and N-acetyl glucosamine acid residues that are cross-linked 
by meso-diamonopimelic acid (Severn et al., 1998). This thickly cross-linked PG layer 
is in turn attached to a unique polysaccharide; AG decorated with long chain fatty 
acids, termed mycolic acids at its distal ends (Vilkas and Lederer, 1956). Many unusual 
free soluble lipids, which are non-covalently linked to the cell envelope, also exist, of 
which, trehalose-based lipooligosaccharides (LOS) and lipoarabinomannan (LAM) 
(Khoo et al., 1995b), are the most significant ones. Together, these components form 
an asymmetric bilayer of exceptional thickness. The cell wall also consists of protein 
channels called porins to allow the passage of the hydrophilic solutes including 
inhibitors and nutrients. 
 
The structural features and distribution of cell wall components and its effects on 
fluidity have been described in a model proposed by (Minnikin et al., 2002)) as 
illustrated in Figure 1.17. This model suggests that the cell wall consist of two layers; 
an outer layer of extractable lipids which includes the LOSs, glycopeptidolipids and 
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phenolic glycolipids and an inner layer consisting of mycolic acids which are 
perpendicularly arranged to the plane of the cell surface. Together, these two layers 
impart an asymmetric appearance and variable fluidity to the cell wall. The entire 
packaging of the cell wall is responsible for providing a highly effective permeability 
barrier that can only be distorted by adding surfactants. Due to the permeability barrier 
MTB is resistant to common antibiotics, therapeutics, alkali and disinfectants, while 
sensitive to aminoglycosides, RIF, FQ, ETH, PZA, PAS and EMB like antimicrobials 
(Birch et al., 2010; Chatterjee et al., 1991). 
 
Figure 1.17: Structural features of mycobacterial cell wall. The cell wall of M. 
tuberculosis consists of an inner-most layer of plasma membrane, a middle layer of cell wall 
core consisting of the components; peptidoglycan (PG), arabinogalactan (AG) comprising of 
arabinan and galactan and mycolates which extend to the outer layer of the cell envelope.The 
plasma membrane is also linked to lipoarabinomannan (LAM) formed of mannan and 
arabinan, capped with mannose residues which extends into the interior of cell wall. – 
Adapted from Grover S. & Jankute M. et al., 2012. 
Chapter 1 
37 
Sixteen mycolate residues are attached at the non-reducing end of the branched 
arabinan motif of AG (Besra et al., 1995). The galactan core of AG is linked to PG via 
a rhamnose-N-acetylglucosamine-phosphate linker unit. Together the mycolates, AG 
and PG are referred to as the mycolyl-arabinogalactan-peptidoglycan (mAGP) 
complex. The lipoglycans, LAM and LM are presumably anchored to the outer leaflet 
of the cell wall. The arrangement of these components in the cell wall creates a 
hydrophobic interior that stops hydrophilic polysaccharides and solutes from entering 
the cell. The various components in the cell wall are extracted for analysis based on 
their polarity using different solvent systems. The free lipids, proteins, LAM and PIMs 
get solubilised, while the mAGP complex remains in the insoluble fraction. The 
soluble components behave as signalling effector molecules in the disease process 
while the insoluble core is essential for the viability of the mycobacteria. 
 
1.4.1 Plasma membrane 
The plasma membrane of mycobacteria is asymmetrical with characteristic regions of 
extra thickness harbouring the carbohydrate rich phosphatidyl-inositol mannosides 
(PIMs), lipomannan (LM) and LAM. These soluble conjugates are one of the major 
structural components of the mycobacterial plasma membrane and are involved in 
interactions with the host-immune system. Aside the PIMs, phospholipids, such as 
phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI), phosphatidyl glycerol and 
cardiolipid (CL), pol yterpene based products, glycosyl phosphopolyprenols, such as β-
mannopyranosyl phosphodecaprenol (PPM), DPA and β-D-ribofuranosyl 
phosphodecaprenol (DPR), which are involved in cell wall biosynthesis are also 
hypothesised to be associated with the plasma membrane. The mycobacterial 
membrane is rich in PE and PI, but contains modest levels of phosphatidyl glycerol. 
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The genes involved in PI biosynthesis are essential in M. smegmatis indicating its vital 
role in the growth and viability of mycobacteria (Jackson et al., 2000). PIs undergo 
extensive glycosylations to generate PIMs, LM and LAM that are unique components 
with a specific structural and biological role in mycobacteria including modulation of 
the host immune response in favour of the pathogen.  
 
1.4.2 Peptidoglycan 
The PG layer is an important component of the bacterial cell envelope. Largely 
consisting of alternating N-acetyl glucosamine (GlcNAc) – N-glycolated muramic acid 
(MurNGly) units (1984; Wietzerbin et al., 1974), linked to each other via β-1,4 
linkages, with L-alanine-D-glutamate-D-isoglutaminsyl-meso-diaminopimelyl (DAP)-
D-alanine-D-alanine penta-peptide side chains also referred to as the stem peptide on 
the 4
th
 position of the muramic acid units (Goffin and Ghuysen, 2002). The cross-
linking of the disaccharide unit includes a portion between two DAP residues and 
between DAP and D-alanine (Wietzerbin et al., 1974). The biosynthesis of PG in MTB 
has not been investigated in detail. However, much detail has been elucidated from the 
PG biosynthesis pathway in E. coli (Van Heijenoort, 2001a; b). The first step in the 
synthesis of PG requires synthesis of UDP-N-acetyl muramic acid (UDP-MurNAc) 
from UDP-GlcNAc via a two step reaction catalysed by enzymes MurA (Rv1315) and 
MurB (Rv0482) (Belanger et al., 2000; De Smet et al., 1999). UDP-MurNAc thus 
generated is converted to UDP-MurNGly via a UDP-N-acetylmuramic acid 
hydroxylase encoded by namH (Rv3818) (Raymond et al., 2005). The enzymes MurC 
(Rv2152c), MurD (Rv2155c), MurE (Rv2158c), and MurF (Rv2157c) are required for 
synthesis of the penta-peptide stem (Belanger et al., 2000; Crick et al., 2001; 
Mahapatra et al., 2000). The penta-peptide synthesised on UDP-MurNGly is 
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transferred onto a molecule of undecaprenyl phosphate, Lipid I, via a translocase, 
MurX (Rv2156c). Addition of a unit of GlcNAc to Lipid I by a transferase MurG 
(Rv2153c) affords Lipid II carrying glycopeptides, which is then translocated to the 
periplasm for PG assembly.  
 
1.4.3 Linker Unit 
The AG component of the mAGP complex is attached to some MurNGly units of PG 
via a linker unit (LU) comprising of -L-rhamnopyranose-(13)--D-GlcNAc-(1P) 
bridge (Daffe et al., 1990). Synthesis of the linker unit requires transfer of GlcNAc-1-P 
from UDP-GlcNAc to the lipid carrier decaprenyl monophosphate (C50-P) catalysed by 
a UDP-GlcNAc transferase WecA (Rfe, Rv1302) (Mikusova et al., 1996). The Rhap 
component of the LU is synthesised via a four-step reaction process that (Ma et al., 
2002) utilises the enzymes RmlA (Rv0334), an α-D-glucose-1-phosphate 
thymidylyltransferase, RmlB (Rv3465), a dTDP-D-glucose-4, 6-dehydratase, RmlC 
(Rv3464), a dTDP-4-keto-6-deoxy-glucose-3,5-epimerase and RmlD (Rv3266c), a 
dTDP-6-deoxy-L-lyxo-4-hexulose reductase which act sequentially to mediate the 
conversion of glucose-1-phosphate and thymidine-triphosphate to generate dTDP-Rhap 
(Giraud et al., 2000). In the last step, the rhamnopyranosyl unit is transferred to C50-P-
P-GlcNAc via a rhamnosyltransferase, WbbL encoded by Rv3265c to yield C50-P-P-
GlcNAc-Rha (Mills et al., 2004). Recent genetic and mutational studies in M. 
smegmatis have demonstrated rmlB, rmlC and rmlD to be essential for viability 
rendering the pathway for biogenesis of LU and the genes involved as attractive targets 




1.4.4 Arabinogalactan  
 
1.4.4.1  Structure 
Measuring up to 35% of the total cell wall of mycobacteria, AG is an important 
structural element that aids in anchoring mycolates to the PG. AG is a hetero-
polysaccharide comprising of arabinose (Ara) and galactose (Gal) sugar units in 
furanose ring form (Mcneil et al., 1987) arranged in a distinctive pattern to generate 
motifs (Fig 1.18) that are characteristic of the polysaccharide (Daffe et al., 1990). AG 
rests at the centre of the mAGP complex where it is linked to mycolates at the non 
reducing end (Kaur et al., 2009) and attached to the LU at the reducing end. The LU 
attaches mAG to the PG at the C-6 position of selected MurNGly residues (Mcneil et 
al., 1990). The galactan core comprises of approximately 30 alternating (15) and 
(16) galactofuranose (Galf) residues arranged linearly. The arabinan component is 
highly branched and built on the galactan. Each galactan core is linked to three 
arabinan chains of approximately 30 arabinofuranosyl (Araf) residues, at the C-5 
position of some (16) Galf residues (Bhamidi et al., 2008; Daffe et al., 1990). Mass 
spectrometric analysis of AG in Corynebacterium glutamicum revealed that the 






 Galf residue in the galactan core 
(Alderwick et al., 2006b). The Araf residues in the backbone of arabinan core comprise 
of a linearly arranged (1→5) linked -D-Araf residues with branching at the C-3 




Figure 1.18: Structural features of AG. Arabinogalactan is a polysaccharide of linearly 
arranged galactose and highly branched arabinose residues decorated with mycolates at the 
distil end of arabinan domain. AG is attached to peptidoglyan via a rhamnopyranosyl-N-
acetylglucosamine linker unit. – Adapted from Grover S. & Jankute M. et al., 2012. 
 
 
The non-reducing termini of arabinan structure consists of a characteristic hexa-
arabinofuranosyl motif [-D-Araf-(12)--D-Araf]2-3,5--D-Araf-(15)--D-Araf], 
with mycolates attached to C-5 of both the terminal -D-Araf units and the penultimate 
2--D-Araf units (Mcneil et al., 1991). Each hexa-arabinofuranosyl motif can 
potentially be attached to four mycolyl residues. However, only two-thirds of the total 
available sites get mycolated under physiological conditions (Mcneil et al., 1991). The 
complete AG structure has a few modifications that vary from species to species. For 
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example slow-growing mycobacteria, such as MTB have a non-acylated galactosamine 
(D-GalN) residue attached to the C-2 position of some 3, 5--D-Araf units in the core 
(Draper et al., 1997; Lee et al., 2006). In addition, the non-mycolated chains of 
arabinan are capped by succinyl residues (Bhamidi et al., 2008), suggesting a possible 
negative control mechanism for mycolylation. Together, both the protonated D-GalN 
and the negatively charged succinates impart rigidity and stability to AG (Bhamidi et 
al., 2008).  
 
1.4.4.2  Biosynthesis of decaprenyl phosphoarabinose (DPA)  
The furanose cyclic form of D-arabinose (Araf) is a key component of both AG and 
LAM in mycobacteria. The sugar donor for Araf is a lipid-linked decaprenyl-phospho-
arabinose (DPA, C50-P-Araf) (Wolucka et al., 1994). The majority of DPA in 
mycobacteria is generated by the pentose phosphate pathway (Marks, 1956). The first 
step of the DPA biosynthesis pathway is the formation of D-ribose-5-phosphate from 
sedoheptulose 7-phosphate, catalysed by Rv1449 transketolase, and/or the 
isomerisation of D-ribulose 5-phosphate, catalysed by Rv2465 D-ribose 5-phosphate 
isomerase (Roos et al., 2004; Roos et al., 2005). Subsequently, ribose 5-phosphate is 
converted into 5-phosphoribosyl-α-1-pyrophosphate (pRpp) (Alderwick et al., 2011b), 
in a reaction catalysed by ribose-5-phosphate diphosphokinase (PrsA) encoded by 
Rv1017c.  
 
The synthesis of DPA and DPR from pRpp occurs by a two-step epimerisation of DPR 
(Mikusova et al., 2005; Scherman et al., 1996). In the first step, pRpp is transferred to 
a decaprenyl-phosphate molecule to form decaprenylphosphoryl-β-D-5-phosphoribose 
(DPPR) via a 5-phospho-α-D-ribose-1-diphosphate: decaprenyl-phosphate-5-phospho-
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ribosyltransferase, UbiA (Rv3806c) (Huang et al., 2005). The dephosphorylation of 
DPPR to DPR is the first committed step of the pathway and is suggested to be 
catalysed by the putative phospholipid phosphatase, Rv3807. The gene Rv3807c, is 
present in the AG biosynthetic cluster (Rv3779-Rv3809c) and is known to encode an 
unknown poly-(A)-polymerase2 (PAP2)-superfamily phospholipid phosphatase. The 
dephosphorylated product, DPR is subsequently oxidised at 2-OH of ribose to yield 
decaprenylphosphoryl-2-keto-β-D-erythro-pentofuranose (DPX), which is then reduced 
to form DPA. DprE1 (Rv3790) and DprE2 (Rv3791) form a heteromer and catalyse the 
epimerisation of the ribosyl unit of DPR yielding the essential DPA donor (Mikusova 
et al., 2005). Interestingly, recent studies have also confirmed Rv3790 as the target of 
BTZs, a new class of antitubercular drugs. Besides being the Araf donor for the 
biosynthesis of the arabinan domain in LAM, DPA also donates Araf residues for the 
biosynthesis of AG, where the Araf residues are transferred directly onto a previously 
generated intermediate, C50-P-P-GlcNAc-Rha-Galf30, utilising the only known 
mycobacterial Araf donor DPA (Wolucka et al., 1994). 
 
1.4.4.3  Biosynthesis of arabinogalactan  
The linker unit assembled on decaprenyl-phosphate functions as a primer for sequential 
addition of approximately 30 Galf residues that are arranged in a linear fashion. The 
first two Galf residues are added to Rha in the linker unit from UDP-Galf by a 
galactofuranosyl transferase enzyme GlfT1 encoded by Rv3782. The remaining Galf 
residues are added by a second transferase GlfT2 encoded by Rv3808c (Kremer et al., 
2001; Szczepina et al., 2010). GlfT2 exhibits dual activity, as it acts both as a UDP-
Galf:-D-(15) GalT and a UDP-Galf:-D-(16) GalT, and is responsible for 
sequentially polymerising the bulk of the galactan polysaccharide in alternating 
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(15) and (16) linkages (Kremer et al., 2001). The activity of GlfT1 and GlfT2 
together generates the galactan intermediate C50-P-P-GlcNAc-Rha-Galf30 to which 
arabinose residues are added by arabinofuranoyltransferases (ArafTs) utilising the Araf 
donor DPA (Wolucka et al., 1994). The galactan intermediate is then primed for 
synthesis of the arabinan core by addition of arabinose residues from DPA onto the 
positions 8, 10 and 12 of the galactan chain (Figure 1.19). This reaction is catalysed by 
a novel (15) ArafT, AftA (Rv3792) (Alderwick et al., 2006b). The arabinan chains 
on the primed galactan core are synthesised by several (15) ArafT namely, EmbA 
and EmbB (Rv3794 and Rv3795), that are predicted to act as a heterodimer (Escuyer et 
al., 2001) (Fig 1.19). Although, AG is a vital component of the mycobacterial cell wall, 
disruption of homologues of either Rv3794 or Rv3795 in M. smegmatis generates a 
viable mutant with an impaired AG structure (Escuyer et al., 2001). Similarly, just one 
orthologue of the non-essential emb gene exists in C. glutamicum (Alderwick et al., 
2005) and its deletion results in synthesis of a truncated AG structure with only 
terminal Araf residues (Alderwick et al., 2005). A novel mycobacterial ArafT, AftC 
(Rv2673), introduces -1, 3 branches (Figure 1.19) by addition of α(1→3) linked Araf 
units to the α(1→5) arabinose chain at the non-reducing end (Birch et al., 2010; Birch 
et al., 2008). 
 
In addition AftC, another ArafT with -1,3-branching activity encoded by aftD 
(Rv0236c) has recently been described in M. tuberculosis (Skovierova et al., 2009). 
The transfer of terminal (12) Araf units from DPA onto the arabinan domain is 
catalysed by AftB (Rv3805c) (Belisle et al., 1997; Seidel et al., 2007a). The complete 
AG structure is now ready for mycolation with four mycolic acid units per AG 
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molecule.  Attachment of mycolates to the complete AG structure is predicted to be 
catalysed by the Antigen 85 Complex (Belisle et al., 1997) composed of three closely 
related proteins FbpA, FbpB and FbpC (Rv3804c, Rv1886c and Rv0129c respectively) 
(Jackson et al., 1999). However in C. glutamicum, mycolyltransferases encoded by 
cmytA and cmytB attach mycolic acid residues to AG (Kacem et al., 2004). 
 
 
Figure 1.19: Biosynthesis of arabinan in AG and site of EMB action. The highly 
branched arabinan domain in AG is synthesised by several arabinofuranosyl transferases. 
Synthesis of a complete arabinan domain is stalled by EMB which inhibits the activity of 
EmbA and EmbB. – Adapted from Grover S. & Jankute M. et al., 2012. 
 
1.4.5 Phosphatidyl-myo-inositol based glycolipids 
The plasma membrane of mycobacteria is rich in free lipids such as phospholipids; PE, 
PI, PIMs, LM, LAM and CL that forms the major structural components. The 
glycophospholipids such as PIMs, LM and LAM are built on a common phosphatidyl-
myo-inositol (PI) backbone that undergoes a series of modifications. The spatial 
distribution of these PI based glycophospholipids in the cell envelope is still unclear. 
However, recent surface labelling experiments have indicated the likelihood of 
Chapter 1 
46 
occurrence of lipoglycans at the surface of mycobacteria predominantly in the outer 
leaflet of the outer membrane (Pitarque et al., 2008). These surface exposed 
lipoglycans which include PIMs, LM and LAM exhibit immunomodulatory properties 
as they modulate immune response in macrophages, including cytokine production, 
inhibition of phagosome maturation, apoptosis in the host and are also instrumental in 
providing cross-protective immunity to mycobacteria (Mishra et al., 2011b).  
 
Based on experimental evidences the modifications of the PI anchor have been 
deduced to follow the order: PI → PIM → LM → LAM (Mishra et al., 2011b). 
Sequential mannosylation of the PI anchor with up to six mannose residues generates 
PIMs that serve as the building blocks of higher lipoglycans, such as LM and LAM 
with highly branched mannose and arabinose units. Biogenesis of early PIM species 
utilises mannosyltransferases and acyltransferases encoded by genes present in an 
operon of six open reading frames that is conserved in the Corynebacterineae family 
(Cole et al., 1998). These open reading frames (ORFs) include a probable threonyl-
tRNA synthase (Rv2614c), a protein of unknown function with probable involvement 
in nucleotide biosynthesis (Rv2613c), PgsA (Rv2612c), a protein involved in PI 
synthesis and an acyltransferase (Rv2611c) (Kordulakova et al., 2003). The fifth ORF 
PimA (Rv2610c), is an α-mannopyranosyltransferase of the GT-B superfamily that 
catalyses the production of PIM1 (Guerin et al., 2007). The last ORF of this gene 
cluster is a putative GDP-Manp hydrolase (Rv2609c) with a conserved MutT domain 
(Kordulakova et al., 2002). The embCAB operon that encodes for ArafTs, such as 
EmbA, EmbB and EmbC in mycobacteria (Belanger et al., 1996; Telenti et al., 1997), 
is in another gene cluster comprising of enzymes employed in the biosynthesies of 
arabinan domains in LAM (Zhang et al., 2003a) and AG (Escuyer et al., 2001). These 
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complex lipoglycans are synonymous with the cell envelopes of all mycobacterial 
species (Besra and Brennan, 1997; Hunter and Brennan, 1990; Nigou et al., 2003). 
 
1.4.5.1  Structural features of PIMs 
PIMs are all based on a common PI unit, a sn-glycero-3-phosphate-(1-D-myo-inositol) 
with glycerol phosphate attached to the L-1-position of myo-inositol (Ballou and Lee, 
1964; Ballou et al., 1963). The mannosyl-phosphate inositol anchor (MPI anchor) that 
binds these PIMs to the cell envelope is essentially a PI unit substituted with mannose 
residues on positions C-2 and C-6 of the inositol ring (Fig 1.20)  (Nigou et al., 2004; 
Severn et al., 1998). The number, location and nature of the fatty acids attached to the 
MPI anchor are highly variable. Acylated PIM species are generated by acylation of 
the MPI anchor which harbours up to four potential acylation sites with two residing in 
the glycerol unit, one in the Manp unit linked to C-2 of myo-inositol and another at the 
C-3 position of the myo-inositol ring (Brennan and Ballou, 1968; Khoo et al., 1996).  
 
Sequential glycosylation of the MPI anchor generates PIMs with PIM1, PIM2, PIM4 
and PIM6. The PI residue in the MPI anchor undergoes mannosylation with an -D-
mannopyranosyl (Manp) residue at position O-2 to yield PIM1, whilst mannosylations 
with Manp at both O-2 and O-6 generates PIM2 (Fig 1.20). A series of glycosylations 
of the MPI anchor generates the terminal PIM species PIM6 with the structure Manp-
α(1→2)-Manp-α(1→2)-Manp-α(1→6)-Manp-α(1→6)-Manp-α(1→.) attached to the 
MPI anchor (Nigou et al., 1999) (Fig 1.21). Whilst mycobacteria accumulate acylated 
PIMs, such as Ac1PIM2 and Ac1PIM6, with acylation occurring at the Manp residue 
attached to C-2 of myo-inositol, the diacyl forms of PIMs, such as Ac2PIM2 and 
Ac2PIM6 also exist. The complex lipoglycans, such as LM and LAM and higher PIM 
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species, such as PIM6 are built on Ac1PIM2 following a series of glycosylations 


























Figure 1.20: Structural features of PIMs. PIMs are based on a common PI anchor which 
attaches them to the membrane. The MPI anchor is glycosylated at 2-OH and 6-OH of 
inositol to generate PIM2. Sequential addition of another two α(1→6) Manp residues 
generates PIM4. The higher PIM species, PIM6 is formed by addition of two α(1→2) Manp 
residues to PIM4. The acylation sites in MPI anchor are represented by R1, R2, R3 and R4.  
 
1.4.5.2 Structural features of LM and LAM 
The extension of PIMs with 20-30 mannose residues generates the mannan core of LM 
and LAM. The C-6 position of the inositol ring is the initiation point to which the first 
Manp residue is attached (Chatterjee et al., 1991; Khoo et al., 1996) (Fig 1.21). The 
mannan backbone comprises of 21-34 linearly linked α(16) mannose residues with 
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branching introduced by 5-10 units of single α(1→2) Manp units at C-2 of some of the 
mannose residues in the backbone in all mycobacterial species (Mishra et al., 2011a) 
except in M. chelonae, where branching occurs at the C-3 position (Chatterjee et al., 
1992; Guerardel et al., 2002).  
 
The arabinan domain in LAM consists of 55-70 Araf units (Khoo et al., 1996) with a 
linear backbone of α(15)-linked Araf residues harbouring occasional branching at 
the 3
rd
 position of some Araf residues (Birch et al., 2010; Kaur et al., 2008) (Figure 
1.21). The branched arabinan domain in LAM is similar to that of AG as it contains the 
hexa-arabinoside motif comprising of [β-D-Araf (1→2)-α-D-Araf ]2-3,5-α-D-Araf 
(1→5)-α-D-Araf as found in AG. In addition to the hexa-motif, a linear tetra-
arabinoside comprising of β-D-Araf (1→2)-α-D-Araf (1→5)-α-D-Araf (1→5)-α-D-
Araf is a second motif in the arabinan domain of LAM (Chatterjee et al., 1991; 
Chatterjee et al., 1993). The non-reducing end of both hexa-and the tetra-motifs are 
identified by a distinctive disaccharide unit, Araf-β(1→2)-Araf-α(1→.) (Chatterjee et 
al., 1991; Chatterjee et al., 1993; Mcneil et al., 1994). 
 
The (12)-linked terminal Araf units in LAM are capped with capping motifs that 
differ with respect to different mycobacterial species. Three different capping units 
have been identified in mycobateria: mannose capped LAM (Man-LAM) an attribute 
of slow-growing and mostly pathogenic mycobacteria, such as M. tuberculosis, M. 
bovis, M. bovis BCG, M. leprae, M. avium, M. xenopi, M. marinum, and M. kansasii 
(Chatterjee et al., 1993), PI-capped LAM (PI-LAM) which is mainly found in fast-
growing species of mycobacteria, such as M. smegmatis and M. fortuitum (Khoo et al., 
1995a), and non-capped LAM (Ara-LAM) that was recently identified in M. chelonae 
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(Guerardel et al., 2002). The ‘Man caps’ in mycobacteria predominantly occur as 
dimannosides of α(12) Manp, whilst single and tri-mannosides also exist (Chatterjee 
et al., 1992; Chatterjee et al., 1993). In addition to the caps, Man-LAM isolated from 
M. bovis BCG (Glaxo, Pasteur, Japanese and Copenhagen strains) is modified with 
succinyl residues on the C-2 of the 3,5-di-α-D-Araf units that can vary from one to four 









Figure 1.21: Structural features of LM and LAM. LM and LAM are formed by 
extensive glycosylation of PIM4. The mannan in both LM and LAM comprises of 21-34 
linearly linked α(1→6) manp residues occasionally branched by addition of α(1→2) manp 
residues. The arabinan domain consists of a branched hexa-motif; [β-D-Araf (1→2)-α-D-
Araf ]2-3,5-α-D-Araf (1→5)-α-D-Araf  which is similar to that of AG and a linear tetra 
motif: β-D-Araf (1→2)-α-D-Araf (1→5)-α-D-Araf (1→5)-α-D-Araf. A distinctive 
disaccharide unit, Araf-β(1→2)-Araf-α(1→.) decorates the non reducing ends. ‘Man-





1.4.5.3 Biosynthesis of PIMs, LM and LAM  
 
1.4.5.3.1 GDP-Manp and polyprenol monophosphomannose biosynthesis 
Mannose is an indispensable component of various glycolipids, lipoglycans, 
glycoproteins and polymethylated polysaccharides prevalent in mycobacteria (Jackson 
and Brennan, 2009). Mycobacteria is capable of sequestering mannose directly from 
the extracellular environment via the sugar transporters which is then phosphorylated 
by hexokinase (Rv2702) (Kowalska et al., 1980) to generate mannose-1-phosphate. In 
an alternative mechanism, mycobacteria obtain mannose from the glycolytic pathway, 
by converting fructose-6-phosphate to mannose-6-phosphate via a phosphomannose 
isomerase (PMI), ManA (Rv3255c) (Patterson et al., 2003) (Figure 1.22). The 
mannose-6-phosphate thus generated is converted to mannose-1-phosphate by a 
phosphotransferase, ManB (Rv3257c) (Mccarthy et al., 2005). The mannose-1-
phosphate thus synthesised is then transferred to guanosine diphosphate (GDP) by 
ManC to generate the intracellular nucleotide-derived mannose donor, GDP-Manp (Ma 
et al., 2001; Ning and Elbein, 1999) that provides Manp residues to the GT-A/B 
superfamily glycosyltransferases for synthesis of several glycolipids in mycobacteria 
(Liu and Mushegian, 2003). 
 
Polyprenyl-phosphate based mannose donors such as C50-decaprenol-phospho-
mannose (C50-P-Manp, PPM) identified in M. tuberculosis (Takayama and Goldman, 
1970) and M. smegmatis (Wolucka and De Hoffmann, 1998), are employed by the GT-
C superfamily of glycosyltransferases for the synthesis of higher PIMs, LM and LAM. 
In addition to the C50-polyprenol-based mannolipid, Takayama et al.(1973) also 
identified a C35-octahydroheptaprenyl-phospho-mannose, C35-P-Manp, in M. 
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smegmatis (Takayama et al., 1973), thus establishing the existence of two prenyl-based 
phosphomannose donors in M. smegmatis that are utilised in the synthesis of cell wall 
components. Synthesis of these prenyl based phosphomannose donors is catalysed by a 
polyprenol monophosphomannose synthase (PPM synthase), Ppm1 (Rv2051c) that 
transfers Manp from GDP-Man to C35/C50-P to afford PPM (Gurcha et al., 2002) 
(Figure 1.22). Recently, in a study conducted by Scherman et. al. (2009) the gene 
Rv3779 was suggested to encode a second PPM synthase implicated in the synthesis of 
the C35/50-P-Manp donor (Scherman et al., 2009). However, in a second investigation 
by Skovierova et al. (2010), Rv3779 was identified as a glycosyltransferase that 
catalyses the transfer of a galactosamine residue from a polyprenyl-phospho-N-
acetylgalactosamine to AG in mycobacteria (Skovierova et al., 2010). The 
contradictory results thus obtained resulted in a re-examination of the role of Rv2051 
and Rv3779, where a conditional mutant of ppm1 in M. smegmatis was analysed for 
gain of function in vivo when complemented with a plasmid encoded copy of Rv2051c 
and Rv3779. The results obtained implicated Rv2051c as the true PPM synthase as it 






Figure 1.22: Biosynthesis of PI and PPM. PI is synthesised by a three step process which 
is initiated by conversion of glucose-6-P to inositol-1-P by Ino1. An IMP synthase converts 
inositol-1-P to myo-inositol which is loaded onto diacylglycerol by PgsA to afford the PI 
anchor. The pathway for PPM biosynthesis obtains mannose either exogenously or by 
converting the glycolysis intermediate fructose-6-P to mannose-6-P. PPM is generated by 
transfer of mannose residue from GDP-Man donor to the C35/C50-Phosphate carrier mediated 
by Ppm1. – Adapted from Grover S. and Jankute M. et. al., Genetics of Arabinogalactan and 
Lipoarabinomannan, Molecular Genetics of Mycobacteria, 2
nd
 Ed. (In Press). 
 
1.4.5.3.2 Biosynthesis of PI 
The PI moiety functions both as a building block for synthesis of PIMs, LM and LAM, 
and as an anchor for high molecular weight lipoglycans, LM and LAM. PI synthesis is 
a three-step process initiated by cyclisation of glucose-6-phosphate via inositol 
phosphate synthase InO1 (Rv0046c), to afford myo-inositol-1-phosphate that is 
consequently dephosphorylated by inositol mono-phosphatase (IMP) to generate myo-
inositol (Bachhawat and Mande, 1999a; Movahedzadeh et al., 2004a) (Figure 1.22). 
The PI synthase, PgsA (Rv2612c) catalyses the transfer of myo-inositol to 
diacylglycerol (DAG), from the cytidine diphosphate-diacylglycerol (CDP-DAG) 
nucleotide donor in the last step to generate the PI anchor. Both enzymes, the PI 
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synthase, PgsA and inositol phosphate synthase Ino1, are essential for the growth and 
viability of mycobacteria (Jackson et al., 2000; Movahedzadeh et al., 2004a). 
Interestingly, several ORFs such suhB (Rv2701c), impA (Rv1604), cysQ (Rv2131c) and 
impC (Rv3137), have been implicated as putative inositol-monophosphatases 
responsible for the synthesis of myo-inositol, of which only ImpC was determined to 
be essential for the growth of MTB and M. smegmatis (Movahedzadeh et al., 2010), 
indicating a possible involvement as a phosphatase for myo-inositol production. 
 
1.4.5.3.3 Biosynthesis of PIMs  
The PI anchor undergoes a series of mannosylations that follow the order: PI → PIM2 
→ PIM4 → PIM6 (Figure 1.23) to generate PI-based mannosides, a crucial component 
of the mycobacterial cell envelope. The synthesis of early PIM species is initiated by 
transfer of Manp from GDP-Manp to position O-2 of the inositol ring of PI, catalysed 
by an α-mannosyltransferase PimA (Rv2610c) to yield PIM1 (Guerin et al., 2007; 
Kordulakova et al., 2002; Kordulakova et al., 2003). The second step in the pathway is 
the generation of a crucial metabolite PIM2 on which the higher PIMs, LM and LAM 
are synthesised (Besra et al., 1997; Khoo et al., 1995b). PIM2 is commonly found in 
mono- and di-acylated forms in MTB (Kordulakova et al., 2003) and two separate 
hypotheses have been suggested for the formation of these acylated PIM species. 
According to the first hypothesis, acylation of PIM1 by an acyltransferase, encoded by 
Rv2611c, at the 6
th
 position of the Manp precedes the mannosylation step catalysed by 
an α-D-mannose-α-(1→6) phosphatidyl myo-inositol-mannopyranosyltransferase 
PimBꞌ (Rv2188c). The second mannosylation occurs at position O-6 of the inositol ring 
(Kordulakova et al., 2002; Kordulakova et al., 2003). Evidence for this hypothesis was 
provided by recent genetic studies conducted in C. glutamicum where AcPIM1 was 
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observed to accumulate in a deletion mutant of pimB' (Kordulakova et al., 2003; Lea-
Smith et al., 2008; Mishra et al., 2008). The second hypothesis favoured co-acylation 
of both PIM1 and PIM2. However, cell free experiments conducted in M. smegmatis 
demonstrated that acylaytion of PIM2 occurs only after its synthesis (Guerin et al., 
2009a), thus ruling out the co-acylation hypothesis. The acyltransferase encoded by 
Rv2611c and the mannosyltransferase PimBꞌ encoded by Rv2188c are essential for 
growth in mycobacteria. (Guerin et al., 2009a; Kaur et al., 2007; Kordulakova et al., 
2003). The function of Rv2188c was initially assigned to Rv0557, earlier designated as 
PimB. However, genetic experiments in M. tuberculosis identified no changes to PIM 
biosynthesis due to disruption of the gene. The results obtained implied that the role of 
PimB, could either be substituted by complementary genes or the function of PimB is 
different to that of PimBꞌ (Torrelles et al., 2009). In addition, recent investigations in 
C. glutamicum have identified Rv2188c as the mannopyranosyltransferase involved in 
the second mannosylation step for the generation of AcPIM2 (Lea-Smith et al., 2008; 
Mishra et al., 2008; Mishra et al., 2009) and caused Rv0557 to be renamed as MgtA, 
due to the α-mannosyl-glucopyranosylglucuronic acid transferase activity responsible 
for production of Cg-LM-B, a glucuronic acid based LM variant and ManGlcAGroAc2, 
a glucuronic acid diacylglycerol based glycolipid found in C. glutamicum (Mishra et 
al., 2009). 
 
The synthesis of AcPIM4 is the next crucial step in the PIM biosynthesis pathway. The 
less abundant intermediary PIM forms, such as Ac1PIM3 or Ac2PIM3 also exist in 
mycobacteria. Ac1PIM3 and Ac2PIM3 are synthesised by mannosyltransferase PimC 
(RvD2-ORF1) identified in M. tuberculosis strain CDC1551. However, no strong 
homologues of pimC were found to be present in M. tuberculosis H37Rv and M. 
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smegmatis. In addition, homologues of pimC in M. bovis BCG when deleted, exhibited 
normal PIM, LM and LAM levels, indicating the presence of other homologues or 
compensatory pathways (Kremer et al., 2002b) to compensate for the loss of gene 
function. Generation of Ac1/Ac2PIM4 by mannosylation of Ac1/Ac2PIM3 at the non-
reducing end is catalysed by an unidentified α(1→6) mannosyltransferase 
hypothesised to be either PimC or the unidentified putative ‘PimD’ protein (Guerin et 
al., 2010). This step marks the point of divergence as the pathway now splits into two 
branches, with one branch leading to the formation of polar PIM species, such as 
Ac1/Ac2PIM5 and Ac1/Ac2PIM6 by two consecutive additions of α(1→2) Manp, 
probably by PimE (Rv1159), and the second branch leading to the formation of LM 
and LAM (Morita et al., 2004; Morita et al., 2006). An unknown flippase translocates 
Ac1/Ac2PIM4 across the membrane to the periplasm for subsequent glycosylation.  
 
Subsequent glycosylations of Ac1/Ac2PIM4 are now mediated by the GT-C superfamily 
of glycosyltransferases that utilise polyprenylphosphate based sugar donors, PPM and 
DPA (Liu and Mushegian, 2003). Whilst the steps for the biosynthesis of the final 
product Ac1/Ac2PIM6 are yet to be deduced, PimE an α(1→2) 
mannopyranosyltransferase of the GT-C superfamily is likely to be responsible for 
addition of one or more mannose residues to Ac1/Ac2PIM4 (Morita et al., 2006). The 
higher PIM species have prominent structural and physiological roles as PIM4 forms 
the structural basis for LM and LAM, while PIM6 is required for maintaining the 




Figure 1.23: Pathway for biosynthesis of PIMs. Biosynthesis of PIMs is initiated by 
transfer of mannose residue from GDP-Man donor to PI by mannosyl transferase PimA. PIM1 
thus produced is acylated by acyltransferase Rv2611 to afford Ac1/Ac2PIM1 which is 
subsequently mannosylated by PimBꞌ, unknown PimC or PimD to generate PIM4. PIM4 serves 
as the scaffold on which polar PIMs such as PIM6 and lipoglycans such as LM and LAM are 
built. – Adapted from Grover S. and Jankute M. et. al., Genetics of Arabinogalactan and 
Lipoarabinomannan, Molecular Genetics of Mycobacteria, 2
nd
 Ed. (In Press). 
 
1.4.5.3.4 Biosynthesis of LM and LAM 
The intermediary PIM species Ac1/Ac2PIM4 undergoes extensive modifications such as 
mannosylations and arabinosylations to yield LM and LAM. Since synthesis of 
Ac1/Ac2PIM4 marks the branching point in lipoglycan and polar PIMs biogenesis, the 
channelling of the intermediate to either of the branches is regulated via a regulatory 
protein LpqW (Rv1166) (Crellin et al., 2008; Kovacevic et al., 2006). The regulator 
LpqW drives Ac1/Ac2PIM4 into LM and LAM biosynthesis by interacting with a 
mannosyltransferase MptB, to promote the synthesis of the mannan core of LM and 
LAM (Crellin et al., 2008; Rainczuk et al., 2012). The mannan core in LM/LAM 
consists of approximately 25-30 linearly linked α(1→6) mannose residues with 
occasional branching at C-2 with single (1→2) linked mannose units in M. 
tuberculosis, M. leprae and M. smegmatis. However, in case of M. chelonae single 
Manp units are substituted at position C-3 in the α(1→6) mannan core. Synthesis of 
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the linear α(1→6) mannan backbone is mediated by mannosyltransferases MptA 
(Rv2174) and MptB (Rv1459c) (Figure 1.24). Recent studies in C. glutamicum have 
highlighted that whilst MptB mediates the synthesis of the proximal end through the 
addition of 12-15 Manp residues to the backbone (Mishra et al., 2008), MptA is 
responsible for the synthesis of distal end of the core (Kaur et al., 2007; Mishra et al., 
2007). However, orthologues of MptB from M. tuberculosis and M. smegmatis when 
examined for their glycosyltransfease activity were unable to complement the C. 
glutamicumΔmptB mutant, indicating that either differences in substrate specificity or 
redundancy of the gene function are responsible for the contradictory observations. 
 
Branching in the α(1→6) mannan core is introduced by MptC (Rv2181) by the 
addition of α(1→2) Manp residues to the linear mannan backbone (Kaur et al., 2006; 
Mishra et al., 2011b) (Figure 1.24). A knockout of MSMEG_4250, the M. smegmatis 
orthologue of MptC synthesises a truncated version of LAM with a reduced number of 
(1→2) Manp branching residues. The mutant also lacked the ability to synthesise LM. 
Complementation of the mutant with the corresponding orthologue of MTB (Rv2181) 
restored normal LM/LAM synthesis indicating Rv2181 as the putative branching 
enzyme of the mannan core. However, regulation of LM and LAM biosynthesis in M. 
smegmatis appears to differ somewhat with M. tuberculosis, as M. 
tuberculosisΔRv2181 produced truncated versions of LM and Man-LAM (Kaur et al., 
2008). 
 
The arabinan domain in LAM is generated by further elaboration of LM with 55-70 
Araf units (Fig 1.24) (Besra and Brennan, 1997). The arabinan domain in AG and 
LAM share a high degree of similarity in both structure and biosynthesis. The addition 
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of Araf residues to the mannan core is mediated by several ArafTs; of which EmbC 
(Rv3793), AftC (Rv2673) and AftD (Rv0236c) have been well characterised 
(Alderwick et al., 2006b). Priming of the mannan core in LM with Araf residues to 
generate the arabinan core is mediated by an unidentified ArafT. The primed LM is 
subjected to sequential addition of 12-16 α(1→5) Araf residues, exclusively catalysed 
by an α(1→5) Araf transferase, EmbC (Alderwick et al., 2011a; Birch et al., 2010; Shi 
et al., 2006). The linear arabinan polymer comprising α(1→5) Araf residues in LAM is 
branched by addition of α(1→3) Araf residues akin to AG. 
 
The branching of the arabinan domain in both AG and LAM is mediated by the same 
branching enzyme, AftC (Birch et al., 2010; Birch et al., 2008). However, other 
branching enzymes with α(1→3) Araf transferase activity have been suggested, such as 
AftD. AftD is hypothesised to be responsible for extension of the arabinan core by 
addition α(1→3) Araf  residues to the branched core. The evidence was provided by in 
vitro assays using artificial chemical acceptors and cell-free extracts from M. 
smegmatis and C. glutamicum. These experiments demonstrated that AftD was able to 
add α(1→3) Araf residues to the linear α-1,5-linked neoglycolipid acceptor resulting in 
branching of the linear arabinan core, thus designating itself as a second branching 
enzyme (Skovierova et al., 2009). The branched Ara-motif is further elaborated with 
Araf residues into distinct tetra-arabinoside and hexa-arabinoside motifs. The enzyme 
AftB (Rv3805c) adds the terminal β(1→2) Araf residues to both tetra and hexa-motifs 




The arabinose domains in AG and LAM are highly similar but harbour certain key 
differences; notably in the modification of the terminal Araf residues. Whilst the 
terminal and penultimate residues in the arabinan domain in AG are attached to 
mycolates (Mcneil et al., 1991), the terminal Araf residue in LAM are instead modified 
with α-mannose units in all pathogenic strains of mycobacteria. Additionally, LAM 
consists of both tetra-arabinoside and hexa-arabinoside motifs in contrast to AG, where 
the highly branched arabinan domain terminates in hexa-arabinoside motifs (Daffe et 
al., 1990) The mannose capped LAM in pathogenic strains of mycobacteria are 
referred to as Man-LAM and consist of one, two or three Manp residues with di-
mannose cap being the most abundant (Chatterjee et al., 1992; Chatterjee et al., 1993). 
Synthesis of mannose caps is mediated in a two step-reaction catalysed by two distinct 
mannosyltansferases CapA (Rv1635c) and MptC (Rv2181) (Dinadayala et al., 2006) 
(Kaur et al., 2008) with α(1→2) mannosyltransferase activity (Figure 1.24). The GT-C 
enzyme CapA (Rv1635c) recognises the fully synthesised arabinan domain and 
catalyses the addition of the first Manp residue, while elongation of the cap with a 





1.4.6 Decaprenyl phosphate 
The poly-prenylphosphates, carriers for activated sugars, are the most important lipid 
molecules involved in cell wall biosynthesis. Since they are larger, these molecules are 
less abundant and their availability in cellular processes is limited. Of all the 
intracellular polyprenols, ω,di-E-poly-Z-undecaprenyl phosphate is the principal 
molecule in all bacterial species except M. tuberculosis and M. smegmatis, where ω,E-
poly-Z-decaprenyl phosphate is predominant (Crick et al., 2000). In case of M. 
tuberculosis, a single polyprenol pool is responsible for generating the carriers for 
activated sugars while in M. smegmatis, heptaprenyl diphosphate and decaprenyl 
diphosphate form the polyprenol pool (Crick et al., 2000).  
 
Figure 1.24: Biosynthesis of LM and LAM. Extensive glycosylation of  AcPIM4 generates 
LM and LAM. The mannan core is synthesised by GT-C superfamily mannosyltransferases 
MptB, MptA and MptC which utilise PPM as the mannose donor. The arabinan domain in 
LAM is synthesised by addition of 55-70 arabinose residues to LM by EmbC, AftC, AftD 
and an unknown transferase. The enzymes, MptC and CapA, synthesise the mannose cap in 
M. tuberculosis. –Adapted from Grover S. and Jankute M. et. al., Genetics of 
Arabinogalactan and Lipoarabinomannan, Molecular Genetics of Mycobacteria, 2
nd




Although the major steps of the decaprenyl diphosphate biosynthesis have been 
elucidated, much of the information is still unknown. In mycobacteria, synthesis of 
polyprenylphosphate is initiated by sequential condensation of isopentenyl phosphate 
(IPP) with allylic prenyl diphosphates to generate longer allylic diphosphates. The 
condensation reactions are catalysed by prenyl diphosphate synthases, which are 
specific for E/Z type of stereochemistry of the allylic double bond. The allylic 
diphosphates thus generated are dephosphorylated to give the appropriate polyprenol 
phosphates. The genes Rv1086 and Rv2361c encode the enzymes, E,Z-Farensyl-
pyrophposphate (FPP) synthase and decaprenyl pyrophosphate synthase, respectively 
(Kaur et al., 2004; Schulbach et al., 2001). The first step of the pathway is the 
condensation of dimethyl allylic pyrophosphate (DMAPP) with isopentenyl 
pyrophosphate (IPP) to generate geranyl pyrophosphate (GPP). This reaction is 
catalysed by a previously unknown GPP synthase. However, a recent study employing 
purified Rv0989 for biochemical assays demonstrated that Rv0989 could efficiently 
condense IPP and DMAPP to generate FPP thus identifying Rv0989 as the ‘missing 
GPP synthase’(Mann et al., 2011). In addition, the enzyme could also afford moderate 
quantities of FPP from GPP indicating non-specificity of substrates for these 
prenyltransferases. The condensation of GPP with IPP by FPP synthase to yeild ω-E,E-
FPP, is considered as the first committed step in the pathway. Subsequent 
condensation of seven IPP units with FPP, catalysed by decaprenyl phosphate synthase 
yields decaprenyl pyrophosphate as the ultimate product. The enzyme decaprenyl 
diphosphatase encoded by Rv2136c, dephosphorylates decaprenyl pyrophosphate to 
generate decaprenyl phosphate, which is channelled for PG, AG and LAM 




1.4.7 Mycolic acids  
Attached to the non reducing terminus in AG are the long chain α-alkyl, β-hydroxy 
fatty acids (Asselineau and Lederer, 1950), which are 70-90 carbon atoms in length in 
mycobacteria (Goodfellow and Minnikin, 1981) and referred to as mycolic acids. 
However, in Corynebacteria, these mycolic acids are shorter, upto 22-38 carbons in 
length and are referred to as corynomycolic acids (Collins et al., 1982a; b; Puech et al., 
2001). Mycolic acids form the major bulk of the mycobacterial cell envelope and also 
impart resistance to common anti-mycobacterial agents. The general structure of 
mycolates includes a meromycolate chain of up to 56-carbon atoms and a saturated α-
side chain, which is C24-C26 in length.  
 
The cell wall of mycobacteria comprises of three predominant types of mycolates, 
which differ from each other in the modifications of the fatty acyl chains. These 
include: non-oxygenated version containing two cyclopropane rings termed -
mycolates (Minnikin et al., 1982; Qureshi et al., 1978; Yuan et al., 1995), 
methoxymycolates that are oxygenated with –OCH3 groups and contain a single 
cyclopropane ring (George et al., 1995), and the keto-mycolates that are oxygenated 
with a keto group and contain a single cyclopropane ring (George et al., 1995). Whilst 
the majority of the mycolates are complexed with AG, free mycolates are prevalent in 
the outer layer of cell wall. These mycolates are glycosylated with either glucose or 
trehalose and are solvent extractable (Asselineau and Lederer, 1950; Minnikin et al., 
2002; Minnikin et al., 1982). Trehalose esterified to a single mycolic acid residue is 
referred to as trehalose monomycolate (TMM) and to two mycolates as trehalose 
dimycolate (TDM), whilst a mycolate with esterified glucose is known as glucose 
monomycolate (GMM). The ‘cord factor’ in mycobacteria is TDM, which is only 
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present on the outer surface of mycobacteria and mediates the host immune response 
(Noll and Bloch, 1953; Noll et al., 1956). 
 
Synthesis of TDM is linked to TMM as TMM is first dephosphorylated and then 
transported to the periplasm with the aid of unknown mycolate transporters where it is 
further mycolated by three mycolyltransferases Ag85A, Ag85B and Ag85C to generate 
TDM (Belisle et al., 1997). Biosynthesis of mycolic acids in mycobacteria is mediated 
by two multi-enzyme proteins FAS-I encoded by a single gene fas (Rv2524c) and FAS-
II which consists of several enzymes including InhA, the primary target of INH 
(Marrakchi et al., 2000), KasA, KasB, FabG1 and HadABC. FAS-I is common to 
eukaryotes, whilst FAS-II is found in bacteria. However, mycobacteria are an eeption 
as they harbour both FAS-I and FAS-II (Dover et al., 2004). The two systems are 
linked via the enzyme mtFabH, a β-ketoacyl-ACP synthase III encoded by Rv0533c 
(Choi et al., 2000) that channels acyl-CoA derivatives generated by FAS-I for 
condensation with the malonyl-acyl carrier protein-(AcpM) (Rv2244) to synthesise 
thioesters which are then directed to FAS-II for extension (Dover et al., 2004; 
Scarsdale et al., 2001). The enzymes KasA and KasB in FAS-II initially extend these 
thioesters by condensing them with malonyl-AcpM and the FAS-II cycle is completed 
by FabG1, HadABC and InhA (Kremer et al., 2002a; Schaeffer et al., 2001). The 
shorter mycolic acid chains in the corynebacterial counterparts are due to the absence 




1.5  Aims  
The primary objective of this thesis was to determine new targets for TB drug 
development and explore novel mechanisms for resistance in mycobacteria. In 
addition, this work also tested new strategies that can be implemented for effective 
targeting by anti-tubercular compounds. The pathway for LAM biosynthesis formed 
the nerve center of the study.  
The first chapter of this thesis focuses on the pathway for decaprenyl phosphate 
recycling and its role in imparting resistance to the recently discovered class of anti-
tubercular compounds, Benzothiazinones. Since benzathiazinones stall the synthesis of 
arabinose donor, DPA, which is involved in production of arabinan domains in cell 
wall components LAM and AG, these components were thoroughly analysed. To 
investigate the role of decaprenyl phosphate recycling in imparting resistance to the 
drug, the gene Z-prenyl diphosphate synthase was over-expressed and the effect of 
drug was re-examined on the cell wall components. This study was performed using C. 
glutamicum as the model organism. 
The second chapter describes the regulation of mycothiol and phosphatidyl inositol 
based lipoglycan biosynthesis by the newly identified transcriptional regulator, IpsA. 
For this purpose, an ipsA deletion mutant was constructed in C. glutamicum and its 
function was characterised using genetic complementation and cell wall analysis.  
The new approaches for design of therapeutic compounds such as ‘co-targeting of 
interacting proteins’ and ‘polar hydrophobicity in design of enzyme inhibitors’ were 
tested in chapter 3 and 4. The ‘co-targeting’ approach, as described in Chapter 3 
focused on identifying interacting partners from the proteins involved in LAM 
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biosynthesis. An E. coli based two-hybrid system was utilised for this purpose. These 
interacting partners could serve as attractive targets for future drug development. 
In Chapter 4, substrate analogues with strategically replaced fluorine atoms in the sugar 
ring were tested for their ability to inhibit the function of glycosyltransferases. The 
activity of these analogues was tested in vitro using the membrane preprations from M. 
smegmatis that served as the source of glycosyltransferases. 
 










2 Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl 
phosphate recycling involved in cell wall biosynthesis 
 
2.1 Introduction  
The nitro-based sulphur containing benzothiazinones are a new class of highly potent 
anti-TB drug candidates that display very low MICs for both pathogenic, slow growing 
M. tuberculosis H37Rv (1 ng/mL) and for non pathogenic, fast-growing 
Mycobacterium species, such as M. smegmatis (4 ng/mL) (Makarov et al., 2009). In 
addition, BTZs exhibit very high efficacy against both sensitive and drug resistant TB 
strains (Pasca et al., 2010). The whole genome sequencing studies of M. smegmatis, M. 
bovis (BCG), and M. tuberculosis mutants with high resistance to BTZ revealed DprE1 
(Rv3790), which is a FAD-containing oxidoreductase as the target, which was further 
validated using biochemical studies (Manina et al., 2010; Trefzer et al., 2010). The 
enzyme DprE1 functions in concert with a NADH-dependent reductase DprE2 
(Rv3791) to catalyse the epimerisation of decaprenylphosphoryl-D-ribose (DPR) to 
decaprenylphosphoryl-D-arabinose (DPA) (Makarov et al., 2009; Mikusova et al., 
2005). DPR is first oxidised to a keto intermediate, DPX via DprE1 and then reduced 
to DPA by DprE2.  
BTZs are said to function in a similar manner to EMB as they both target the same 
pathway responsible for the synthesis of cell wall components, LAM and AG 
(Makarov et al., 2009). Whilst EMB targets the embCAB encoded arabinofuranosyl 
transferases that utilises DPA as the sole arabinose donor, BTZs surpress the synthesis 
of this donor, thus inhibiting the formation of LAM and AG that are crucial for 
maintaining cellular integrity. However, BTZ is different to EMB in terms of potency 
as it displays a 1000-fold more activity against M. tuberculosis (Makarov et al., 2009).
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Since BTZs target the generation of DPA, a crucial metabolic intermediate, the oxido-
reductase DprE1/E2 responsible for its synthesis has been tested for essentiality in 
several species of Corynebacterineae. Attempts to knock-out or knock-down the 
chromosomal copy of dprE1 in M. smegmatis (MSMEG_6382) and its C. glutamicum 
orthologue (NCgl0187) have been successful only in presence of a plasmid-encoded 
copy (Crellin et al., 2011; Meniche et al., 2008). Interestingly, the DPPR phosphatase 
(Rv3807c) , which catalyses dephosphorylation of DPPR to yield the DprE1 substrate 
DPR is not essential in M. tuberculosis (Sassetti et al., 2003) and redundancy is 
observed for DprE2 in both M. smegmatis and C. glutamicum (Crellin et al., 2011; 
Meniche et al., 2008). These experiments illustrate that the production of DPA and its 
utilisation in arabinan biosynthesis are a pre-requisite for formation of a complete cell 
wall in Corynebacterineae (Wolucka, 2008).  
 
The two-step process for generation of DPR utilises a ribosyltransferase UbiA that 
condenses pRPP with decaprenyl phosphate to yield DPPR, a phosphatase (Rv3807) 
subsequently dephosphorylates DPPR to afford DPR. Since UbiA catalyses the first 
committed step in this pathway, its activity should thus be critical for survival. 
However, inactivation of ubiA in C. glutamicum produced a viable mutant devoid of 
cell wall arabinan. As expected, this mutant had lost its ability to synthesise DPA, an 
otherwise important metabolite suggesting that neither DPA production nor synthesis 
of cell wall arabinan are required for viability of C. glutamicum (Alderwick et al., 
2005; Tatituri et al., 2007). These contrasting findings established a paradigm that even 
though BTZs target DprE1 and block DPA biosynthesis, the action of the drug is 
insufficient to cause a lethal effect on the bacilli. Therefore, to deduce an alternative 
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explanation for BTZ’s lethal action, we examined the biochemical effects of BTZ 
inhibition on C. glutamicum and the DPA deficient strain, C. glutamicum::ubiA. 
The data revealed that BTZ clearly inhibits growth and DPA production in wild type  
C. glutamicum but fails to have any deleterious effects on the Cg-UbiA mutant with a 
functional DprE1. Additionally, the effect of BTZ was also examined on growth and 
cell wall arabinan biosynthesis by over-expressing C. glutamicum Z-decaprenyl 
diphosphate synthase, encoded by NCgl2203 (UppS) in C. glutamicum. The results 
demonstrated that over-expression of UppS could rescue the wild type strain (BTZ 
MIC 20 µg/mL) and shift its MIC to >40 µg/mL and restore arabinan biosynthesis that 
is otherwise blocked by BTZ treatment. Therefore, our results suggest that BTZ causes 
a lethal effect by blocking the recycling of decaprenyl phosphate as in its presence; the 
cell continually synthesises DPR, a toxic intermediate that renders decaprenyl 
phosphate unavailable for other macromolecules, such as peptidoglycan, LAM and 
AG. However, the over-expression of a prenylsynthase supplements enough decaprenyl 




2.2 Material and Methods 
2.2.1 Bacterial strains and growth conditions 
E. coli Top 10 cells were cultured in Luria-Bertani broth (LB, Difco) at 37°C. C. 
glutamicum ATCC 13032, C. glutamicum-pVWEx2 and C. glutamicum-pVWEx2-
uppS (10 µg/mL tetracycline) was grown on rich Brain Heart Infusion medium (BHI, 
Difco) and C. glutamicum::ubiA (25 µg/mL kanamycin) on BHI containing 9.1% 
sorbitol (BHIS) supplemented with appropriate antibiotics for selection.  
 
2.2.2 Construction of plasmids and strains 
C. glutamicum-uppS (NCgl2203) was amplified from genomic DNA using the primers, 
2203vwex_Fwd: 5' GCATGTCTAGAAGGAGATATAGATGTGAGTGAATTCCA 
AGTA 3' and 2203vwex_Rev 5' ATTAGGATCCTTATGCGCTTCCGAATCTGCG 3' 
(restriction sites underlined) and cloned in pVWEx2 under the isopropyl-β-D-
thiogalactopyranoside (IPTG) inducible Ptac promoter. The vector and PCR product 
were digested using XbaI and BamHI and ligated to generate the C. glutamicum-
pVWEx2-uppS construct. The pVWEx2-uppS plasmid thus obtained was confirmed by 
sequencing by Eurofins MWG Operon. The C. glutamicum::ubiA strain was obtained 
as described previously (Tatituri et al., 2007). The empty pVWEx2 and pVWEx2-uppS 
plasmids were electroporated into C. glutamicum using a standard protocol as shown in 
General Materials and Methods, section 7.3.8 and 7.3.9. 
 
2.2.3 Expression of UppS in C. glutamicum 
Overnight cultures (5 mL BHI containing tetracycline) of selected C. glutamicum-
pVWEx2-uppS colonies were used to inoculate 50 mL BHIS with 10 µg/mL 
tetracycline (30°C, 180 rpm). The cultures were induced with 0.5 mM IPTG at OD600 
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0.6 and incubated at 30°C for 24 hours. Cells were harvested (7000 x g, 15 minutes), 
washed twice with phosphate buffered saline and resuspended in lysis buffer (50 mM 
MOPS (pH 7.9), 0.2 mg/mL lysozyme). The resuspended cell pellets were incubated at 
37°C for 1 hour to allow cell lysis. The suspension was centrifuged (27000 x g, 20 
minutes) and supernatant was checked for presence of protein on 12 % SDS PAGE gel. 
 
2.2.4 Effect of BTZ043 on growth and viability of C. glutamicum strains 
To determine the MIC of BTZ043 for C. glutamicum and C. glutamicum pVWEx2, 
approximately 10
8
 cells were used to inoculate 2 mL of BHI broth containing 0 to 20 
µg/mL BTZ043 in a step-wise gradient and the OD600 was measured up to 48 hours. To 
determine the effect of increasing concentrations of BTZ043 on growth of C. 
glutamicum::ubiA and C.glutamicum-pVWEx2-uppS, approximately 10
8
 cells were 
used (30°C, BHIS, 200 rpm) to inoculate 2 mL BHIS containing 0 and 20 µg/mL 
BTZ043 and the OD600 was measured up to 48 hours. The cultures were also grown for 
48  hours as above and the viability count was determined by spotting 10 µL of serially 
diluted cultures (up to dilution 10
-8
) on BHIS plates for C. glutamicum::ubiA and BHI 
plates C.glutamicum-pVWEx2-uppS. The MIC was defined as the minimal 




2.2.5 Effect of BTZ043 on DPA synthesis in C. glutamicum strains 
To characterise the effect of BTZ043 on DprE1, p[
14
C]Rpp was synthesised as 
described in General Material and Methods, section 7.4.7 and supplemented as a 
substrate for the in vitro synthesis of DPA. Accumulation of DPR in the presence of 
BTZ043 was chosen as a parameter to monitor the effect of BTZ043. Cell membranes 
from C. glutamicum and C. glutamicum::ubiA were prepared as described in the 
General Materials and Methods, section 7.4.6 and assayed for DPA biosynthesis 
(Pathak et al., 2002).  
 
Briefly, decaprenyl phosphate (50 µg, 5 mg/mL stored in ethanol, 1 µL) was dried 
under nitrogen and was resuspended in buffer A (50 mM MOPS, 10 mM MgCl2 pH 
8.0). The mixture was sonicated until a colloidal suspension was visible. The basic 
assay mix consisted of 400 µg of membranes and a P60 fraction (Besra et al., 1997), 25 
mM ATP, 25 mM FAD, 25 mM NAD and 25 mM NADP, BTZ043 (stock  
concentration 20 µg/mL in DMSO) in a final volume of 55 µL of buffer A and initiated 
by the addition of p[
14
C]Rpp (65,000 cpm), as described in the General Materials and 
Methods section 7.4.7. The reactions were incubated at 30°C for 1 hour and quenched 
by the addition of 110 µL of chloroform/methanol (1:1, v/v) and 55 µL of water, mixed 
for 15 minutes on a rotating mixer. The assay mixture was then centrifuged at 26,000 x 
g for 10 minutes and the lower organic phase was recovered and dried under nitrogen. 
The resulting products were resuspended in 20 µL of chloroform/methanol (2:1, v/v) 
and an aliquot was subjected to scintillation counting using 5 mL scintillation fluid, 
and a second aliquot was subjected to TLC analysis using silica gel plates (5735 silica 
gel 60F254, Merck) developed in chloroform/methanol/water/ammonium 
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hydroxide/ammonium acetate (180:140:23:9:9 v/v/v/v/v) and visualised by phosphor 
imaging by exposing the TLCs to a phosphor imaging screen (Kodak) for 24 hours. 
 
2.2.6 Function of DprE1 in C. glutamicum and C. glutamicum::ubiA  
To characterise the effect of BTZ043 on DprE1, DP[
14
C]R was supplemented as a 
substrate for the in vitro synthesis of DP[
14
C]A (Scherman et al., 1996). Cell 
membranes from C. glutamicum and C. glutamicum::ubiA were assayed for DPA 
biosynthesis activity using p[
14
C]Rpp as a substrate by previously described protocol 
(section 2.2.5). For estimating the activity of DprE1 in C. glutamicum::ubiA, reactions 
were initiated with DP[
14
C]R that was prepared using p[
14
C]Rpp with a few 
modifications to the protocol. To prepare DP[
14
C]R, the reactions were supplemented 
with decaprenyl phosphate, buffer A containing all the co-factors, 400 µg membranes 
and P60, which was pre-incubated with BTZ043 and initiated by addition of p[
14
C]Rpp 
(65,000 cpm). The resulting DP[
14
C]R was extracted using 110 uL of 2:1 
chloroform/MeOH and 55 µL water. The lower organic phase was recovered by 
centrifugation (26,000 x g, 10 minutes), transferred to a fresh tube and dried under a 
stream of nitrogen. The assay products were resuspended in 20 µL of 
chloroform/methanol (2:1, v/v) and an aliquot was subjected to TLC analysis using 
silica gel plates (5735 silica gel 60F254, Merck) developed in 
chloroform/methanol/water/ammonium hydroxide/ammonium acetate (180:140:23:9:9 
v/v/v/v/v) and visualised by autoradiography by exposure of TLCs to X-ray film 




C]R was used as a substrate for determining the functionality of DprE1 in C. 





(20,000 cpm) dried and resuspended in buffer A, 500 µg membranes and P60 fraction, 
co-factor mix and BTZ043 (20 µg/mL in DMSO) in a final volume of 55 µL of Buffer 
A. The extractions were performed using the previously mentioned protocol (section 
2.2.5). The recovered organic phase was dried and resuspended in 20 µL of 
chloroform/methanol (2:1, v/v). Equal counts (10,000 cpm) from these extracts were 
subjected to TLC analysis using silica gel plates (5735 silica gel 60F254, Merck) 
developed in chloroform/methanol/water/ammonium hydroxide/ammonium acetate 
(180:140:23:9:9 v/v/v/v/v) and visualised by phosphor imaging by exposing the TLCs 
to a phosphor screen (Kodak) for 24 hours. 
 
2.2.7 Estimation of decaprenyl phosphate synthesis in C. glutamicum-
pVWEx2-uppS 
To characterise the effect of over-expression of the C. glutamicum decaprenyl 
phosphate synthase (UppS) on decaprenyl phosphate synthesis, the reactions were 
supplemented with [4-
14
C]-isopentenyl pyrophosphate (IPP) triammonium salt (40-60 
mCi/mmol, PerkinElmer Inc.) as a substrate. Cell membranes from C. glutamicum-
pVWEx2 and C. glutamicum-pVWEx2-uppS were prepared as described in the General 
Materials and Methods, section 7.4.6 and assayed for decaprenyl phosphate synthesis 
activity. 
 
For the reactions, the substrate [
14
C]IPP (30 µM stored in ethanol) was dried and 
resuspended in appropriate volume of buffer A (50 mM MOPS, 10 mM MgCl2 pH 8.0) 
and supplemented with 400 µg of membranes, 100 µM geranyl diphosphate (GPP, 1 
mg/mL in methanol), 100 µM dimethyl allyl diphosphate (DMAPP, 1 mg/mL in 
methanol) as primers and BTZ043 (20 µg/mL in DMSO), where required in a final 
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volume of 80 µL of buffer A. The reactions were incubated at 30°C for 1 hour and 
quenched by the addition of 1 mL of water saturated NaCl. The mixture was 
partitioned into an aqueous and organic phase by adding 1 mL of butanol saturated 
with water. The lower organic phase of butanol was recovered and the process was 
repeated twice. The butanol fraction was dried under nitrogen and resuspended in 1mL 
0.1 N HCl in 50% ethanol. Mild acid hydrolysis was performed by incubating the 
suspension at 37°C for 12 hours. To recover the radiolabeled dephosphorylated 
products, equal volume of chloroform was added to the hydrolysed fraction and mixed 
on the rotator for 15 minutes. The lower organic phase containing the 
dephosphorylated products were recovered and washed twice with water. The organic 
phase was recovered, dried and resuspended in 20 µL of chloroform/methanol (2:1, 
v/v). An aliquot was taken for liquid scintillation counting and equal counts (20,000 
cpm) were subjected to TLC analysis using reverse phase silica gel plates (silica gel 60 
RP-18 F254S, Merck) developed in methanol/acetone (8:2, v/v) and visualised by 
autoradiography by exposing the TLCs to X-ray film (Kodak X-omat) for 24 hours.  
 
For product analysis and comparision, known standards were spotted on a separate 
reverse phase silica gel plate (silica gel 60 RP-18 F254S, Merck) developed in 
methanol/acetone (8:2, v/v), stained with ethanolic molybdophosphoric acid and heated 
gently using a heat-gun. Densitometric analysis was performed by scanning the 
autoradiogram in Bio-Rad GS-800 imaging densitometer and spots were quantified 





2.2.8 Analysis of AG and LAM biosynthesis in C. glutamicum-pVWEx2 and 
C. glutamicum-pVWEx2-uppS treated with BTZ043 
To analyse the effect of over-expression of decaprenyl phosphate synthase on the cell 
wall component AG in C. glutamicum, overnight cultures of C. glutamicum-pVWEx2 
and C. glutamicum-pVWEx2-uppS were used to sub-culture 20 mL of BHI media and 
grown to OD600 0.4-0.6 (30ºC, 200 rpm, 4-5 hours), induced with 0.5 mM IPTG and 
split into two separate cultures of equal volume (10 mL each). To monitor the effect of 
the drug on arabinose incorporation in AG, one half of the culture was treated with 
BTZ043 at 0.75 x MIC (15 µg/mL) for 2 hours (30°C, 200 rpm). Both treated and 
untreated cultures were labelled with 1.0 µCi/mL of [
14
C]-glucose (250-360 
mCi/mmol, PerkinElmer Inc.) and grown for 48 hours (30°C, 200 rpm). The mAGP 
complex was isolated and sugar hydrolysis was performed on all the samples using the 
protocols described in General Materials and Methods, section 7.4.3 and 7.4.4. The 
radioactive sugar samples were analysed by loading equal counts (20,000 cpm) on 
aluminium backed HPTLC-cellulose plates (Merck) developed thrice in formic 
acid/water/tertiary-butanol/methylethyl ketone (3:3:8:6) and visualised by 
autoradiography by exposing the TLC to X-ray film (Kodak X-omat) for 4 days.  
 
To analyse the effect of over-expression of decaprenyl phosphate synthase on the cell 
wall component LAM/LM in C. glutamicum, overnight cultures of C. glutamicum-
pVWEx2 and C. glutamicum-pVWEx2-uppS were used to sub-culture 40 mL of BHI 
media and grown to OD600 0.4-0.6 (30ºC, 200 rpm, 4-5 hours). The cultures were 
induced with 0.5 mM IPTG and labelled with 1.0 µCi/mL of [
14
C]-glucose (250-360 
mCi/mmol, PerkinElmer Inc.) and grown for 1 hour (30°C, 200 rpm) to allow its 
incorporation in cell wall. The effect of drug on LAM biogenesis was analysed in a 
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time dependant manner. At time 0 hour, the culture was split into 5 mL aliquots and 
BTZ043 (20 µg/mL) was introduced into half of the aliquots to afford treated and 
untreated cultures. The cultures were then sampled every 2 hours by taking 5mL 
aliquots, centrifuged and snap frozen using liquid nitrogen. The components LAM/LM 
were extracted from all the samples using previously described protocols as mentioned 
in the General Materials and Methods, section 7.4.5. The [
14
C]LAM/LM samples were 
analysed by loading equal counts (3000 cpm) on 12% SDS-PAGE gels and visualised 
by autoradiography by exposing the gels to X-ray film (Kodak X-omat) for 14 days.  
 
2.3 Results  
 
2.3.1 Effect of benzothiazinone on C. glutamicum wild type and C. 
glutamicum::ubiA 
The lead compound of the BTZ series BTZ043 targets DprE1, a FAD-containing 
oxidoreductase that is highly conserved across the Corynebacterineae (Batt et al., 
2012). The amino acid sequences of MTB DprE1 (Rv3790) and its orthologue in C. 
glutamicum (NCgl0187) when aligned display 65% identity (Meniche et al., 2008) and 
a remarkable conservation of the active site residues, including Cys414, which 
corresponds to Cys387 in Mt-DprE1. The Cys387 residue in Mt-DprE1 forms a 
covalent semimercaptal linkage with the activated nitroso-group of BTZ043 which 
inactivates the enzyme (Manina et al., 2010; Trefzer et al., 2010; Trefzer et al., 2012).  
In this study, we have attempted to analyse the effect of BTZ043 on the synthesis of 
cell wall components using C. glutamicum as a model system. C. glutamicum has 
extensively been used in our previous studies to understand the molecular genetics of 
mycobacterial cell wall biosynthesis (Mishra et al., 2007; Mishra et al., 2009; Tatituri 
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et al., 2007). Both. C. glutamicum  and M. tuberculosis are members of the same 
family Corynebacterineae with similar cell wall ultra-structure and biosynthetic 
machinery (Dover et al., 2004). However, the faster growth rate, lesser complexity, 
ease of genetic manipulation and ability to tolerate mutations better than other 
mycobacterial species makes C. glutamicum an excellent model to study the function 
of otherwise essential genes in mycobacteria. (Cerdeno-Tarraga et al., 2003; Seidel et 
al., 2007b).  
The drug BTZ043 stalls arabinan biosynthesis by targeting DprE1 and leads to 
production of arabinose deficient cell wall components. The effect produced by 
BTZ043 is functionally equivalent to the phenotype exhibited by C. glutamicum::ubiA, 
as the strain is completely devoid of arabinan in its cell wall. Therefore, to establish 
this equivalency and determine the effect of BTZ043, we cultured C. glutamicum (wild 
type) and C. glutamicum::ubiA in liquid media over a 48 hour period and examined 
their susceptibility to BTZ043 at a range of concentrations. The MIC of BTZ043 for C. 












Figure 2.1: Effect of BTZ043 on growth of C. glutamicum ATCC 13032. The wild type 
C. glutamicum was tested for susceptibility to BTZ043 in liquid media at a range of 
concentrations (0, 1, 4, 10, 20 µg/mL). The maximum inhibition in growth (99%) was 
observed at [BTZ043] of 20 µg/mL and was chosen as the MIC for C. glutamicum. The 
data is representative of two separate experiments.  
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The C. glutamicum::ubiA strain was inherently slow-growing, and the effect of 
BTZ043 was tested on the growth rate of C. glutamicum::ubiA at the concentration that 
corresponds to the MIC (Figure 2.2) of the wild type strain. The results demonstrate 
that the arabinan deficient mutant is resistant to BTZ043 as no change was observed in 














Figure 2.2: C. glutamicum::ubiA is resistant to BTZ043. C. glutamicum::ubiA was 
examined for its susceptibility to BTZ043 in liquid media at a final concentration of 20 
µg/mL (MIC for C. glutamicum). The data is representative of two separate experiments. 
 
The growth rate of C. glutamicum::ubiA mutant was also compared to that of wild type 
at different concentrations of BTZ043 (Figure 2.3). In comparison to wildtype, C. 
glutamicum::ubiA is a slow growing strain (Figure 2.3A) with an approximately five-
fold lesser growth rate. When BTZ043 is added at concentrations of 1 µg/mL (Figure 
2.3B), 4 µg/mL (Figure 2.3C), 10 µg/mL (Figure 2.3D) and at 20 µg/mL (Figure 2.3E), 
a shift in the growth rate is observed for wild type. An increase in drug concentration 
causes a sharp decrease in growth for the wild type and completely inhibits the strain at 
MIC whereas the growth of C. glutamicum::ubiA remains unaffected at all 





Figure 2.3: Comparison of growth rate and susceptibility to BTZ043 of C. glutamicum 
wild type and C. glutamicum::ubiA. A. C. glutamicum::ubiA is a slow growing strain in 
comparison to wild type. A decrease in growth rate of C. glutamicum wild type was observed 
for concentrations B. 1 µg/mL, C. 4 µg/mL, D. 10 µg/mL until the growth completely stalled at 
E. 20 µg/mL. The data is representative of two separate experiments. 
 
Since OD600 is a measure of both viable and non-viable cells, cell viability assays were 
performed for C. glutamicum and C. glutamicum::ubiA against increasing 
concentrations of BTZ043 to estimate the viable population for each strain (Figure 
2.4). The results demonstrate that BTZ043 elicits a 1000-fold decrease in cell viability 
against C. glutamicum in comparison to C. glutamicum::ubiA with no observable effect 
on cell viability. Therefore, C. glutamicum::ubiA was determined to be resistant to 


















Figure 2.4: Effect of BTZ043 on of viability of C. glutamicum and C. glutamicum::ubiA. 
The cell viability of C. glutamicum and C. glutamicum::ubiA was tested at a range of BTZ043 




 cells on BHI 
agar plates incubated at 30°C for 48 hours after treatment with 20 µg/mL BTZ043. The data is 
representative of three biological replicates.  
 
2.3.2 BTZ043 inhibits DPA synthesis in C. glutamicum and C. 
glutamicum::ubiA with a functional DprE1 
The C. glutamicum::ubiA though defective in DPA biosynthesis retains a functional 
copy of the BTZ target, DprE1. To biochemically evaluate the effect of BTZ043 on 
DprE1, membrane extracts were prepared from C. glutamicum and C. 
glutamicum::ubiA and were examined for their ability to generate DPA in absence and 
presence of BTZ043. In the initial experiments, p[
14
C]Rpp was supplemented as an 







C]A. The reaction products were analysed using thin-layer chromatography 
(TLC) followed by phosphorimaging (Figure 2.5). Analysis of the radiolabelled 
products by TLC clearly demonstrates that C. glutamicum is able to utilise p[
14
C]Rpp 
as a substrate and synthesise DP[
14
C]A (Figure 2.5, lane 3). However, this conversion 
to DP[
14
C]A is inhibited when reaction mixtures are incubated with BTZ043, affording 
only DP[
14
C]R (Figure 2.5, lane 2). As expected, no [
14
C]-products were evident when 
reactions were carried out using membranes prepared from C. glutamiucm::ubiA either 
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in the absence or presence of BTZ043 (Figure 2.5, lane 4 and 5). This inability of C. 
glutamiucm::ubiA to synthesise DPR/DPA is attributed to the absence of 
decaprenylphosphoryl-5-phosphor-β-D-ribose synthase UbiA, that is required for 
transfer of ribose-5-phosphate from p[
14
C]Rpp to decaprenyl phosphate, and marks the 





Figure 2.5: C. glutamicum::ubiA is deficient in DPA synthesis. Membrane and “P60” 
extracts prepared from C. glutamicum (WT) and C. glutamicum::ubiA (WT::ubiA) were 




C]Rpp in the absence and presence 
of BTZ043 (20 µg/mL). Preparations from C. glutamicum were capable of synthesising 
DP[
14
C]A (lane 3) and inhibited in assays that included BTZ043 (lane 2). No [
14
C]-products 
were apparent in preparations from C. glutamicum::ubiA (lane 4 and 5).  
 
The strains C. glutamicum and C. glutamicum::ubiA were biochemically examined for 
their endogenous DprE1 activity by exogenously supplying DP[
14
C]R as a substrate in 
the absence and presence of BTZ043. Extracted reaction products were separated by 
TLC and analysed by phosphorimaging. The results highlight that membrane extracts 
from C. glutamicum and C. glutamicum::ubiA strains are equally capable of 
synthesising DP[
14
C]A (Figure 2.6 lane 2 and 4). However in presence of BTZ043, no 
DP[
14
C]A is produced by either of the strains indicating that both C. glutamicum and 
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C. glutamicum::ubiA express a functional copy of DprE1 that is effectively inhibited by 
BTZ043 (Figure 2.6 lane 3 and 5). 
 
Figure 2.6: DprE1 is effectively inhibited by BTZ043 in C. glutamicum and C. 
glutamicum::ubiA. Membrane and “P60” extracts prepared from C. glutamicum (WT) and 





C]R in the absence and presence of BTZ043 (20 µg/mL). 
Formation of DP[
14
C]A was observed for both the strains in absence of BTZ043 (lane 2 and 
4), whilst complete inhibition was apparent when extracts were supplemented with  BTZ043 
(lane 3 and 5), indicating the presence of a fully functional DprE1 in C. glutamicum::ubiA. 
 
These findings highlight a stark contrast in the ability of BTZ043 to have an effect on 
viability of C. glutamimcum and C. glutamicum::ubiA in liquid media even though the 
target enzyme DprE1 is functionally intact in both the strains. As evident, this synthetic 
viable phenotype is a result of interruption of ubiA that renders C. glutamicum 
insensitive to BTZ043. These results also suggest that DprE1 inhibition by BTZ043 
may not be the sole cause of cell death. 
 
Alternatively, we hypothesise that BTZ043 primarily causes an accumulation of DPR 
in C. glutamicum that subsequently results in a failure by the cell to recycle decaprenyl 
phosphate. Inhibition of decaprenyl phosphate recycling and its limited availability for 
other cellular process severely disrupts growth in Corynebacterianane. The lethal 
effect of BTZ043 is removed in C. glutamicum::ubiA as the strain does not produce 
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DPPR as a precursor to DPR, thus allowing for the recycling of decaprenyl phosphate 
to occur. This recycling is critical for other major cellular processes that employ 
decaprenyl phosphate based donors, such as the peptidoglycan biosynthesis. 
2.3.3 Over-expression of Cg-uppS, a prenylphosphate synthase in C. 
glutamicum 
The protein BLAST search revealed NCgl2203 as the C. glutamicum orthologue of 
MTB Z-decaprenyl diphosphate synthase with 65% identity between the sequences. 
The gene NCgl2203 was amplified, cloned in expression vector pVWEx2 and 
transformed into C. glutamicum wild type. The gene expression was induced by 
0.5mM IPTG and cell pellets were used to prepare membrane and cytosolic fractions. 
The fractions were resolved on 12% SDS-PAGE gels (Figure 2.7). The membrane 
(Lane 3) and cytosol (Lane 4) preparations from C. glutamicum pVWEx2-uppS 
















Figure 2.7: Over-expression of Cg-UppS. NCgl2203 (UppS) was cloned in pVWEx2 and 
over-expressed in C. glutamicum wild type. UppS expression was checked in wild type (Lane 1 
& 2) and in over-expressed strain (Lane 3 & 4). Both membrane (Lane 3) and cytosolic (Lane 
4) of C. glutamicum pVWEx2_uppS showed over-expression of UppS (28.23 kDa).  
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2.3.4 Over-expression of Cg-uppS protects C. glutamicum from inhibition by 
BTZ043 
From the data it is apparent that distribution of decaprenyl phosphate into the pathways 
for DPA and lipid II formation which are employed in AG and peptidoglycan 
biosynthesis is highly equilibrated. To determine the role of decaprenyl phosphate in 
cell wall biosynthesis, decaprenyl phosphate synthase uppS (NCgl2203) was over-
expressed by transforming C. glutamicum with pVWEx2-uppS. Since decaprenyl 
phosphate is synthesised in regulated amounts in a healthy cell, the over-expressed 
strain was examined for any growth defects when compared to wild type (Figure 2.8). 
The over-expressed strain showed growth kinetics akin to wild type and eliminated the 












Figure 2.8: Over-expression of Cg-uppS is non toxic. The growth rates of both C. 
glutamicum and C. glutamicum-pVWEx2-uppS were monitored in BHI liquid media for 48 
hours to check the effect of over-expression. The strains exhibited comparable growth rates 
with no visible harmful effects. The data is representative of three biological replicates. 
 
The growth and viability of both C. glutamicum-pVWEx2 and C. glutamicum-
pVWEx2-uppS was also examined by exposing the strains to BTZ043 at 1 x MIC and 2 
x MIC in liquid media for 48 hours and the end-point readings for optical density 
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(Figure 2.9) and cell viability (Figure 2.10) were measured. As expected, BTZ043 
inhibits the growth of C. glutamicum-pVWEx2 at a concentration of 1 x MIC and 2 x 
MIC. The decaprenyl phosphate over-expressing strain C. glutamicum-pVWEx2-uppS 
on the other hand displayed a significantly increased resistance to BTZ043 with a MIC 














Figure 2.9: Effect of BTZ043 on growth of C. glutamicum-pVWEx2 and C. glutamicum-
pVWEx2-uppS. The growth of C. glutamicum-pVWEx2 and C. glutamicum-pVWEx2-uppS 
was measured in the presence of BTZ043 at 1 x MIC (20 µg/mL) and 2 x MIC (40 µg/mL). 
The optical density (OD600) obtained for C. glutamicum-pVWEx2-uppS was higher than C. 
glutamicum-pVWEx2 at both 1 x MIC and 2 x MIC, indicating increased tolerance to 
BTZ043. The data is representative of three biological replicates. 
 
To estimate the proportion of viable cells for each strain, the cultures were pre-treated 
with BTZ043 at MIC (20 µg/mL) and 2 x MIC (40 µg/mL) incubated for 48 hours, 
serially diluted and spotted on BHI plates with tetracycline (10 µg/mL) and the colony 
forming units were determined. As expected, the viable counts for C. glutamicum-
pVWEx2-uppS were 10
4
-fold higher than C. glutamicum-pVWEx2 at the MIC (20 
µg/mL) and 10
6
 fold higher at 2 x MIC (40 µg/mL) of BTZ043, respectively (Figure 
2.10). These results indicate that Cg-UppS prenylphosphate synthase, when over-




Figure 2.10: Effect of BTZ043 on viability of C. glutamicum-pVWEx2 and C. 
glutamicum-pVWEx2-uppS. Cell viability counts were determined for C. glutamicum-
pVWEx2 and C. glutamicum-pVWEx2-uppS treated with BTZ043 at 1x MIC and 2x MIC 
after plating on BHI agar plates incubated at 30ºC for 48 hours. The data is representative of 
three biological replicates. 
 
2.3.5 UppS over-expression increases decaprenyl phosphate synthesis in C. 
glutamicum 
To biochemically determine the effect of UppS over expression on C. glutamicum, 
membrane and cytosol extracts from C. glutamicum-pVWEx2 and C. glutamicum-
pVWEx2-uppS, were examined for their ability to synthesise decaprenyl phosphate in 
the absence and presence of BTZ043. The isoprenyl pyrophosphate synthases in 
mycobacteria and corynebacteria use allylic diphosphates to generate the decaprenyl 
phosphate lipid carrier. To initiate the pathway, DMAPP functions as an allylic primer 
to which IPP is repeatedly added by these isoprenyl pyrophosphate synthases until a 
prenyl diphosphate of a defined length and stereochemistry is generated. Therefore, to 





C]-IPP) was supplied as an exogenous substrate with membrane and 





phosphate. The products were evaluated using TLC followed by phosphor imaging 
(Figure 2.11). Analysis of the [
14
C]-products by TLC clearly demonstrates that C. 
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glutamicum is able to utilise [
14
C]-IPP and generate [
14
C]-decaprenyl phosphate as the 
product (Figure 2.11). 
 
Densitometric analysis of the bands migrating on the TLC that correspond to 
decaprenyl phosphate was performed for C. glutamicum-pVWEx2 and C. glutamicum-
pVWEx2-uppS. The proportion of counts for [
14
C]-decaprenyl phosphate was 
calculated from a total of 20,000 cpm loaded per reaction as apparent on the TLC and 
from the total cpm value as returned by the assay. The strain C. glutamicum produced 
481±72 cpm/µg protein whlist the amount of [
14
C]-decaprenyl phosphate increased by 
77% (853±16 cpm/µg of protein) when uppS was over-expressed. These results are 
illustrated by an increase in density of the decaprenyl phosphate on the TLC for C. 
glutamicum-pVWEx2-uppS (Figure 2.11). When reactions were performed with 
membrane and cytosol extracts, pre-treated with 20 µg/mL of BTZ043, a reduction in 
the synthesis of the decaprenyl phosphate pool was apparent in wild type C. 
glutamicum-pVWEx2 whilst no significant change could be observed for C. 
glutamicum-pVWEx2-uppS, when compared to assays conducted in the absence of 
BTZ043 (Figure 2.11). To estimate the actual proportion of counts incorporated into 
decaprenyl phosphate per reaction, the fraction of decaprenyl phosphate turn over as 
estimated from the TLC were applied to the total counts recovered for each reaction. 
These estimates highlighted a small, yet significant increase in the synthesis of 
decaprenyl phosphate for BTZ043 treated reactions, which equates to 8% and 10% for 
C. glutamicum-pVWEx2 and C. glutamicum-pVWEx2-uppS, respectively. These 
results suggest that BTZ043 inhibits DprE1 activity and results in a block in DPA 
biosynthesis, which prevents decaprenyl phosphate to be recycled back into the cellular 
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pool. In absence of this recycling, synthesis of other decaprenyl phosphate-linked 




















Figure 2.11. Over-expression of uppS in C. glutamicum elicits an increase in 
decaprenyl phosphate synthesis. Cell free extracts prepared form C. glutamicum-
pVWEx2 (Cg-pVWEx2) and C. glutamicum-pVWEx2-uppS (Cg-pVWEx2-uppS) were 
examined for any increased biosynthesis of decaprenyl phosphate in the presence and 
absence of BTZ043 (20 µg/mL), by supplementing assay mixtures with exogenous 
[
14
C]IPP. Assays were quenched after 1 hour incubation at 30C and reaction products 
were extracted with organic solvent. Equal counts (20,000 cpm) were loaded onto a 
reverse phase silica gel plates (silica gel 60 RP-18 F254S, Merck) developed in 





2.3.6 Over-expression of UppS restores AG biosynthesis in C. glutamicum 
treated with BTZ043 
Since BTZ043 targets DPA biosynthesis, the sole arabinose donor for cell wall 
arabinan synthesis, arabinose containing cell wall components AG and LAM were 
assessed for incorporation of arabinose in the presence of BTZ043 in strains C. 
glutamicum-pVWEx2 and C. glutamicum-pVWEx2-uppS (Figure 2.12). The cultures 
were labelled with [
14
C]-glucose and mAGP complex was prepared from samples 
collected at 48 hours from BTZ043 (15 µg/mL) treated and non-treated cultures. Mild 








estimated after separation by TLC followed by autoradiography. Chromatographic 
analysis show a reduced incorporation of arabinose in AG for C. glutamicum-pVWEx2 
treated with BTZ043. However, no significant changes were observed in the level of 
arabinose being incorporated in C. glutamicum-pVWEx2-uppS upon exposure to 
BTZ043. The TLC analysis of hydrolysed cell wall preparations also showed presence 
of mannose, which we apportion to being an impurity coming from LM and LAM 
contaminants. The galactan levels remain unchanged for both C. glutamicum-pVWEx2 
and C. glutamicum-pVWEx2-uppS either treated or untreated with BTZ043 (Figure 
2.12). Thus, C. glutamicum-pVWEx2-uppS was able to synthesise AG unhindered in 

















Figure 2.12: Effect of BTZ043 on AG biosynthesis in C. glutamicum-pVWEx2 and C. 
glutamicum-pVWEx2-uppS. Radioactive mAGP extracts were prepared from 0.75 x MIC 
BTZ043 (15 µg/mL) treated and untreated cultures of C. glutamicum-pVWEx2 (Cg-pVWEx2) 
and C. glutamicum-pVWEx2-uppS (Cg-pVWEx2-uppS) after 48 hours of treatment and were 
analysed for their sugar content. The [
14
C]-arabinose content decreased in Cg-pVWEx2 
treated with BTZ043 but remained unchanged for Cg-pVWEx2-uppS. 
 
 
2.3.7 Over-expression of UppS restores LAM biosynthesis in C. glutamicum 
treated with BTZ043 
Aside AG, LAM also utilises DPA for synthesis of the arabinan component. The 
strains C. glutamicum-pVWEx2 and C. glutamicum-pVWEx2-uppS were assessed for 
their ability to synthesise LAM in presence of BTZ043 (20 µg/mL) (Figure 2.13). The 
cultures of C. glutamicum-pVWEx2 and C. glutamicum-pVWEx2-uppS were labelled 
with [
14
C]-glucose followed by treatment with BTZ043. The samples were removed 
every 2 hours from BTZ043 treated as well as non-treated cultures and lipoglycan 
extraction was performed. The presence of [
14
C]-LAM was detected in SDS PAGE 
gels by autoradiography (Figure 2.13). The results demonstrate a significant reduction 
over time in LM and LAM synthesis for C. glutamicum-pVWEx2 cultures treated with 
BTZ043 (20 µg/mL), when compared to untreated cultures of C. glutamicum-pVWEx2 
(Figure 2.13 A, B). However, the strain C. glutamicum-pVWEx2-uppS displayed 
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modest levels of LM and LAM when exposed to BTZ043 (20 µg/mL), as shown at 6 
hours when compared to both C. glutamicum-pVWEx2 and C. glutamicum-pVWEx2-
uppS treated with BTZ043 (Figure 2.13 C and D). Thus, C. glutamicum-pVWEx2-uppS 
was able to continually synthesise LAM in the presence of BTZ013 at 2 x MIC. 
 
Figure 2.13: SDS PAGE analysis of lipoglycans extracts from A. C. glutamicum-
pVWEx2 (Cg-pVWEx2), B. Cg-pVWEx2 treated with BTZ043, C. C. glutamicum-
pVWEx2-uppS (Cg-pVWEx2-uppS) and D. Cg-pVWEx2-uppS treated with BTZ043. 
The cultures were grown in liquid media to an OD600 of 0.5 before the addition of 
[
14
C]-glucose and BTZ043 (20 µg/mL). The growth was continued for upto 6 hours 





2.4  Discussion 
Benzothiazinones are newly discovered class of nitro-compounds with very high anti-
tubercular activity (Makarov et al., 2009). The lead compound of this series, BTZ043, 
was shown to target DprE1, a FAD-containing oxidoreductase that catalyses the 
conversion of DPR to DPX (Figure 2.14). The structural basis for DprE1 inhibition was 
recently determined using X-ray crystallography studies of the enzyme DprE1 in 
complex with BTZ043. These studies highlighted the importance of Cys387 residue in 
the active site which is responsible for forming a covalent semimercaptal linkage with 
the nitroso group in BTZ thus providing the basis for suicide inhibition by BTZ (Batt et 
al., 2012; Neres et al., 2012). DprE1 works in conjunction with a NADH-dependant 
reductase DprE2 that reduces DPX to DPA (Mikusova et al., 2005). DPA is the sole 
arabinose donor that is utilised by an array of membrane embedded arabinofuranosyl 
transferases (ArafTs) that are employed for forming the D-arabinan, attached to LM 
and galactan and subsequently generating LAM and AG, respectively. Of the several 
ArafTs found in mycobacteria, EmbA, EmbB and EmbC, that are partly responsible for 
synthesis of the arabinan motif are targets for ethambutol, a front-line drug currently in 
use for TB treatment (Belanger et al., 1996; Telenti et al., 1997). 
 
The high potency of BTZ043 and several other recently discovered unrelated 
compounds that target DprE1 have added onto its druggability factor and designated 
DprE1 as a ‘magic drug target’. Efforts are underway to develop new approaches for 
drug design and to identify other targetable characteristics of this enzyme. Whilst 
unlinking the PG layer from the outer layer of mycolic acids by targeting D-arabinan 
biosynthesis is a credible approach, it still doesn’t justify DprE1 as the ‘Achilles’ heel 
of MTB’. In this study, the enzyme DprE1 was thoroughly evaluated for its 
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susceptibility as a drug target and attempts were made to clarify its ‘highly druggable’ 
status.  
 
The high degree of similarity in cell wall for MTB and C. glutamicum in terms of 
structure, biochemical processes and genetic make-up renders C. glutamicum as an 
excellent model organism for studying the molecular genetics of cell wall biogenesis in 
MTB (Alderwick et al., 2006b; Dover et al., 2004; Minnikin, 1978; Seidel et al., 
2007a; Varela et al., 2012). Several mutants of C. glutamicum defective in cell wall 
arabinan biosynthesis have aided in understanding the processing of DPA. C. 
glutamicum::ubiA is one such mutant that displays an extremely intriguing phenotype 
of a cell wall completely devoid of arabinan and corynomycolates (Alderwick et al., 
2006a; Alderwick et al., 2005; Tatituri et al., 2007). This mutant when tested for its 
susceptibility to BTZ043 displayed no deleterious effects and was resistant to action of 
BTZ043 whilst high bactericidal activity was evident for C. glutamicum (MIC = 20 
µg/mL). This stark contrast in findings questions the very basis of BTZ043 mediated 
killing by blocking D-arabinan biosynthesis in members of Corynebacterineae. To 
investigate the underlying cause of BTZ043 induced lethality, the enzyme UppS, a 
decaprenyl phosphate synthase, was over-expressed in C. glutamicum and its effect on 
bactericidal activity of the drug was monitored. The Cg-UppS over-expressed strain 
demonstrated increased tolerance to BTZ043 (Figure 2.9 and 2.10 ) ensuing upon 
augmented synthesis of decaprenyl phosphate which is required primarily for the 
production of lipid II, an essential intermediate involved in PG biosynthesis. These 
findings form the basis of an alternative hypothesis for BTZ’s mechanism of action and 
suggest acute toxicity due to DPR accumulation and consequent halting of decaprenyl 
phosphate recycling as the primary cause for death (Figure 2.14). Accumulation of 
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DPR in cell membrane represents a metabolic ‘dead end’ in pathway for cell wall 
biogenesis. This data is in accordance with our previous observations that although C. 
glutamicum has a cell wall with enough plasticity to dispense with D-arabinan, it still 
requires PG to protect against the internal osmotic stress across the cytoplasmic 
membrane (Moker et al., 2004; Radmacher et al., 2005). 
 
Interestingly, osmotic stress is apparent on BTZ treatment in M. tuberculosis H37Rv as 
demonstrated by swelling and ultimately bursting of the cells due to a weakened cell 
wall (Makarov et al., 2009). In addition, the increase in susceptibility to many late-
acting cell wall antibiotics, such as -lactams and to the PG inhibitors fosfomycin and 
D-cycloserine, as a consequence of a decrease in the expression of uppS has already 
been reported in Bacillus subtilis. The enzyme UppS in B. subtilis generates 
undecaprenyl phosphate (C55-P), the major polyprenyl carrier for PG and teichoic acid 
synthesis (D'elia et al., 2009; D'elia et al., 2006; Lee and Helmann, 2013). 
Furthermore, similar effects have also been reported in Staphylococcus aureus, 
whereby Targocil, a teichoic acid biosynthesis inhibitor, results in accumulation of 
undecaprenyl-linked intermediates, thus preventing recycling of the undecaprenyl-
phosphate lipid carrier (Campbell et al., 2012). The cell wall deficient bacteria, such as 
Mycoplasma, lack the necessary enzymes for synthesis and condensation of IPP, the 
precursor molecule for prenyl phosphate synthesis (Henrickson, 1966; Lange et al., 
2000). Whilst L-forms such as Rickettsia prowazekii is lacking in enzymes for IPP 
synthesis (Andersson et al., 1998), the other member Borrelia burgdorferi contains 
highly divergent and uncharacterized genes encoding enzymes in IPP synthesis via the 






Figure 2.14. A schematic representation of the proposed mechanism of decaprenyl 
phosphate recycling. The lipid carrier decaprenyl phosphate is employed in biogenesis of 
peptidoglycan (PG), lipoarabinomannan (LAM) and arabinogalactan (AG) pathways in the form 
of Lipid II and DPA. Synthesis of DPA is crucial for producing the arabinan component of LAM 
and AG and is initiated by transfer of ribose phosphate from pRPP to decaprenyl phosphate and 
follows the pathway (black) where DprE1/E2 generates DPA from DPR. Treatment with BTZ043 
(red) results in accumulation of DPR, thus stalling LAM and AG biosynthesis and blocking the 
decaprenyl phosphate recycling. This block interrupts the channelling of decaprenyl phosphate for 
Lipid II formation, thus affecting PG biosynthesis. The weakened cell wall is unable to bear 
osmotic stress arising from DPR toxicity and leads to cell lysis. Over-expression of UppS, the 
prenyl synthase (green) restores the recycling by supplementing enough decaprenyl phosphate for 
synthesis of cell wall components. 
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In addition to Lipid II, members of Corynebacterineae, such as M. tuberculosis and C. 
glutamicum, employ decaprenyl phosphate for generating the sugar donors, DPA and 
decaprenyl phosphomannose (DPM). Whilst DPA is directed for formation of D-
arabinan in AG and LAM, DPM is utilised for synthesis of mannan in LM and LAM. 
Therefore, the effect of uppS overexpression was examined on these polysaccharides 
upon exposure to BTZ043 (15 µg/mL). The total sugar content from mAGP fractions 
prepared from C. glutamicum-pVWEx2 was analysed for distribution of radioactivity 
in sugars. As expected, an overall reduction in arabinose content was evident for 
BTZ043 treated samples mainly due to BTZ mediated inhibition of DPA synthesis. 
However, by over-expressing uppS, the effect of the drug on C. glutamicum could be 
evaded as [
14
C]-arabinose was effectively incorporated into mAGP (Figure 2.12). 
Similarly, when lipoglycans were isolated from BTZ043 treated C. glutamicum-
pVWEx2, a sharp decrease in radioactivity was observed for both LM and LAM. 
However, when uppS was overexpressed, LM and LAM were unaffected (Figure 2.13). 
These results demonstrate the ability of UppS to restore arabinan and mannan synthesis 
in the cell wall components by evading the action of the drug and challenge the 
prevailing notion on BTZ’s mechanism of action.  
 
Since BTZ is a newly discovered class of anti-tubercular compounds, our 
understanding of the mechanisms of resistance to this drug is fairly superficial. Natural 
resistance to BTZ is prevalent in mycobacterial species, such as M. avium and M. 
aurum and is attributed to the occurrence of a single mutation, Cys387 in DprE1 that 
substitutes Cys with an Ala in M. avium or Ser in M. aurum (Makarov et al., 2009). 
Furthermore, BTZ043’s activation requires reduction of the nitro-group to an 
electrophilic nitroso-derivative in order to react with the Cys387 residue in the active 
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site of DprE1 (Batt et al., 2012). The activation of BTZ043 is catalysed either by 
DprE1 itself or by other oxygen sensitive nitroreductases (Manina et al., 2010). This 
property of BTZ has also revealed an alternative mechanism for resistance to the drug 
mediated by bacterial nitroreductases such as NfnB that reduce the nitro group to the 
corresponding amine as observed in case of M. smegmatis (Manina et al., 2010).  
The results obtained from this study imply that increased expression of decaprenyl 
phosphate synthase (uppS) might provide a unique mechanism for Corynebacterineae, 
to become resistant to BTZ. Over-expression of prenylphosphate synthase, UppS 
generates DprE1 substrate DPR in increased amounts that out-competes BTZ043 at the 
active site of the enzyme. Consequently, accumulation of DPR is impeded and DPA 
synthesis is restored. Restoration of DPA synthesis imparts integrity to the cell wall 
whilst ensuring continuous recycling of decaprenyl phosphate pool. In this regard, 
UppS might also serve as an effective drug target since its role is crucial in synthesis of 














3 IpsA, a novel LacI-type regulator, is required for inositol-derived lipid 
formation in Corynebacteria and Mycobacteria 
 
3.1 Introduction  
The cell envelope of the human pathogens M. tuberculosis and Corynebacterium 
diphtheriae, of the order Corynebacteriales, play an important role in virulence and 
also confer resistance against current therapies (Mishra et al., 2011c). The development 
of new drugs against tuberculosis and diphtheria infections is focused on enzymes and 
regulatory mechanisms involved in the biogenesis of the cell envelope. The plasma 
membrane of mycobacteria and corynebacteria are rich in phospholipids, such as PI 
that plays a role in the biosynthesis of glycolipids and lipoglycans. The PI anchors the 
PIMs together with LM and LAM to the plasma membrane and also serves as the 
scaffold for these components. Inositol, an essential polyol in eukaryotes, is present 
only in the order Corynebacteriales where it forms a constituent of structural 
components of the cell wall and serves as a building block of mycothiol (MSH), the 
major antioxidant in mycobacteria (Fahey, 2013).  
 
In mycobacteria, the three step process for synthesis of PI is initiated by cyclisation of 
glucose-6-phosphate to myo-inositol-1-phosphate, catalysed by inositol phosphate 
synthase InO1 (Rv0046c) (Bachhawat and Mande, 1999a). In the second step, myo-
inositol-1-phosphate is dephosphorylated by inositol mono-phosphatase (IMP) (Nigou 
and Besra, 2002), to yield myo-inositol. The transfer of DAG from CDP-DAG to myo-
inositol by PI synthase, PgsA (Rv2612c) forms the third step of the pathway 
(Movahedzadeh et al., 2010). The enzymes, inositol phosphate synthase, PI synthase, 
Ino1 and PgsA, are essential for viability of mycobacteria (Jackson et al., 2000; 
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Movahedzadeh et al., 2004a). In addition, an ino1 mutant of M. tuberculosis could only 
survive in high concentrations of inositol and was no longer virulent in SCID mice 
(Haites et al., 2005b). Therefore, Ino1 has been proposed as a target for developing 
new antibiotics (Hernick, 2013; Movahedzadeh et al., 2004b).  
 
In contrast to the wealth of knowledge about the biogenesis of the Corynebacterium 
cell wall, little is known about the regulatory circuits that control these processes 
(Morita et al., 2011). In this study, we have examined the function of a novel 
transcriptional regulator IpsA, encoded by Cg2910 (NCgl2538) in C. glutamicum. We 
propose IpsA, as a novel LacI-type regulator that acts as an inositol-dependent 
transcriptional activator of the myo-inositol-phosphate synthase, ino1. Its function is 
conserved throughout corynebacteria and mycobacteria, including the prominent 
pathogenic species C. diphtheria and M. tuberculosis. The transcriptional regulators of 
Lac-I family are characterised by a distinct helix-turn-helix motif in the DNA binding 
N-terminal domain. The central region binds the sugar inducer whilst C-terminus aids 
in formation of a tetramer. The regulators in this class can function either as repressors 
such as, LacI in lac operon, CcpB in several operons in B. subitilis or as activators of 
gene transcription for example DegA in degradation of pRPP amidotransferase in B. 
subitils (Bussey and Switzer, 1993; Nguyen and Saier, 1995) . LacI family of 
transcriptional regulators also includes transcriptional factors with dual activity such as 
CcpA in B. subtilis and FruR in E. coli that functions both as a repressor and as an 
activator to direct carbon metabolism (Henkin, 1996; Ramseier et al., 1995). The 
structure of IpsA (PDB:3H5T) from C. glutamicum was resolved recently. Structual 
analysis of IpsA revealed a helix-turn-helix motif in the DNA binding domain that 
designated it as a regulator of LacI family. 
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In this study, we have characterised the ipsA deletion mutant of C. glutamicum and its 
possible homologues in C. diphtheria (DIP1969) and in M. tuberculosis (Rv3575c). 
Targets of IpsA with putative functions in cell wall biogenesis were identified and a 
conserved palindromic motif within the corresponding promoter regions was 
designated as the binding site. Myo-inositol was identified as an effector for IpsA as it 
led to dissociation of the IpsA-DNA complex in vitro. The deletion mutant showed 
growth defects when cultured on glucose and presented elongated cell morphology. 
Analysis of the cell wall lipid composition revealed the absence of ionsitol-derived 
lipids including PI, PIMs and LAM. The cells were completely devoid of any 
mycothiol.  
 
This work was performed in collaboration with Meike Baumgart, Kerstin Luder, 
Cornelia Gätgens and Julia Frunzke at Institut für Bio- und Geowissenschaften, IBG-1: 
Biotechnologie, Forschungszentrum Jülich, Jülich, Germany. MB designed and 
coordinated the study, constructed the mutant, performed the microarray experiments 
and fluorescence microscopy and prepared the figures. KL and CG carried out the 
recombinant DNA work, EMSAs, protein purification, promoter fusion studies and 
growth experiments. SG and GSB performed and analysed the cell wall lipid studies. 






3.2  Materials and Methods 
 
3.2.1 Bacterial strains, plasmids and growth media  
All C. glutamicum strains used in this study unless specified were grown in Brain Heart 
Infusion broth (BHI, Sigma-Aldrich) at 30°C. E. coli DH5 was grown in Luria-
Bertani broth (LB, Difco) at 37°C. The wild type C. glutamicum strain ATCC 13032 
was used for construction of mutants. All cloning experiements were performed in E 
coli DH5α cultivated at 37 °C in LB broth, (Sambrook and Russell, 2001) 
supplemented with 50 µg/mL kanamycin.  
 
3.2.2 Growth experiments 
For growth experiments, 5 mL of BHI broth (Difco Laboratories) was inoculated with 
a colony from a fresh BHI agar plate and incubated for 6-8 hours at 30°C and 220 rpm. 
Cells from this pre-culture were washed once in phosphate buffered saline (PBS, 137 
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3) and used to 
inoculate a second pre-culture, consisting of 20 mL CGXII minimal medium 
(Keilhauer et al., 1993) supplemented with 3,4-dihydroxybenzoate (30 mg/L) as an 
iron chelator and 2 % (w/v) glucose as a carbon source, to an OD600 of about 1. For 
sequential cultivation, the cells from this culture were diluted in fresh medium to a 
starting OD600 of 1 and incubated overnight at 30°C and 120 rpm. These cultures were 
then used to set up main cultures that were inoculated to an OD600 of about 1 and 
incubated at 30°C and 120 rpm in a Biolector (m2p-labs, Baesweiler, Germany) in 48-
well FlowerPlates containing 750 µL CGXII minimal medium and different carbon 
sources, as specified in the results section. For induction of the expression of genes 
under the control of the Ptac-promoter, IPTG was used at the concentrations specified. 
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Where appropriate, the medium was supplemented with 25 µg/mL kanamycin. All the 
strains constructed and utilised in this study are listed in Table 3.1.  
Table 3.1: Strains and plasmid constructs used in this study (Data provided by 
Baumgart et al.) 
Strain or plasmid Relevant characteristics 
Source or 
Reference 
M. tuberculosis H37Rv 
wild-type laboratory strain, 
DNA used as PCR template 
ATCC 25618 
C. diphtheriae ATCC 
27010 
wild-type laboratory strain, 













deoR thi-1 phoA supE44 λ
-




F- ompT hsdSB (rB-, mB-) gal 
dcm (DE3); host for protein 
production 




Biotin-auxotrophic wild type 
(Kinoshita et al., 
1957) 
ATCC13032 ΔipsA 
ATCC13032 with an in-frame 
deletion of cg2910 
This work 
ATCC13032::pK18int  This work 
ATCC13032 
ΔipsA::pK18int 
 This work 
ATCC13032::pK18int-
ipsA 
 This work 
ATCC13032 
ΔipsA::pK18int-ipsA 
 This work 
ATCC13032 ΔmshC 
ATCC13032 with a deletion 
of cg1709, defect in 
mycothiol biosynthesis 









.; plasmid for allelic 
exchange in C. glutamicum; 
(pK18 oriVE.c., sacB, lacZα) 





derivative containing a PCR 
product covering the up- and 






; plasmid for integration 
of foreign DNA into the 
intergenic region between 
cg1121-cg1122 (oriVE.c., 
sacB, lacZα) 





; plasmid for integration 
of the ipsA enconding region 
including the native promoter 






, pEKEx2 containing 
eyfp with artificial RBS, 
under control of Ptac 





; C. glutamicum/E. coli 
shuttle vector for regulated 
gene expression, derivative of 
pEKEx2 





; pAN6-derivative for 
overproduction of IpsA with a 
C-terminal STREP-tag under 





; pAN6-derivative for 
expression of Rv3575c (IpsA 
homolog from M. 
tuberculosis) under control of 





; pAN6-derivative for 
expression of DIP1969 (IpsA 
homolog from C. diphtheriae) 






; pAN6-derivative for 
expression of ino1 under 







; pET28b derivative for 
over-expression of genes in 
E. coli, adding an N-terminal 
decahistdine tag and a TEV 
protease cleavage site to the 
target protein (pBR322 
oriVE.c., PT7, lacI) 





; pET-TEV derivative 
for overproduction of IpsA 
with an N-terminal 
decahistidine tag which can 









glutamicum/E. coli shuttle 
vector 
(Cremer et al., 1991) 
pXVENC-2 Kan
R
, oriT oriV, Pxyl, venus 





, pJC1 derivative 
carrying the venus coding 







derivative carrying the 
promoter of ino1 (cg3323) 







3.2.3 Recombinant DNA work 
The C. glutamicum ∆ipsA mutant was constructed via a two-step homologous 
recombination protocol as described previously (Niebisch and Bott, 2001). For the 
construction of the deletion plasmid, the up- and downstream regions (~500 bp) of ipsA 
were amplified using the primer pairs ∆_cg2910_1(XmaI)/ ∆_cg2910_2 and 
∆_cg2910_3/∆_cg2910_4 (XbaI), respectively. The resulting PCR products were used 
as templates for overlap extension PCR using the oligonucleotide pair 
∆_cg2910_1(XmaI)/ ∆_cg2910_4 (XbaI). The DNA fragment thus obtained was 
digested with XmaI and XbaI and cloned into recombination vector pK19mobsacB. 
The sequenced plasmid pK19mobsacB-ΔipsA was transformed into C. glutamicum and 
screened for the first and second recombination event using previously described 
protocols (Niebisch and Bott, 2001). The transformants were selected for kanamycin-
sensitivity and sucrose-resistance and screened for the deletion of cg2910 by colony 
PCR analysis with the primer pair ∆_cg2910_for/∆_cg2910_rev.  
To generate the vector constructs pET-TEV-ipsA, pAN6-ipsA and pAN6-ipsA-STREP, 
the ipsA-coding region was amplified from genomic DNA of C. glutamicum using the 
primer pairs cg2910-NdeI-fw/cg2910-EcoRI-rv (for pET-TEV-ipsA and pAN6-ipsA) 
and cg2910-NdeI-fw/cg2910-NheI-rv-nostop (for pAN6-ipsA-STREP). The PCR 
products were cut with the respective enzymes provided in the oligoname and ligated 
into pET-TEV and pAN6 double digested with same enzymes.  
 
The plasmid pAN6-cg3323 was constructed by amplifying the cg3323 coding region 
using the primer pair cg3323-NdeI-fw/cg3323-NheI-rv using genomic DNA of C. 
glutamicum as template. The PCR product was cut with the NdeI-NheI and ligated into 
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pAN6 double digested with the same enzymes. For plasmid pJC1-venus-term, the 
venus coding region was amplified using the primer pair eYFP-Bam-NdeI-fw/Venus-
term2-rv and plasmid DNA of pXVENC-2 as template. The terminator-encoding 
region was amplified using the primer pair Venus-term3-fw/Term4-SalI-rv and plasmid 
DNA of pAN6 as template. The fragments were joined by overlap extension PCR, cut 
with BamHI and SalI and ligated into pJC1 cut with the same enzymes.  
 
To construct plasmid pJC1-Pcg3323-eYFP, promoter region of cg3323 was amplified 
from genomic DNA of C. glutamicum using the primer pair Promcg3323-rv-
YFP/Promcg3323-fw-BamHI. The eyfp-coding sequence was amplified from plasmid 
DNA of pEKEx2-eyfp using the primer pair eYFP-SpeI-rv/eYFP-fw. The fragments 
were joined by overlap extension PCR, digested with BamHI and SpeI and ligated into 
pJC1-venus-term double digested with the same enzymes. Since SpeI site is located 
between venus and the terminator, venus is thus removed from the plasmid and only the 
eyfp reporter is available for use. 
 
All primers used in this study were synthesised by Eurofins MWG Operon (Ebersberg, 
Germany). All constructs have been sequenced by Eurofins MWG Operon (Ebersberg, 






Table 3.2: Oligonucleotides used in this study. (Data provided by Baumgart et. al., 
Julich) 
Oligonucleotide Sequence (5ꞌ → 3ꞌ) and properties
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PCR products and oligonucleotides used for the determination of the IpsA binding sites 


















PCR products and oligonucleotides used for the determination of the IpsA binding site 



















PCR products and oligonucleotides used for the investigation of putative IpsA binding 
























































PCR products and oligonucleotides used for the determination of the IpsA binding site 

































In some cases oligonucleotides were designed to introduce recognition sites for restriction 
endonucleases(recognition sites underlined). Complementary sequences used for overlap 
extension PCR are written in bold letters. Red letters indicate mutated bases. 
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3.2.4 DNA microarrays 
For transcriptome analysis, C. glutamicum wild type and ΔipsA cells were grown in 5 
mL BHI (Brain Heart Infusion, Difco) for about 6 hours at 30°C and were then used to 
inoculate CGXII minimal medium containing 2% (w/v) glucose as carbon source. The 
main cultures were inoculated using the pre-inoculum to an OD600 of 0.5 in CGXII 
minimal medium with 2% (w/v) glucose. The cells were harvested at an OD600 of 5 by 
centrifugation (4120 x g, 10 minutes and 4°C). The cell pellet was subsequently frozen 
in liquid nitrogen and stored at -70°C. Total RNA was prepared with the RNeasy Kit 
(Qiagen) using the previously described protocols (Möker et al., 2004). Fluorescently-
labeled cDNA was synthesised as described previously (Lange et al., 2003; Möker et 
al., 2004). Purified cDNA samples to be compared were pooled and the prepared two-
color samples were hybridised at 65°C while rotating for 17 hours using Agilent’s 
Gene Expression Hybridisation Kit, hybridisation oven and hybridisation chamber. 
After hybridisation the arrays were washed using Agilent’s Wash Buffer Kit according 
to the manufacturer’s instructions. Fluorescence signals from hybridised DNA 
microarrays was measured at 532 nm (Cy3) and 635 nm (Cy5) at 5 μm resolution with 
a GenePix 4000B laser scanner and GenePix Pro 6.0 software (Molecular Devices, 
Sunnyvale, CA, USA). Fluorescence images were saved as raw data files in TIFF 
format (GenePix Pro 6.0). Quantitative TIFF image analysis was carried out using 
GenePix image analysis software and results were saved as GPR-file (GenePix Pro 
6.0). For background correction of spot intensities, ratio calculation and ratio 
normalisation, GPR-files were processed using the BioConductor R-packages limma 
and marray (http://www.bioconductor.org). Array data was deposited in the GEO 




3.2.5 Overproduction and purification of IpsA 
Overnight cultures of E. coli BL21(DE3) cells harbouring the expression plasmids 
pET-TEV-ipsA or pAN6-ipsA-STREP were set up in 1L LB medium at 37°C and 120 
rpm. For expression analysis, cultures were induced by addition of 50 µM IPTG and 
transferred to 16°C for 20 hours before the cells were harvested by centrifugation. The 
protein was purified from lysates using Nickel chelate and StrepTactin affinity 
chromatography as described previously (Garcia-Nafria et al., 2010; Niebisch et al., 
2006). To further purify the protein preparation and determine the molecular weight, 
gel filtration was performed using a Superdex™ 200 10/300 GL column (GE 
Healthcare, Munich, Germany) in Tris buffer (50 mM Tris-HCl pH 8, 250 mM NaCl, 1 
mM DTT). Fewer aggregates were obtained for IpsA-variant with the C-terminal 
STREP-tag in comparison to the His10-tag. SDS-PAGE analysis of the eluted fraction 
revealed a band for IpsA at 79 kDa suggesting dimer formation. The protein was 
concentrated, flash frozen in liquid nitrogen and stored in the gel filtration buffer at -
70˚C. 
 
3.2.6 Electrophoretic mobility shift assays (EMSAs) 
Unless otherwise stated, EMSAs were performed with purified STREP-tag variant of 
IpsA and DNA fragments of the predicted target genes using previously described 
protocols (Heyer et al., 2012) with the stated modifications. The purified protein was 
incubated with DNA fragments (30-500 bp, final concentration 0.028-1 µM) in 
bandshift buffer (50 mM TRIS-HCl pH 7.5, 40 mM KCl, 5 mM MgCl2) in a total 
volume of 10 µL. The DNA-protein complex was resolved on 10-15% non-denaturing 
polyacrylamide gels at room temperature run at 150 or 180 V for 45-60 minutes (varied 
w. r. t. DNA fragments being analysed). To determine the effector molecules, purified 
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IpsA was pre-incubated with the effector for 20 minutes at room temperature. The pre-
incubated effector-protein mix was then incubated with target DNA for 20 minutes and 
electrophoresed as described above. AcnR protein and the acn promoter fragment was 
used as experimental control (Garcia-Nafria et al., 2013). ImageQuant TL software 
(GE Heathcare) was used for quantifying the shifted DNA. 
 
3.2.7 Fluorescence microscopy 
DAPI and nile red staining was performed on the previously cultured strains for 
flouresence microscopy analysis. The cells were centrifuged and resuspended in 
phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 
mM KH2PO4, pH 7.3) containing 200 ng/mL 4',6-diamidino-2-phenylindole (DAPI) 
and 300 ng/mL nile red and incubated for 5-10 minutes at room temperature. For 
analysis, the cells were mounted on agar pads and analysed using Zeiss Axioplan 2 
imaging microscope with an AxioCam MRm camera and a Plan-Apochromat 100x, 
1.40 Oil DIC oil-Immersion objective. Digital images were acquired and analysed with 
AxioVision 4.6 software (Zeiss, Göttingen, Germany). 
 
3.2.8 Promoter fusion studies 
The effect of IpsA as a regulator on the ino1 promoter in vivo was analysed using 
promoter-reporter fusion constructs. For this purpose, a DNA fragment containing the 
cg3323 promoter region was fused to the eyfp-coding sequence and cloned into pJCI to 
generate the pJC1-Pcg3323-eYFP construct. The resulting plasmid was then 
transformed into wild type and ΔipsA cells and analysed for fluorescence output on 




3.2.9 Growth of bacteria for [14C]-labelled lipid analysis 
Overnight cultures of C. glutamicum wild type ATCC 13032, C. glutamicum ΔipsA, C. 
glutamicum ΔipsA::pK18int_ipsA, and C.glutamicum ΔipsA harbouring cg3323 
(NCgl2894), Rv3575c and DIP1969 in plasmid pAN6 were pre-grown in 20 mL of 
3.7% BHI (Sigma) containing kanamycin (25 µg/mL). The cells were washed once 
with phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 
mM KH2PO4, pH 7.3, PBS) and were used to inoculate a second pre-culture to an 
OD600 of 1 in 50 mL CGXII minimal medium (50mL) supplemented with 2% glucose 
and incubated with gentle shaking overnight at 30°C. The cells of the second pre-
culture were washed once with PBS and used to inoculate the main cultures to an 
OD600 of 0.1 in 10 mL CGXII minimal medium (10 mL), supplemented with either 2% 
glucose or 2% myo-inositol and grown until early log phase. At early log phase, the 
cells were labelled with 1 µCi/mL of [1,2-
14
C]-acetate (1.66-2.22 GBq/mmol, 
PerkinElmer Inc.) and incubated overnight at 30ºC with gentle shaking. The cells were 
recovered following centrifugation at 3,500 x g and dried.  
 
3.2.10 Analysis of polar lipids 
Polar and apolar lipid extracts were prepared from the dried cell pellets using 
established procedures (Dobson G., 1985) as mentioned in General Materials and 
Methods, section 7.4.2. Briefly, the dried polar lipid extracts were re-suspended in 
chloroform:methanol (100 µL, 2:1, v/v) and the incorporation of [1,2-
14
C]-acetate in 
lipid extracts was determined by counting an aliquot (5%) using scintillation fluid (5 
mL). To analyse the lipid profiles, equal counts of polar lipid extracts (20,000 cpm) 
were applied to silica thin layer chromatography (silica gel 60 F254 Merck 5554, TLC 
plates) and developed using the solvent system: chloroform/methanol/water (60:30:6, 
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v/v/v) in the first dimension and chloroform/acetate/methanol/water (40:25:3:6, 
v/v/v/v) in the second dimension. The autoradiograms were obtained by exposing the 
TLCs to X-ray films (Kodak-Biomax MR) for 48 hours. 
 
3.2.11 Extraction and purification of lipoglycans  
Lipoglycans were extracted using previously described protocols (Ludwiczak et al., 
2001) as described in General Materials and Methods, section 7.4.5. Briefly, dried cell 
pellets from a 10 mL volume culture were resuspended in water and refluxed five times 
with equal volume of 50% aqueous ethanol at 85°C, for 6 hour intervals. The 
suspension was centrifuged and the supernatant recovered between each extraction 
following centrifugation. The combined supernatant fractions were dried and subjected 
to hot phenol-water treatment at 65°C. The aqueous phase containing the crude 
lipoglycan fraction was recovered and dialyzed (MWCO 3.5 KDa) against water. The 
dialyzed fraction was dried and 20 µg of lipoglycans were loaded on a 15% SDS-
PAGE gel. The lipoglycans were visualised using Pro-Q emerald glycoprotein stain 
(Life Technologies). 
 
3.2.12 Mycothiol extraction and analysis.  
The extraction of mycothiol was carried out using previously published protocols 
(Newton et al., 1996) with a few modifications. Briefly, relevant strains were cultured 
in BHI medium for 6 hours and then sub-cultured twice in CGXII minimal medium 
supplemented with 4% glucose (w/v) as carbon source and grown at 30 °C and 120 
rpm for 16 hours and 24 hours, respectively. For extraction, 200 mg of wet cells were 
resuspended in 1 mL of warm (60°C) acetonitrile containing 20 mM Tris-HCl, pH 8.0 
and 2 mM bromobimane (Sigma) and sonicated for 20 seconds. The resuspended cells 
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were further incubated in dark at 60°C for 15 minutes. The samples were then treated 
with 5 µL of 5 M methanesulfonic acid and centrifuged at 16000 x g for 10 minutes to 
remove debris. The supernatant was separated, filtered and diluted 5-fold in 10 mM 
methanesulfonic acid. To block thiol groups, the control sample from wild type was 
pre-incubated with 5 mM N-methylmaleimide (NMM) and then derivatised with 
bromobimane.  For HPLC analysis, the samples were loaded onto a C18 column 
(LiChrospher RP 18, 125 × 4 mm) and eluted using the solvents A (100 mM sodium 
acetate buffer pH 7.2) and B (100% methanol) at a flow rate of 0.7 mL/minutes at a 
gradient: 0 minutes, 15% B; 1 minutes, 15% B; 1.5 minutes, 35% B; 11 minutes, 80% 
B; 12 minutes, 95% B; 13 minutes 100% B. To identify the peak for mycothiol (5.61 
minutes) wild type chromatogram was compared to that of ΔmshC strain and the NMM 
treated sample. In addition, previously published chromatograms for glutathione (5.14) 
obtained using similar methods also indicated the peak at 5.61 minutes to correspond to 






3.3.1 IpsA is a novel LacI-type regulator conserved in the Corynebacteriales 
The genomic loci of IpsA from C. glutamicum wild type was compared across the 
Corynebacteriales and the homologues for the protein were identified using BLAST 
search. The comparison of genome loci from species of this order revealed a high 
degree of conservation (Figure 3.1). The crystal structure (PDB ID: 3H5T) and 
sequence homology have designated IpsA as a member of  LacI family of 
transcriptional regulators (Swint-Kruse and Matthews, 2009).  
 
Figure 3.1: Conservation of IpsA in Corynebacteriales. The organization of genome 
locus harbouring ipsA in C. glutamicum and related species revealed a remarkable 
degree of conservation across the species, IpsA homologues are depicted in black. Data 
was obtained from www.microbesonline.org (Alm et al., 2005). (The figure and data 




3.3.2 Effect of IpsA deletion on cell shape and growth 
An in-frame deletion mutant of ipsA was constructed to study the function and 
determine possible target genes that are regulated by IpsA. The growth rate of ∆ipsA 
was measured in cells cultured in minimal media supplemented with glucose. These 
cells were also checked for backscatter. The growth rate and backscattering of ∆ipsA 
strain was significantly below the control levels. These deficiencies were enhanced 
with successive sub-cultivation (Figure 3.2).  
 
 
Figure 3.2: Growth of C. glutamicum wild type and ΔipsA. A. The growth curves for C. 
glutamicum wild type and C. glutamicum ΔipsA from sequential cultures in minimal 
medium supplemented either with glucose (1, 2, 3) or with myo-inositol (3) as carbon 
source revealed a decrease in backscatter with subsequent cultivations for glucose while no 
change was observed with myo-inositol. The data is representative of three biological 




Fluorescence microscopy analysis of DNA (DAPI) and membranes (nile-red) from 
∆ipsA revealed an alerted morphology as the mutant cells demonstrated formation of 
chain-like structures, failure of cell division and an intact cell septa in several unshaped 
cells. Uneven distribution was observed for the DNA and its frequent presence in 





















Figure 3.3: Cell shape of C. glutamicum wild type and ΔipsA. Fluorescence microscopic 
images of membrane and DNA preparations from wildtype and ΔipsA strains depict 
abnormal phenotype for the mutant. The ΔipsA cells cultured in minimal media with 
glucose were elongated in shape with intact septa whilst those cultured in minimal media 
with myo-inositol as carbon source were normal and identical to wild type. The scale bar is 





Attempts were made to complement the mutant with plasmid-encoded ipsA with an 
inducible promoter, plasmid encoded putative target ino1 (cg3323) and by genomic 
reintegration of ipsA into the intergenic region between cg1121-cg1122. Whilst 
controlled expression of IpsA under the inducible promoter could partially restore 
growth, full complementation was achieved only in case of an integrated copy of ipsA 
under the control of native promoter (Figure 3.4A). The growth defects were also 
overcome in a ∆ipsA strain containing the plasmid encoded copy of target gene ino1 
under an inducible promoter (Figure 3.4B). 
 
Figure 3.4: Complementation of the ΔipsA phenotype with ipsA and the target gene ino1 
(cg3323). A. Growth curves obtained for mutant strain complemented with the integrated 
copy of the gene ipsA cultured in minimal media with glucose as carbon source. B. The 
growth curves obtained for mutant strain with plasmid encoded copy of the target gene ino1 
(cg3323) depicting full restoration of phenotype. The data is representative of three biological 






Fluorescence microscopy analysis of the mutant and the complemented strains showed 














Figure 3.5: Flouresence microscopy depicting complementation of the ΔipsA 
phenotype with ipsA. Fluorescence microscopy images of stationary phase cells of the 
cultures depicting full restoration of phenotype in the complemented strain. The data is 
representative of three biological replicates. (Data and figure provided by Baumgart et. 
al., Julich) 
 
3.3.3 Transcriptome analysis of ipsA deletion mutant 
Global transcriptional profiling was performed to study the transcriptional changes 
introduced by ipsA deletion. DNA microarray analysis of cells in exponential phase 
(OD600=5) cultured in minimal media supplemented with glucose, revealed increased 
transcription for more than 450 genes (mRNA level greater than a factor of two). Some 
of the relevant genes are summarised in Table 3.3 and full data for the study was 





Table 3.3: Gene loci with more than four-fold regulation in ∆ipsA mutant in 
comparison to wild type.  (Data provided by Baumgart et. al., Julich) 
Locus 
tag 
Gene Annotated function Ratio n p-value 




0.082 3 0.004 
cg2896  
putative secreted protein, hypothetical 
endoglucanase 
0.114 3 0.003 
cg2181  
ABC-type peptide transport system, 
secreted component 
0.128 3 0.005 
cg0446 sdhA succinate dehydrogenase 0.138 3 0.003 
cg0045  
probable ABC transport protein, 
membrane component 
0.138 3 0.028 
cg2636 catA1 catechol 1,2-dioxygenase 0.143 3 0.003 
cg0622  
duplicated ATPase component SCO2324 
of energising module of predicted 
cobalamine ECF transporter 
0.160 3 0.003 
cg2182  
ABC-type peptide transport system, 
permease component 
0.167 3 0.022 
cg1918  putative secreted protein 0.169 3 0.005 
cg3138 ppmA 
putative membrane-bound protease 
modulator 
0.171 3 0.004 
cg2910 ipsA transcriptional regulator, LacI family 0.173 3 0.030 
cg3195  flavin-containing monooxygenase (FMO) 0.178 3 0.010 
cg0447 sdhB succinate dehydrogenase 0.185 3 0.002 
cg0621  
substrate-specific component SCO2325 
of predicted cobalamine ECF transporter 
0.187 3 0.006 
cg0445 sdhC succinate dehydrogenase 0.189 3 0.005 
cg0623  
transmembrane component SCO2323 of 
energising module of predicted 
cobalamine ECF transporter 
0.194 3 0.004 
cg3048 pta phosphate acetyltransferase 0.202 2 0.082 
cg0601 rpsC 30S ribosomal protein S3 0.212 3 0.007 
cg3139  hypothetical protein cg3139 0.213 3 0.002 
cg0599 rpsS 30S ribosomal protein S19 0.215 3 0.009 
cg0600 rplV 50S ribosomal protein L22 0.216 3 0.007 
cg0598 rplB 50S ribosomal protein L2 0.217 3 0.011 
cg1487 leuC isopropylmalate isomerase large subunit 0.218 3 0.035 
cg0624  secreted oxidoreductase 0.219 3 0.005 
cg0602 rplP 50S ribosomal protein L16 0.226 3 0.005 




cg0594 rplC 50S ribosomal protein L3 0.233 2 0.085 
cg0593 rpsJ 30S ribosomal protein S10 0.237 2 0.064 
cg2061 psp3 putative secreted protein 0.244 3 0.000 
cg0936 rpf1 resuscitation promoting factor 0.247 2 0.098 
cg3107 adhA Zn-dependent alcohol dehydrogenase 0.251 3 0.033 
cg3210  
cell envelope-related transcriptional 
regulator 
0.411 2 0.024 
cg2870 dctA Na+/H+-dicarboxylate symporter 3.948 3 0.004 
cg3286  putative secreted protein 4.073 2 0.013 




4.798 3 0.003 
cg3391 oxiD myo-Inositol dehydrogenase 4.979 3 0.018 
cg1421  putative dinucleotide-binding enzyme 5.214 3 0.000 
cg0533 menE O-succinylbenzoic acid-CoA ligase 5.467 3 0.001 
cg0753  secreted protein 5.507 3 0.000 
cg2797  hypothetical protein cg2797 5.517 3 0.023 
cg3389 oxiC myo-Inositol dehydrogenase 5.528 3 0.006 
cg0471 htaC 
secreted heme transport-associated 
protein 
5.553 3 0.003 
cg1476 thiC thiamine biosynthesis protein ThiC 5.554 3 0.000 
cg0534  putative integral membrane protein 5.597 3 0.000 
cg0998  trypsin-like serine protease 5.798 3 0.001 
cg2311  SAM-dependent methyltransferase 6.217 2 0.032 
cg1120 ripA 
transcriptional regulator of iron proteins, 
AraC family 
6.983 3 0.005 
cg3390  
myo-Inositol catabolism, sugar phosphate 
isomerase/epimerase 
7.674 3 0.012 
cg0470 htaA 
secreted heme transport-associated 
protein 
8.972 3 0.008 
cg3156 htaD 
secreted heme transport-associated 
protein 
9.695 3 0.002 





Significant alteration was observed in mRNA level for genes which are the 
components of DtxR/RipA-regulon (shaded in grey, Table 3.3) that is required for iron 
homeostasis in C. glutamicum (Wennerhold and Bott, 2006; Wennerhold et al., 2005). 
These alterations could manifest from impaired iron uptake resulting from a damaged 
cell wall. IpsA is not part of the DtxR-stimulon as no conserved DtxR motif is present 
in the ipsA or ino1 promoter regions. The genes that encode ribosomal proteins (shaded 
in grey, Table 3.3) were also not included for analysis. More than ten-fold decrease in 
gene expression levels was observed for cg3323, which encodes a myo-inositol-
phosphate synthase (ino1), and of the operon (cg0044-46), which encodes an 
uncharacterised ABC transporter in the mutant strain (Table 3.3). Other down-
regulated genes include a flavin-containing monooxygenase (cg3195), a hypothetical 
endoglucanase (cg2896), and two further transporters (cg0621-23 and cg2181-84) 
(Table 3.3). Strong upregulation was evident for genes clusters with enzymes for 
inositol catabolism (cg3389-92), menE and a putative integral membrane protein 
(cg0533-34) and a putative dinucleotide binding enzyme (cg1421). On the basis of 
gene expression analysis, all genes that were either up-regulated or down-regulated by 
a factor of four and were not a part of DtxR-stimulon or encode for ribosomal proteins 
were selected for EMSA studies.  
3.3.4 Identification of direct IpsA target promoter, binding site and effecter 
molecules 
The promoter regions of the putative target genes of IpsA, as implicated by microarray 
experiments were tested for direct regulation by IpsA using electrophoretic mobility 
shift assays (EMSAs) and mutational analysis. DNA fragments (~30 & 500 bp) 
harboring the promoter regions of predicted target genes were incubated with 
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increasing concentrations of IpsA and analysed for formation of IpsA-DNA complex. 
EMSA analysis revealed high affinity binding of IpsA to the promoter regions of 
cg0044 and ino1 (cg3323) lower affinity for the promoter regions of cg0534, cg1421, 
cg1476 (thiC), cg3210, and cg3195 (Figure 3.6 and 3.7). The EMSA results for all the 













Figure 3.6: Binding efficiency of IpsA to promoter regions of putative target genes. The 
30bp sequence located immediately downstream of IpsA binding site in cg3323 was used as 







The high affinity binding sites from promoter regions of ino1 (cg3323) and cg0044 as 
identified by EMSA (Figure 3.6) were subjected to motif based sequence analysis tool 
MEME, (http://meme.ebi.edu.au/meme/) to generate a preliminary palindrome motif 
 
Figure. 3.7: IpsA binding with promoter regions of predicted target genes. 30bp DNA 
fragments containing promoter regions of putative target genes were incubated with IpsA at 
mentioned concentrations and analysed on 10% native polyacrylamide gels, stained with 
SYBR green for bandshift due to DNA-IpsA formation. (Figure and data were provided by 
Baumgart et. al., Julich) 
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(Figure 3.8) that was further verified using mutational analysis.Three nucleotides of the 
proposed motif were substituted in DNA fragment containing ino1 promoter and 
EMSA was performed (Figure 3.8). The results highlighted central six base pairs to be 

























Figure 3.8: Mutational analysis of IpsA binding site in the ino1 promoter. The mutated 
DNA fragments marked with + exhibited same affinity for binding as the wild type 
fragment (pos. control); while those with (+) showed reduced binding affinity. The 
fragments marked with - indicate loss of binding such as in case of M3 and M4 highlighting 
the importance of central six base pairs in IpsA binding. (Figure and data were provided by 




The binding site information thus generated from EMSA analysis of promoter regions 
of cg3323, cg0044, cg1421, cg3195, cg3210 and cg0534 and the mutational analysis of 














Figure 3.9: Consensus motif for IpsA binding as defined by MEME and EMSA 
analysis (Figure and data were provided by Baumgart et. al., Julich) 
 
Since EMSA analysis revealed a very high affinity of IpsA for ino1, that encodes a 
myo-inositol phosphate synthase (Bachhawat and Mande, 1999b), metabolites 
generated in myo-inositol biosynthesis pathway were chosen as prime candidates for 
effector molecules that influence IpsA-DNA complex formation. The purified IpsA 
was pre-incubated with effector molecules to be tested and then subjected to EMSA. 
Electrophoresis highlighted backshift only for myo-inositol whilst no differences were 
observed for 1D-myo-inositol-1-phosphate, 1D-myo-inositol-3-phosphate or glucose-6-






3.3.5 Inositol-dependent regulation of ino1 by IpsA 
The results obtained so far suggest involvement of IpsA in regulation of myo-inostiol 
synthesis by activating ino1 in absence of exogenous inositol. This initial observation 
was made from complementation studies with a plasmid encoded functional copy of 
ino1 in C. glutamicum ΔipsA where constitutive expression of Ino1 could successfully 
restore the wild type phenotype (Figure 3.4). To test the effect of IpsA and myo-
inositol on ino1 promoter, promoter-reporter fusion constructs were generated where 
ino1 promoter was fused to eyfp (enhanced yellow fluorescent protein). The 
fluorescence output was recorded from wild type and ΔipsA strain grown in minimal 
media supplemented with either glucose or myo-inositol (Figure 3.11). High eyfp 
expression was observed for wild type strain cultured using glucose as a carbon source. 
However, the gene expression levels for ΔipsA strain were significantly low when the 
mutant was cultured in glucose. Both the strains showed highly reduced YFP levels 


















Figure 3.10: Effect of metabolites inositol metabolism on IpsA- ino1 promoter complex. 















Figure 3.11: Promoter-fusion studies using the promoter of ino1 fused to eyfp (pJC1-
Pcg3323-eyfp). The specific fluorescence of ATCC 13032 on glucose was set to 1 and the 
other values were calculated accordingly. (Figure and data were provided by Baumgart et. 
al., Julich) 
 
3.3.6 Function of IpsA in C. diphtheria and M. tuberculosis 
IpsA homologues were identified in members of Corynebacteriales and a high degree 
of conservation was observed for the gene loci (Figure 3.1). This implicated its role in 
the pathogenic species of the order such as C. diphtheria and MTB. To deduce the 
function of ipsA in pathogens, homologues of IpsA in M. tuberculosis (Rv3575) and C. 
diphtheriae (DIP1969) were tested for restoration of wild type phenotype in C. 
glutamicum ΔipsA. The expression of IpsA homologues from pathogenic species could 
partially restore the wild type phenotype in the mutant as slight retardation in growth 
(Figure 3.12 A and B) and shorter chain-clusters were evident in the complemented 
strains (Figure 3.12 C). IpsA homologue from C. diphtheria (DIP1969) could 
complement the loss of phenotype to a greater extent than the M. tuberculosis 

























Figure 3.12: Complementation of phenotype of IpsA homolgues in C. diphtheria and 
M. tuberculosis. Growth curves for C. glutamicum ΔipsA with plasmids pAN6, pAN6-
DIP1969 (A) or pAN6-Rv3575c (B) and C. glutamicum wild type with pAN6 as control in 
CGXII with glucose without IPTG (A) or with 50 µM IPTG (B). C. Morphology of the 
complemented strains with DAPI stained DNA (cyan) and nile red stained membrane 
regions (red), scale bar 5 µm.  The data is respresentative of three biological replicates. 
(Figure and data were provided by Baumgart et. al., Julich) 
 
The IpsA binding site analysis for cg3323 and cg0044 homologues in C. diphtheriae 
and MTB revealed strong binding affnity of IpsA for C. diphtheriae promoters 
DIP0115 and DIP0021 (Figure 3.13A) and a binding site within the orf of Rv0047c, 
located upstream of Rv0046c in Rv0047c-46 operon in MTB. The binding sites as 
revealed by MEME and EMSA analysis are summarised in Figure 3.13 B. The 
complex location of identified binding site within the gene highlights the possibility of 





Figure 3.13: Binding affinity and motif for IpsA homologues in C. diphtheria and M. 
tuberculosis. A. EMSA analysis for predicted IpsA binding sites of DIP0021, DIP0115, 
Rv0047 and the neg. control. B. IpsA binding motif as generated by MEME analysis of IpsA 
binding sites in C. diphtheriae and M. tuberculosis target genes. (Figure and data were 
provided by Baumgart et. al., Julich) 
 
3.3.7 Chromatographic analysis of polar lipid extracts from C. glutamicum 
∆2910 and complemented strains.  
Since myo-inostiol is implicated in synthesises of PI, the building block of PIMs, LM 
and LAM, the effect of IpsA deletion was also studied on these cell wall components. 
For this purpose, [
14
C]-labelled polar lipids were extracted from the wild type, C. 
glutamicum ∆ipsA and the complemented strains grown on glucose (Figure 3.14) and 
inositol (Figure 3.15) and the respective glycolipid profiles were examined using 2D-
TLC. The wild-type strain showed spots corresponding to AcPIM2, PI, Gl-A 
(GlcAGroAc2) and Gl-X (ManGlcAGroAc2) in lipid extracts (Figure 3.14A and 







glucopyranosyl uronic acid, incorporation of [
14
C]-acetate label was evident and weak 
spots were obtained for both Gl-A and Gl-X. The predominant spot on the TLCs 
migrating at the same position as Gl-X corresponds to PI. Interestingly, no AcPIM2 was 
observed in lipid extracts isolated from the mutant C. glutamicum ∆ipsA (Figure 
3.14B) when cultured in minimal media supplemented with glucose indicating absence 
of PI based glycolipid synthesis in the mutant. Successful complementation of the loss 
of gene function was observed for ∆ipsA complemented with cg3323 (Figure 3.14C), 
cg2910 (Figure 3.14D), DIP1969 (Figure 3.14F) with an exception of Rv3575c (Figure 
3.13E), as none of the components were stained with phosphate specific stain. The 
lipid extracts isolated from the mutant and complemented strains cultured in minimal 
media supplemented with inositol were similar to wildtype with distinct AcPIM2 and PI 





Figure 3.14. 2D-TLC analysis of [
14
C]-labelled polar lipids from glucose grown cells. A. 
C. glutamicum ATCC 13032, B. ATCC 13032 ΔipsA, C. ATCC 13032 ΔipsA pAN6-cg3323, 
D. ATCC 13032 ΔipsA::pK18int-ipsA, E. ATCC 13032 ΔipsA pAN6-Rv3575c and F. ATCC 
13032 ΔipsA pAN6-DIP1969, cultured in CGXII supplemented with 2% (w/v) glucose. The 
polar lipids extracts were loaded on silica gel 60 TLCs and developed in the solvent system: 
chloroform/methanol/water (60:30:6, v/v/v) in direction 1 and 









































Figure 3.15. 2D-TLC analysis of [
14
C]-labelled polar lipids from myo-inositol-grown cells. 
A. C. glutamicum ATCC 13032, B. ATCC 13032 ΔipsA, C. ATCC 13032 ΔipsA pAN6-
cg3323, D. ATCC 13032 ΔipsA::pK18int-ipsA, E. ATCC 13032 ΔipsA pAN6-Rv3575c and F. 
ATCC 13032 ΔipsA pAN6-DIP1969, cultured in CGXII supplemented with 2% (w/v) inositol. 
The polar lipids extracts were loaded on silica gel 60 TLCs and developed in the solvent 
system: chloroform/methanol/water (60:30:6, v/v/v) in direction 1 and 




3.3.8 Analysis of lipoglycan extracts.  
Since the lipoglycans LM and LAM are built on PIMs which are mannosylated 
products of PI, effect of transcriptional regulator IpsA was also studied on these 
lipoglycans extracted from the wild type, mutant strain C. glutamicum ∆ipsA and the 
complemented strains cultured in minimal media supplemented with glucose or inositol 
and analysed by 15% SDS-PAGE gels stained using Pro-Q emerald stain specific for 
glycoproteins (Figure 3.16 A and B). The lipoglycan extracts from the wildtype 
cultured in glucose or inositol showed clear presence of LAM and Cg-LM-A/B. 
However, the lipoglycan extracts from the mutant C. glutamicum ∆ipsA grown on 
minimal media supplemented with glucose revealed no LAM while a band 
corresponding to Cg-LM-B could be observed (Fig 3.16A). The complemented strains 
C. glutamicum ΔipsA::pK18int-ipsA and C.glutamicum ΔipsA containing cg3323 and 
DIP1926 in plasmid pAN6 grown in minimal media supplemented with glucose 
exhibited lipoglycan profiles identical to the wildtype (Figure 3.16A). However, no 
band corresponding to LAM was observed in lipoglycan extracts of C.glutamicum 
ΔipsA complemented with Rv3575c in pAN6 plasmid grown in minimal media 
supplemented with glucose (Fig 3.16A). Instead, a band corresponding to Cg-LM-B 
was evident. Absence of LAM in lipoglycan isolates from the mutant strain 
complemented with Rv3575 was a result of partial complementation of phenotype by 
Rv3575c in C.glutamicum ΔipsA. The lipoglycans isolated from the mutant and 
complemented strains cultured in minimal media supplemented with inositol were 


































Figure 3.16: Lipoglycan profiles of C. glutamicum ATCC 13032, ATCC 13032 ΔipsA, 
ATCC 13032 ΔipsA pAN6-cg3323, ATCC 13032 ΔipsA::pK18int-ipsA, ATCC 13032 
ΔipsA pAN6-DIP1969 and ATCC 13032 ΔipsA, pAN6-Rv3575c A. cultured in CGXII 
supplemented with 2% (w/v) glucose and B. in CGXII supplemented with 2% (w/v
-
) 
inositol. Lipoglycans were analysed on 15% SDS-PAGE and visualised using Pro-Q 
emerald glycoprotein stain. The two major bands represented by Cg-LAM and Cg-LM-
A/B are highlighted. The mutant C. glutamicum ΔipsA was not complemented with pAN6-





3.3.9 Effect of IpsA on mycothiol synthesis 
As implicated from previous results, the ∆ipsA strain loses its ability to synthesise myo-
inositol. Therefore, the effect of loss of ipsA gene function should also be evident on 
mycothiol biosynthesis. To test this hypothesis, intracellular levels of mycothiol were 
measured in wild type, deletion mutant and the complemented strains (Figure 3.17) 
using a previously described protocol (Feng et al., 2006). To identify the peak 
corresponding to Mycothiol, chromatograms obtained for the wild type, IpsA deletion 
mutant and complemented strains were compared to those of mutant lacking mycothiol 
(ΔmshC) and to a control sample from wild type pre-treated with NMM (N-methyl-
maleimide) that served as standards.  The largest peak in wild type sample at ≈5 
minutes was absent in control samples thus implying it as mycothiol. The ΔipsA strain 
showed no peak corresponding to mycothiol but full complementation was seen for 
mutant with plasmid-encoded copy of IpsA (Figure 3.17). However, only partial 
complementation of mycothiol biosynthesis was observed in IpsA homologs from C. 
diphtheriae and M. tuberculosis consistent with the growth and morphology 
phenotypes. The mutant strain C. glutamicum ΔmshC exhibited a slow growth 
particularly during the pre-culture, consistent with previous studies (Feng et al., 2006; 
Newton et al., 2008). It is likely that MSH may have an important role to play in 
initiation of cell metabolism in an oxygen rich environment (Newton et al., 2008). 
However, in this study the C. glutamicum ΔmshC strain was not analysed for any 





































Figure 3.17: Analysis of mycothiol biosynthesis in C. glutamicum wild type, IpsA mutant 
and complemented strains. Mycothiol was extracted from relevant strains, derivatised and 
subjected to HPLC. The eluted fractions were checked using a fluorescence detector (390 nm 
excitation and 475 nm emission) for presence of mycothiol. Based on the chromatograms from 
mycothiol lacking ∆msh strain and NMM treated wild type samples as standards, the 
corresponding peak for mycothiol (marked with the dotted line) was identified and analysed 




3.4  Discussion 
The pathways for biogenesis of the cell wall components are well characterised in 
mycobacteria and corynebacteria with few missing pieces. However the regulation of 
biosynthesis of these components in both the organisms remains poorly understood. In 
an attempt to understand the regulation of biosynthesis of these cell wall components, 
we have identified a novel transcriptional regulator, named IpsA in corynebacteria and 
mycobacteria that functions as an activator of ino1, an inositol monophosphate 
synthase which is responsible for myo-inositol synthesis in Corynebacteriales. Inositol 
is an important component in mycobacteria and corynebacteria as it functions as a key 
component in synthesis of cell wall lipogycans and the antioxidant MSH (Fahey, 2013; 
Mishra et al., 2011c). Disruption in inositol or mycothiol biosynthesis in MTB can lead 
to serious growth defects (Movahedzadeh et al., 2004b; Vilcheze et al., 2008), thus 
highlighting its significance in development of new drugs and its potential as a putative 
target. In this study, we have demonstrated that deletion of ipsA in C. glutamicum leads 
to a complete loss of mycothiol, PI and its derived lipids thus suggesting the 
significance of IpsA in these biosynthetic pathways. The two genes ino1 and cg0044, 
were identified as major targets of IpsA that are activated in an inositol-dependant 
manner (Klaffl et al., 2013; Krings et al., 2006). Our findings are consistent with 
previous studies that have identified tranporters, regulators and enzymes for inostiol 
catabolism and suggested myo-insoitol to function as an alternative carbon source in C. 
glutamicum (Turner et al., 2002).  
The bioinformatic analysis of genomic loci of ipsA and its homologues in other 
corynebacteria and mycobacteria revealed a high degree of conservation of this gene 
among these species (Figure 3.1). In the genomes analysed, ipsA was found to be 
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situated downstream to znuACB, that encodes a putative zinc transport system (Krings 
et al., 2006). Interestingly, zinc ion is required as a co-factor for catalytic function of 
IpsA target, Ino1 along with NAD
+
 (Norman et al., 2002). Downstream region of ipsA 
shows variability in terms of genetic arrangement dominated by genes encoding for 
proteins in trehalose biosynthesis (otsAB) (Schröder et al., 2010). 
 
DNA microarray analysis revealed several targets of IpsA whose promoters were 
subsequently tested for their binding efficiency with purified IpsA using EMSA. These 
results suggested ino1 as the primary target which was further confirmed with genetic 
complementation studies. Whilst ino1 may serve as the major target for IpsA, it is 
likely that other target genes, as suggested by DNA microarray and binding assays can 
also function as secondary targets, but the effect of IpsA on regulation of these genes is 
only important in specific stress conditions like shortage of carbon source, nutrients, 
metal ions etc. Majority of the targets as revealed by microarray and EMSA analysis 
are uncharacterised but might be important for regulation of cell wall and MSH 
biosynthesis with a potential to serve as drug targets for development of therapeutics. 





Table 3.4: IpsA targets with probable link to cell wall and MSH biosynthesis.  (As 
suggested by Baumgart et. al., Julich) 
 




Uptake of inositol (-
derived) carbohydrates 
for cell wall biogenesis 
cg3210 
Cell envelope-related 
transcriptional regulator of 
the LytR type 




binding enzyme similar to 
coenzyme F420-dependent 
NADP oxidoreductases 
Supply or regeneration 







NAD(P) binding domain 
 
Interestingly, information about regulation of target genes by IpsA, as generated from 
microarray analysis suggested a strong correlation between the location of IpsA 
binding site and the -35 region of promoter sequences. The analysis of these regions 
highlighted that the IpsA binding site is located upstream of the -35 region in the target 
genes which are up-regulated (cg3323, cg0044, cg3210, and cg3195) in ∆ipsA strain 
while the for the down-regulated genes (cg1421 and cg0534), the sites show 
overlapping with the -35 and/or the -10 region indicating a direct correlation between 




Figure 3.18: Transcription start sites, IpsA binding sites and promoter regions of the 
IpsA target genes in C. glutamicum. Transcriptional start sites for target genes (red) and 
binding sites for IpsA (blue) in the target genes and their location in the promoter including 
the -35 and -10 regions and  transcription ratio as obtained from microarray of IpsA mutant. 
IpsA binds the -35 regions in cg1421 and cg0534 that prevents ribosome from translating the 
genes. (Figure and data were provided by Baumgart et. al., Julich). 
 
The data obtained from microarray, EMSA, growth and morphology studies identified 
IpsA as a transcriptional regulator of ino1, inositol monophosphate synthase that 
catalyses the conversion of glucose-6-phosphate to inositol-1-monophosphate, the first 
step of PI biosynthesis. Since PI serves as the scaffold on which the cell wall 
components such as PIMs, LM and LAM are built, the mutant and the complemented 
strains were analysed for polar lipids and lipoglycans. The chromatographic analysis of 
radiolabelled polar lipids extracts of the mutant C. glutamicum ∆ipsA grown in 
minimal media supplemented with glucose displayed deficiency of AcPIM2 and PI 
whilst Gl-A and Gl-X remained unaffected. In addition, the mutant strain grown on 
minimal media supplemented with glucose failed to produce PI based LAM and 
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instead, GL-X based LM, Cg-LM-B was apparent on SDS-PAGE analysis of 
lipoglycans. The loss of phenotype in C. glutamicum ∆ipsA was checked for self 
complementation in C. glutamicum::pK18int-ipsA. The polar lipid and lipoglycan 
extracts from this strain grown on minimal media supplemented with glucose displayed 
adequate AcPIM2, PI, LM and LAM biosynthesis and profiles akin to wild type 
suggesting that the deletion of this putative transcriptional regulator in C. glutamicum 
abolishes the capacity of the bacteria to synthesise AcPIM2 and PI based LM and LAM 
thus implying its involvement in early stages of PI biosynthesis.  
 
To validate ino1 as the effector target for IpsA, C. glutamicum ∆ipsA was checked for 
reversal of mutant phenotype when complemented with plasmid harbouring ino1. The 
polar and lipoglycan extracts obtained from the complemented strain grown in glucose 
when analysed, displayed profiles identical to that of wild type due to restoration of PI 
biosynthesis. The results obtained strongly imply that in absence of IpsA , PI based 
PIMs, LM and LAM are not synthesised as the mutant strain no longer produces the 
inositol monophosphate synthase (ino1) required for synthesis of myo-inositol, a 
substrate for PI production. These findings supplement the possibility of IpsA to 
function as a transcriptional activator of inositol monophosphate synthase, Ino1. 
Furthermore, the polar lipid and lipoglycan extract of C. glutamicum ∆ipsA 
complemented with its C. diphtheria homologue (DIP1926) exhibited lipid profiles 
akin to wildtype indicating DIP1926 to be a functional equivalent of IpsA and can be 
designated as a transcriptional activator of ino1 (DIP0115) in this pathogen. The IpsA 
homologue in M. tuberculosis (Rv3575) demonstrated partial complementation in 
terms of growth, morphology and mycothiol biosynthesis, no PI based lipids or 
lipogylcans were identified on the TLCs. It is possible that any inositol generated in 
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this state is diverted for mycothiol biosynthesis probably due to higher affinity of the 
enzyme at this step than for PgsA. This diversion of inostiol away from PI biosynthesis 
pathway could result in generation of low quantities of PI and its derived lipids, 
sufficient enough for growth but not for detection by TLC. Additionally, the strategic 
placement of PadR like transcriptional regulator, upstream of ino1 in the genomic loci 
of M. tuberculosis and its co-transcription with IpsA target, ino1 (Norman et al., 2002) 
hint towards its involvement as an extra regulator in ino1 expression. Further studies are 
required to confirm the function of IpsA in mycobacteria.  
 
This study has identified IpsA, as a novel LacI based transcriptional regulator for 
inositol biosynthesis in Corynebacteriales. The function of IpsA and its regulatory 
mechanism highlights the fine control of cell wall biogenesis by interplay of various 
enzymes. Since disruption of any of these pathways could drastically affect cell wall, 
the first line of defense in species of mycolata taxon, these pathways thus generate 
novel targets for therapy and drug development. In addition, identification and 
characterisation of this novel regulator could prove as a stepping-stone for further 














4 Mapping the protein-protein interactions between mycobacterial 
glycosyltransferases for LAM biosynthesis using adenylate cyclase based bacterial 
two hybrid system and its potential applications in drug discovery 
 
4.1 Introduction 
The availability of whole genome sequence data for MTB has helped the research 
community make major advancements into tackling the problems of high-level TB drug 
resistance. The advent of the genomic era triggered a change in experimentation and 
helped researchers shift their focus towards identifying and characterising the gene 
products of mycobacteria that play an important role in virulence, immunity and 
survival of this pathogen. This approach enabled the mycobacterial research community 
to recognise several genes in mycobacteria with a potential to serve as drug targets. 
Numerous new compounds are generated each year but fail to translate into future 
drugs. In an attempt to bridge this gap, the post-genomic era in TB research has made 
use of data from sequencing, microarrays and other high-throughput methods, and 
successfully applied it to the fairly new field of proteomics. In this regard, protein-
protein interactions has emerged as a valuable tool in drug discovery. Protein-protein 
interactions (PPI) has been employed to study protein dimerisation (Mai et al., 2011), 
formation of enzymatic complexes (Veyron-Churlet et al., 2005; Veyron-Churlet et al., 
2004), signal transduction (Cui et al., 2009; Lee et al., 2012a), and transport systems 
(Raman and Chandra, 2008)  in mycobacteria. In addition, PPI studies at the proteome-
level have aided in dissecting the pathways to drug resistance (Cui et al., 2009; Raman 
and Chandra, 2008). This information can be exploited to assess druggablity of the 




The cell wall of mycobacteria has always served as a very attractive target for 
developing anti-tubercular compounds. The free lipids in the mycobacterial cell wall, 
such as PIMs, LM, and LAM are important structural components, that play a central 
role in the pathogen’s viability and the modulation of host immune responses (Mishra et 
al., 2011a). Therefore, the pathways for the biogenesis of these components provides a 
valuable system to discover new anti-tubercular agents. The arabinan and mannan 
motifs in LAM are extensively branched and require a series of glycosylation reactions 
which are mediated by numerous mannopyranosyl transferases (ManTs) and 
arabinofuranosyl transferases (AraTs) that are tightly regulated. For this purpose, a rapid 
and efficient flux of the metabolic intermediates from one catalytic site to another is 
necessary and can likely be achieved if the intermediates are channeled through the 
pathway. Therefore, these AraTs, ManTs and other associated enzymes of LAM 
biosynthesis can possibly exist in metabolons that are dependent on protein-protein 
interactions to aid in the channeling process. This hypothesis is further strengthened by 
blue native poly-acrylamide gel electrophoresis (BN-PAGE) studies on the proteome of 
M. bovis BCG that identified several proteins clustered together in multi-enzyme 
complexes, which included the AraTs EmbA, EmbB and EmbC (Zheng et al., 2011). In 
addition, the genetic organisation of the emb operon, reveals a high degree of similarity 
between the Emb proteins (61% - 68%) (Wolucka, 2008), similar catalytic activities and 
their contribution to EMB resistance all favour the possibility of  EmbA (Rv3794), 
EmbB (Rv3795)  and EmbC (Rv3793) to exist as a metabolon in M. tuberculosis. 
 
The BN-PAGE study also identified the regulatory protein LpqW (Rv1166) to be 
associated with the probable Emb complex as a soluble functional partner of these 
AraTs (Zheng et al., 2011). The function of LpqW is critical as it mediates the flux of 
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PIM4, to polar PIMs and LAM (Kovacevic et al., 2006; Rainczuk et al., 2012). 
Synthesis of PIM4 serves as a branch point in the pathway as it can either be flipped 
towards the extra-cytoplasmic side by unknown flippases (Berg et al., 2007) and 
subsequently mannosylated by the GT-C superfamily glycosyltransferases MptB, MptA 
and MptC (Besra et al., 1997) or be directed towards PIM6 formation that is catalysed 
by another GT-C superfamily glycosyltransferase, PimE (Haites et al., 2005a; Morita et 
al., 2004). The relative distribution of PIM4 is determined by regulating the competing 
mannosyltransferases PimE (Rv1159) and MptB (Rv1459c) by LpqW (Berg et al., 
2007), that is possibly dependent on PimE-LpqW, MptB-LpqW interactions. 
 
Therefore, in this study, we have attempted to deduce the critical homotypic and 
heterotypic interactions between the glycosyltransferases and accessory proteins of the 
lipoglycan biosynthesis pathway using a Bacterial Two Hybrid system based on the 
reconstitution of adenylate cyclase (Karimova et al., 1998b). This system relies on 
functional complementation between the two fragments (T25: residues 1-224 and T18: 
residues 225-399) of the catalytic domains in adenylate cyclase (AC) enzyme (cyaA) 
from Bordetella pertussis to reconstruct the cAMP signalling cascade in E. coli. The 
individual proteins in LAM biosynthesis were fused to the T25 and T18 fragments and 
co-expressed in Cya
-
 E. coli. Positive interactions result in heterodimerisation of 
chimeric T25 and T18 that confers a Cya
+ 
phenotype that is detected using 
indicator/selective media. The degree of interaction between the proteins was also 
assessed using β-galactosidase assays. The principle and methodology of the procedure 






















NO REPORTER GENE EXPRESSION
(Lac-, Mal-, Cya- phenotype)
 
 
Figure 4.1: Principle of detecting protein-protein interactions using two-hybrid system. 
A. The interaction between the two domains (T18 and T25) is necessary for reconstitution of a 
functional adenylate cyclase (AC). AC synthesises the regulatory molecule cAMP that has a 
pleiotroipc effect on transcription in E. coli by binding to the catabolite activator protein 
(CAP). The cAMP-CAP complex controls the expression of many genes involved in 
catabolism of carbohydrates, including the lac or mal genes of lactose and maltose catabolism. 
The strains used for selecting the positive clones lack the endogenous adenylate cyclase (cya) 
and thus are unable to ferment these carbohydrates. When adenylate cyclase is reconstituted in 
Cya
-
 E.coli, it drives the synthesis of cAMP to give a Cya
+
 phenotype that can be 
distinguished from Cya
-
 on indicator media such as LB supplemented with X-Gal, 
MacConkey or on selective media such as M63. B. The fusion of the T25 and T18 domains 
with proteins of interest (A and B) would result in a Cya
+
 phenotype only when the proteins 
interact. C. In absence of any interaction between the proteins of interest (A and C) would not 










Figure 4.2: Methodology for detecting protein-protein interactions using two-hybrid 
system based on reassembly of adenylate cyclase. The proteins of interest (A and B) are 
cloned into the IPTG inducible vectors with an N or C-terminal T25 (pKT25/pKNT25) or T18 
domain (pUT18C/pUT18) and co-transformed into Cya
-
 E. coli strain (BTH101). The 
transformants are selected on LB agar plates with antibiotics and overnight cultures are set up 
in LB broth with antibiotics. The cultures are also induced with 0.5 mM IPTG for expression 





spotting or streaking on LB agar plates with 40 µg/mL X-gal and MacConkey agar plates with 
1% maltose. The plates are supplemented with 0.5 mM IPTG and antibiotics. The colonies are 
also tested for growth on minimal M63 agar plates with 0.2% maltose. For characterisation, β-
galactosidase assays are performed to assay the activity of the enzyme and the extent of 
interaction. Additionally, the plasmids are retransformed into BTH101 and put through the 
same procedure to confirm the interaction.  A true positive interaction is characterised by blue 
colonies on LB-X-gal, red colonies on MacConkey-maltose, growth on M63-maltose, 










pKT25 (or pKNT25) pUT18C (or pUT18)
Co-transform into BTH101
Plate transformants on LB+Antibiotics
Screen on LB-X-gal + Antibiotics + IPTG plates
and MacConkey-maltose + Antibiotics
Select on M63-maltose + X-gal + Antibiotics + IPTG  plates
Characterise clones by β-galactosidase assay and Retransformation
A and B interact  
• Blue colonies on LB-X-gal  • Pink colonies on MacConkey-maltose 
• Growth on M63 • β-galactosidase activity 
• Same results on Retransformation
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4.2 Materials and Methods 
 
4.2.1 Chemicals, reagents and enzymes 
All chemicals and solvents were bought from Sigma-Aldrich (Dorset, UK), Bio- Rad 
(Ca, USA) and Fisher Chemicals (UK) unless otherwise stated, and were of AnalR 
grade or equivalent. Plasmids were propagated during cloning in E. coli XL-1 Blue cells 
(Invitrogen). All restriction enzymes, T4 DNA ligase and Phusion DNA polymerase 
enzyme were sourced from New England Biolabs. Oligonucleotides were from MWG 
Biotech Ltd and PCR fragments were purified using the QIAquick gel extraction kit 
(Qiagen). Plasmid DNA was purified using the QIAprep purification kit (Qiagen). 
 
4.2.2 Bacterial strains, plasmids and growth conditions 
The vector plasmids were propagated in E. coli XL-1 Blue cells using the protocol 
mentioned in General Materials and Methods section 7.3.6 and 7.3.7. The strain 
BTH101 (F
-
, cya-99, araD139, galE15, galK16, rpsL1 (Str 
r
), hsdR2, mcrA1, mcrB1) 
was used as the host organism for detection of protein-protein interactions (Claessen et 
al., 2008; Karimova et al., 1998a). The strains were routinely grown in Luria-Bertani 
broth (LB, Difco) at 37°C (Sambrook et al. 1989) unless otherwise stated. Appropriate 
antibiotics were added for selection of required strains. 
Plasmids were isolated using the QIAprep Spin Miniprep Kit. The E. coli cells were 
transformed using rubidium chloride method as mentioned in the General Materials and 




4.2.3  Construction of plasmids and strains 
The plasmids used in this work are IPTG inducible E. coli expression vectors. To 
generate C-term and/or N-term T25 and/or T18 fused proteins, pUT18 (T18 fusion in N-
terminus), pUT18C (T18 fusion in C-terminus), pKT25 (T25 fusion in C-terminus) and 
pKNT25 (T25 fusion in N-terminus) vectors were used for cloning the gene of interest. 
The genes for LAM biosynthesis pathway in M. tuberculosis were amplified from 
genomic DNA of M. tuberculosis H37Rv. The primers and the restriction sites used for 
the study are listed in Table 4.1. The BACTH system kit (Karimova et al., 1998b) 
comprising of vectors, positive controls and relevant strains required for analysis of 
complementation were obtained from Euromedex. All the constructs were confirmed by 
sequencing by Eurofins DNA Ltd. using the standard M13 reverse primer (29mer) and 
gene specific internal primers where necessary. 
4.2.4 Control plasmids 
The plasmid pKT25-zip is a derivative of pKT25 in which the leucine zipper of 
eukaryotic transcriptional activiator GCN4 is genetically fused in frame to the T25 
fragment (cloned within the KpnI site of pKT25) of adenylate cyclase enzyme. The 
vector construct pUT18C-zip is a derivative of pUT18C in which the leucine zipper of 
GCN4 is genetically fused in frame to the T18 fragment (cloned between the restriction 
sites, KpnI and EcoRI of pUT18C). The constructs pKT25-zip and pUT18C-zip 
function as positive controls for complementation analysis as the T25-zip and T18-zip 
fusion proteins expressed by these plasmids interact due to dimerization of the leucine 
zipper motifs attached to the T25 and T18 fragments. When pKT25-zip and pUT18C-
zip are co-transformed into BTH101, they restore the characteristic Cya
+
 phenotype that 
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is detected by red colonies on MacConkey, blue colonies on LB-X-gal and growth on 
M63 minimal media plates. 
 
4.2.5 Screening of protein-protein interactions using the bacterial two hybrid 
system 
The screening of potential protein-protein interactions relies on reverting Cya
-
 E. coli 
strain to Cya
+
 by co-expressing the fusion constructs. The reversion of mutant 
phenotype happens only during a positive interaction as in this case the adenylate 
cyclase is successfully reconstituted, thus resulting in expression of resident reporter 
genes that confer β-galactosidase activity, ability to utilise lactose and maltose as a 
carbon source to the mutant.  
 
The genes encoding the glycosyltransferases and accessory proteins of the LAM 
biosynthesis pathway (Table 4.1) were amplified from genomic DNA of M. tuberculosis 
H37Rv by PCR using suitable primer pairs (Table 4.1) and were ligated in frame with 
the T25 and T18 fragment of pKT25 (or pKNT25) and pUT18 (or pUT18C) vectors 
linearised via appropriate restriction enzymes (Table 4.1). The ligation reactions were 
performed using T4 DNA ligase. Since the vectors do not encode the LacI repressor, to 
avoid accumulation of mutations in the constructs, the vectors and recombinant 
plasmids were commonly propagated at 30°C in standard E. coli strain, such as XL1-
Blue with lacI
q
. Plasmid DNA was routinely purified using the QIAgen miniprep kit 
used for mini-preparation of DNA, according to the manufacturer’s instructions. 
Positive clones were subsequently verified by sequencing using M13 reverse primer (5ꞌ- 
CAGGAAACAGCTATGACC-3ꞌ) and internal primer where necessary. The two 
recombinant plasmids encoding the N or C-terminal T25 domain and N or C-terminal 
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T18 domain tagged hybrid proteins were transformed into competent BTH101 reporter 
cells. Transformants were plated on LB agar plates supplemented with antibiotics (100 
µg/mL Amp, 50 µg/mL Kan) for selection of both plasmids and incubated at 30°C for 
24 hours. A positive control using the pKT25-zip and pUT18C-zip was subjected 
through the same process and was employed for detecting the interactions. The 
combinations pKT25-pUT18, pKT25-pUT18C, pKNT25-pUT18, pKNT25-pUT18C 
were used as negative experimental controls. To eliminate false positives due to sticky 
proteins, the fusion constructs were transformed with empty vector with the second 
interacting domain (For eg. A-pKT25 was tested with pUT18 and pUT18C) and 
analysed using the same method. 
 
For screening, 2-3 colonies of the co-transformants were used to initiate overnight 
cultures (200 rpm, 30ºC, 16 hours) in 2 mL LB broth supplemented with antibiotics 
(100 µg/mL Amp, 50 µg/mL Kan, 50 µg/mL Strep) and 0.5 mM IPTG to induce protein 
expression. To analyse the expression of the β-galactosidase (lacZ) in co-transformants, 
3-5µL of the overnight cultures were spotted on LB agar plates with 40 µg/mL X-gal (5-
bromo-4-chloro-3-indolyl-β-d-galactopyranoside), 0.5 mM IPTG and antibiotics (100 
µg/mL Amp, 50 µg/mL Kan, 50 µg/mL Strep). The plates were incubated at 30ºC for 48 
hours and the colour change was noted. As a second screening procedure, the co-
transformants were also spotted on MacConkey agar plates with 1% maltose, 0.5 mM 
IPTG and antibiotics (100 µg/mL Amp, 50 µg/mL Kan, 50 µg/mL Strep) and incubated 
at 30ºC for 2-3 days. The phenotype of the colonies on indicator plates was compared to 
that of the positive control. The blue colonies on LB-X-gal plates and red colonies on 
MacConkey-maltose plates were indicative of positive interactions. 
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Table 4.1: Oligonucleotides and plasmid constructs used in this study. 
Construct 
Oligonucleotide Sequence 






,  pSU40 derivative with T25 
domain of CyaA under lac promoter, 




,  pSU40 derivative with T25 
domain of CyaA under lac promoter, 




,  pUC19 derivative with T18 
domain of CyaA under lac promoter, 




,  pUC19 derivative with T18 
domain of CyaA under lacpromoter, 




,  pSU40 derivative with T25 
domain of CyaA fused in frame with 
leucine zipper of GCN4 within KpnI 




,  pUC19 derivative with T18 
domain of CyaA fused in frame with 
leucine zipper of GCN4 within KpnI  








,  Rv2610 fused in frame with 
T25 domain of CyaA at N-terminus 









,  Rv2610 fused in frame with 
T18 domain of CyaA at C-terminus 









,  Rv2188c fused in frame with 
T25 domain of CyaA at C-terminus 









,  Rv2188c fused in frame with 
T25 domain of CyaA at N-terminus 











,  Rv2188c fused in frame with 
T18 domain of CyaA at N-terminus 









,  Rv2188c fused in frame with 
T18 domain of CyaA at C-terminus 









,  Rv2611c fused in frame with 
T25 domain of CyaA at C-terminus 









,  Rv2611c fused in frame with 
T25 domain of CyaA at N-terminus 









,  Rv2611c fused in frame with 
T18 domain of CyaA at C-terminus 









,  Rv1166 fused in frame with 
T25 domain of CyaA at N-terminus 









,  Rv1166 fused in frame with 
T18 domain of CyaA at C-terminus 











,  Rv1159 fused in frame with 
T18 domain of CyaA at C-terminus 











,  Rv2174 fused in frame with 
T25 domain of CyaA at C-terminus 













,  Rv1459c fused in frame with 
T25 domain of CyaA at N-terminus 











,  Rv1459c fused in frame with 
T18 domain of CyaA at C-terminus 









,  Rv2181 fused in frame with 
T25 domain of CyaA at C-terminus 










,  Rv2181 fused in frame with 
T25 domain of CyaA at N-terminus 










,  Rv2181 fused in frame with 
T18 domain of CyaA at N-terminus 









,  Rv3794 fused in frame with 
T25 domain of CyaA at C-terminus 











,  Rv3795 fused in frame with 
T25 domain of CyaA at N-terminus 











,  Rv3795 fused in frame with 
T18 domain of CyaA at C-terminus 













,  Rv3793 fused in frame with 
T25 domain of CyaA at N-terminus 









,  Rv3793 fused in frame with 
T18 domain of CyaA at C-terminus 









,  Rv2673 fused in frame with 
T25 domain of CyaA at N-terminus 









,  Rv2673 fused in frame with 
T18 domain of CyaA at C-terminus 









,  Rv0236c fused in frame with 
T25 domain of CyaA at N-terminus 









,  Rv0236c fused in frame with 
T18 domain of CyaA at N-terminus 










,  Rv1635c fused in frame with 
T25 domain of CyaA at N-terminus 











,  Rv1635c fused in frame with 
T18 domain of CyaA at C-terminus 




4.2.6 Selection of positive interactions as determined by the screening 
procedure 
The transfomants screened for a Lac
+ 
phenotype were further selected for Mal
+
 by 
spotting the co-transformants on M63-maltose plates. For this purpose, the co-
transformants previously cultured on the LB-X-gal plates were used to inoculate 2 mL 
of LB broth supplemented with antibiotics (100 µg/mL Amp, 50 µg/mL Kan, 50 µg/mL 
Strep) and 0.5 mM IPTG to induce protein expression. The cultures were grown 
overnight at 30ºC, 200 rpm and harvested by centrifugation at 4000 rpm, 10 minutes. 
The pellets were washed twice with 2 mL of M63 minimal media (2 g (NH4)2SO4, 13.6 
g KH2PO4, 0.5 mg FeSO4.7H2O, 1 mg vitamin B1, pH 7.0 adjusted with KOH) in order 
to remove all traces of the rich medium and were resuspended in 2 mL of M63 minimal 
medium with 0.2 % maltose, 0.5 mM IPTG and antibiotics (50 µg/mL Amp, 25 µg/mL 
Kan, 25 µg/mL Strep). The suspension volume of 3-5 µL was used to spot M63 agar 
plates with 0.2 % maltose, 40 µg/mL X-gal, 0.5 mM IPTG and antibiotics (50 µg/mL 
Amp, 25 µg/mL Kan, 25 µg/mL Strep) and incubated at 30ºC for 2-7 days. The plates 
were examined for growth of Mal
+
 colonies after 3-7 days of incubation at 30°C. Since 







4.2.7 Characterisation of selected positive interactions using β-galactosidase 
activity assay 
The co-transformants that were tested positive were analysed for β-galactosidase 
activity due to restoration of Cya
+
 phenotype in the Cya
- 
BTH101. Freshly co-
transformed cells, selected on LB plates with antibiotics (100 µg/mL Amp, 50 µg/mL 
Kan) were cultured in 2 mL LB broth supplemented with antibiotics (100 µg/mL Amp, 
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50 µg/mL Kan, 50 µg/mL Strep) and 0.5 mM IPTG at 200 rpm, 30ºC  for 16 hours to 
induce protein expression. The cultures were spotted on LB agar plates with 40 µg/mL 
X-gal, 0.5 mM IPTG and antibiotics (100 µg/mL Amp, 50 µg/mL Kan, 50 µg/mL Strep) 
and the plates were incubated at 30ºC for 2 days. These co-transformants were then used 
to inoculate 2 mL of LB broth supplemented with antibiotics (100 µg/mL Amp, 50 
µg/mL Kan, 50 µg/mL Strep) and 0.5 mM IPTG to induce protein expression. The 
cultures were grown overnight at 30ºC, 200 rpm and harvested by centrifugation at 3219 
x g, 10 minutes. The pellets were washed twice with 2 mL of M63 minimal media in 
order to remove all traces of the rich medium and resuspended in 2 mL of M63-maltose 
(M63 minimal medium with 0.2% maltose), 0.5 mM IPTG and antibiotics (50 µg/mL 
Amp, 25 µg/mL Kan, 25 µg/mL Strep). 
 
For the assay, the overnight cultures were diluted four-fold (0.5 mL cell culture in 1.5 
mL M63-maltose) in M63-maltose with antibiotics and 0.5 mM IPTG. The optical 
density at 600 nm was measured for 1 mL of the diluted cultures. The cells in remaining 
1 mL of the diluted cultures were permeabilised with a few drops (20-30 µL) of toluene 
and 1% SDS solution and were rigorously vortexed for 10 seconds to allow thorough 
mixing of the components. The traces of toluene were removed by incubating the 
cultures at 37ºC for 30 minutes. To assess the enzyme activity, 100 µL of permeabilised 
cells were added to 900 µL of PM2 buffer (70 mM Na2HPO4.12H2O, 30 mM 
NaH2PO4.H2O, 1 mM MgSO4, 0.2 mM MnSO4, 100 mM β-mercaptoethanol, pH 7) and 
the reaction was initiated by addition of 250 µL of 0.4 % ONPG (o-nitrophenol-
galactoside, prepared in PM2 buffer without 100 mM β-mercaptoethanol). A reaction 
containing all assay components but lacking in the cells was used as a blank. The assay 
mixture was incubated at 28ºC for 15 minutes and stopped by addition of 1 mL of 1 M 
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aqueous Na2CO3 solution. The optical density at 420 nm was measured for the samples 
and the extent of β-galactosidase activity was calculated in terms of Miller Unit (in 
units/mL) values using Miller’s formula, Miller Units = (OD420 X 1000) / (Reaction 
time X Volume of culture assayed X OD600) and Activity Units (in units/mL) using the 
formula, Activity Units = 200 X OD420 / (Reaction time) X dilution factor (i.e. dilution 
factor 10 for 100 µL cells in 900 µL PM2 buffer). The readings were expressed in 
Activity Units/mg protein. The concentration of the protein was determined considering 
the Euromedex prescribed conversions i.e 1mL of culture with OD600 = 1 corresponds to 
300µg of dry weight of bacteria.  
 
The positive control of pKT25-zip and pUT18C-zip, negative controls from 
combinations pKT25-pUT18, pKT25-pUT18C, pKNT25-pUT18, pKNT25-pUT18C 
and the fusion constructs were transformed with empty vector with the second 
interacting domain were assayed for β-glactosidase activity to eliminate false positives.  
 
4.2.8 Validation of the positive interactions by re-transformation  
The plasmid pairs that were screened positive were validated as true positives by re-
transforming into BTH101 and re-checking on indicator plates (MacConkey-maltose 
and M63-maltose) using the afore-mentioned protocols. The co-transformants of the 
pairs that showed consistent Cya
+





4.3 Results  
Adenylate cyclase based bacterial two-hybrid system relies on reconstitution of the 
cAMP triggered signal transduction pathway in E. coli. Calmodulin binding adenylate 
cyclase (AC) of Bordetella pertussis is a 1706 amino acid with a catalytic domain 
residing in the first 400 amino acid residues. The catalytic site is further divided into 
two sub-domains, a 25kDa fragment (1-224 residues) which is responsible for catalysis, 
and a 18kDa fragment (225-399 residues) that binds calmodulin. The enzyme AC that 
synthesises cAMP from ATP is re-assembled in advent of protein-protein interaction 
when the plasmids bearing the T25 and T18 domains of the enzyme are co-expressed in 
Cya
-
 E. coli. Expression and reassembly of AC in Cya
-
 E. coli restores the cAMP 
cascade which further drives the expression of the endogenous genes of the lac and mal 
operon, that is easily detected on indicator plates. When the proteins of interest are 
fused to the T25 and T18 domains of AC, their interaction serves the purpose of 
calmodulin in bringing the two domains together, thus restoring the enzyme function.  
 
4.3.1 Screening and selection of protein-protein interactions using the 
bacterial two-hybrid system 
To identify the potential protein-protein interactions in the LAM biosynthesis pathway, 
the genes encoding the enzymes of the pathway were cloned in T25 and T18 domain 
bearing plasmids (summarised in Table 4.1) and co-expressed in BTH101, a Cya
-
 E. coli 
strain. The co-transformants, thus obtained were examined for expression of lac operon 
and mal operon on LB-X-gal or MacConkey-maltose and on M63-maltose plates after 
48 hours of incubation at 30ºC to enable accumulation of cAMP. Inability of Cya
- 
 E. 
coli to use X-gal or lactose due to absence of β-galactosidase activity results in white 
colonies on LB-X-gal and MacConkey-maltose. In addition, since no cAMP-CAP 
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complex is formed in these cells, expression of mal operon is completely inhibited. 
Consequently, these cells are unable to utilise maltose and cease to grow on M63 
minimal media plates supplemented with maltose as the sole carbohydrate. These 
attributes of Cya
-
 E. coli are reversed in the case of an interaction between the proteins 
fused to the T25 and T18 domains and is characterised by blue colonies on LB-X-gal, 
red colonies on MacConkey-maltose and growth on M63-maltose plates. The strains 
that produced blue colonies on LB-X-gal and/or red colonies on MacConkey-maltose 
were designated to have a Lac
+ 
phenotype and the ones with an ability to grow on M63-
maltose were conferred to have a Mal
+
 phenotype. Since, M63-maltose plates were also 
supplemented with X-gal, any blue colonies on these plates are also Lac
+
. 
The genes were cloned into the vectors with T25 and T18 tags either at the N-terminus 
or at the C-terminus, such that the hybrid protein with either an N or a C-terminal tag 
could be generated. However, despite several attempts at cloning, a few genes such as 
PimE, MptA, EmbA could only be tagged with either of the two domains at only one 
terminus. An interaction can only be detected in case of synthesis of a full-length 
protein which is properly folded. In addition, for a membrane protein to show 
interaction, the protein should correctly be inserted into the membrane with both T25 
and T18 tags facing either the peripasmic or cytoplasmic side at the same instance. The 
corresponding phenotypes obtained for the various prey and bait combinations tested are 




Table 4.2: Probable interacting partners in LAM biosynthesis pathway and their 
phenotypes on indicator plates.  
Prey - T25 fusion 
construct 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Several of the interactions analysed in the screening revealed occasional Lac
+
 revertants 
(Table 4.2) that clustered in a few small colonies in culture spots. These revertants could 
mainly arise in response to stress, such as over-expression of a protein that imparts a 
significant growth disadvantage. To overcome this defect, mutations can be introduced 
in sites that promote growth (Quinones-Soto and Roth, 2011), consequently reverting 
the phenotype to Lac
+
. Additionally, introduction of the plasmid can augment the rate of 
spontaneous mutations in the strain, thus conferring it a mutator phenotype. This 
phenomenon is resultant of defective DNA repair machinery that causes the strain to 




The screening process identified eight putative interactions in the system that include, 
two homotypic interactions; PimA-PimA and LpqW-LpqW and six heterotypic 
interactions; LpqW-PimE, LpqW-MptC, EmbC-MptB, AftC-MptC, AftD-MptC, AftD-




phenotypes on respective indicator plates 
(Figure 4.3). The colony morphologies and phenotypes of protein combinations that 
resulted in a positive signal (Figure 4.3) for interaction were further analysed and 
compared to the negative controls to adjudge their significance. The culture spots were 
homogenous for the afore-mentioned interactions, however sectoring due to revertants 
was evident on MacConkey-maltose in case of LpqW-LpqW (Figure 4.3B). This 
interaction showed a clear positive signal on LB-X-gal and M63-maltose plates. The 
LpqW-PimE pair on the other hand demonstrated a large number of sectors on all the 
plates. Both the interactions could neither be classified as a definite positive or a 




Red papillae and sectoring were also a feature of negative vector controls comprising of 
pKT25 and pKNT25 vectors paired with pUT18C plasmid (Figure 4.3A). These 
revertants in negative controls arise upon introduction of pUT18C plasmid that renders 
a mutator phenotype to the BTH101 strain. The empty vector controls for all the 




phenotype to eliminate false 
positives due to mis-folded or sticky proteins. All the empty vector controls except 




. The sectoring observed for 
the pKNT25-PimA + pUT18C combination was evident on both MacConkey-maltose 
and on M63-maltose. Over-expression of PimA could impart a growth disadvantage on 
nutrient deficient medium or lead to membrane overcrowding that results in a weak 
Lac
+ 
phenotype. However, none of the other negative controls presented a Mal
+
 














































Figure 4.3: Screening of the putative interactions in LAM biosynthesis pathway. A. Vector 
controls for the two-hybrid system. B. Putative interactions from the array of interactions 





and the resultant positive interactions are highlighted. C. Empty vector controls of the screened 
positive interactions. Blue colonies on LB-X-gal, pink colonies on MacConkey and growth on 




4.3.2 Quantification of functional complementation between the hybrid 
proteins by measuring β-galactosidase activity 
A successful interaction is characterised by reconstitution of a functional AC enzyme 
that drives the synthesis of cAMP. This leads to formation of cAMP-CAP complex, 
which switches on the expression of the lac operon including the enzyme β-
glactosidase, encoded by lacZ. The activity of β-glactosidase in co-tranformants 
harbouring prey and bait constructs is therefore an indirect measurement of the protein-
protein interaction between the expressed hybrid proteins. The pairs that were selected 
positive for interaction were also examined for β-galactosidase activity to quantify their 
degree of interaction. The enzyme activity was expressed in activity units (AU) per 
milligram of the dry weight of the cells and were compared to that of the positive 
control (pKT25-Zip + pUT18C-Zip) and negative experimental controls to establish the 
upper and lower limits. The base line activity as determined by negative controls was 
estimated between 75-110 AU/mg and highest enzyme activity as determined by 
positive controls was estimated between 3400-4400 AU/mg (Figure 4.4). The sectoring 
prominent for pUT18C controls had no significant contribution to the activity levels 
thus validating its status as a negative control. 
The enzyme activity of interaction pairs was tested along with the respective empty 
vector controls to establish a true interaction. Of the pairs tested, highest activity was 
obtained for PimA-PimA pair estimated at 2482 ± 993 AU/mg (Figure 4.4A). The 
negative controls for this interaction had activities ranged between 42-58 AU/mg 
(Figure 4.4A). The sectoring and accumulation of revertants as observed in case of 
pKNT25-PimA + pUT18C  (Figure 4.3C) did not affect the β-galactosidase activity 
levels thus rendering PimA-PimA as the true interaction pair with a significant degree of 
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complementation. The interaction pairs LpqW-PimE (Figure 4.4A) and AftD-EmbC 
(Figure 4.4B) recorded moderate β-galactosidase activity levels estimated at 812 ± 165 
AU/mg and 1206 ± 116 AU/mg, respectively. Insignificant activity was observed for the 
corresponding controls, thus establishing LpqW-PimE and AftD-EmbC as a true 
complementation pair. The pairs MptC-LpqW and LpqW-LpqW recorded very low 
levels of β-glactosidase activity (Figure 4.4A) estimated at 327 ± 77 AU/mg and 209 ± 
12 AU/mg, respectively. These values could result either from a weak interaction 






4.3.3 Validating the selected positive interactions 
The prey and bait pairs predicted to interact by the screening and selection process 
were  re-transformed into Cya
- 





phenotype to eliminate any possibility of a false positive to have been selected (Figure 
4.5). The combinations with consistent results as obtained previously were designated 
 
 
Figure 4.4: Quantification of functional complementation between the hybrid proteins 
by β-galactosidase assay. The positive interactions as determined by the screening process 
were evaluated for their ability to reconstitute adenylate cyclase using β-galactosidase assays. 
The values are representative of three independent assays performed. The error bars indicate 
the standard error as from the mean. 
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phenotypes while the results could not be replicated for 
LpqW-LpqW, EmbC-MptB, AftC-MptC and AftD-MptC. Interestingly, a stronger 
signal for interaction was evident in case of LpqW-PimE prey-bait pair. Amplification 
of signal for LpqW-PimE pair on retransformation could signify a weak interaction 
between the pair. In addition, a very weak signal was prominent for LpqW-LpqW pair 
on indicator plates. It is likely that expression of LpqW may have deleterious growth 
defects on BTH101which results in instability of this plasmid over generations. 
Sectoring was evident for LpqW-LpqW and EmbC-MptB on MacConkey plates.  
 
 
Figure 4.5: Validation of the interactions determined by the screening process. The 




 phenotype by 
plating on respective indicator plates. The pairs PimA-PimA, MptC-LpqW and AftD-EmbC 
were tested positive for the interaction while inconsistencies were apparent for LpqW-PimE, 





The bacterial two-hybrid system based on reassembly of cAMP signaling pathway 
(Karimova et al., 1998b) was employed to study protein-protein interactions between 
membrane and soluble proteins of the LAM biosynthetic pathway. The enzymes were 
tagged with domains T25 (prey) and T18 (bait) at either N-terminus or the C-terminus 
and tested for interactions. Following a stringent selection process, we identified four 
hybrid pairs that displayed consistent phenotypes on retransformation and also 
demonstrated significant β-galactosidase activity. These include; self-association 
between PimA, heterotypic association between LpqW and the mannosyl transferase 
PimE and a close involvement between the arabinosyltransferases EmbC and AftD. 
The self-association of PimA as suggested by complementation of Cya
+ 
phenotype by 
PimA fused to T25 domain at C-terminus and PimA fused to T18 domain at N-terminus 
highlights a high possibility of PimA to function as a dimer. PimA catalyses the transfer 
of the first mannose residue from GDP-mannose to the PI anchor, thus affording the 
primary PIM species, PIM1 (Besra et al., 1997; Kordulakova et al., 2002). Although, the 
crystal structure of M. smegmatis homologue of PimA in complex with donor substrate 
GDP-mannose provided no evidence for its dimerisation in solution, a multimer 
formation for catalysis is a prominent feature of several glycosyltransferases of the GT-
B superfamily (Buschiazzo et al., 2004; Horcajada et al., 2006; Metzger and Raetz, 
2009). These evidences hint towards a novel process of dimerisation of a 
glycosyltransferase facilitated by a ligand, such as phosphatidyl inositol (PI) to either 
mediate transfer of mannose from GDP-Mannose to the PI acceptor or aid in release of 
the synthesised phosphatidyl inositol mannoside (PIM1) product. Ligand-mediated 
protein dimerisation has also been reported in Carbohydrate Binding Module (CBM) 
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with protein-carbohydrate interactions (Flint et al., 2004). Self-association in case of 
CBMs contribute to the substrate specificity of these proteins. Conformational studies 
on M. smegmatis homologue of PimA bound to GDP-Mannose suggest a switch in 
conformation from the previously closed state to a relaxed state for the enzyme upon 
binding with PI (Giganti et al., 2013; Guerin et al., 2009b). Therefore, it is highly 
probable that oligomerisation of mannosyltransferase PimA could play an important 
role either in allosteric regulation or in determining the specificity of protein-lipoglycan 
interaction for this enzyme. Dimerisation of PimA can further be analysed using the 
same approach to map the essential domains that mediate the interaction. Furthermore, 
mutations can be introduced into the mapped domains to identify amino acid residues 
critical for this interaction. The information thus generated can aid in the design of 
novel compounds that inhibit this interaction. 
 
The flux of intermediary PIM species PIM4 for generation of LAM and polar PIM 
species requires LpqW to interact with the mannosyltransferases PimE and MptB 
(Crellin et al., 2008; Kovacevic et al., 2006; Rainczuk et al., 2012). The heterotypic 
associations of LpqW with the mannosyltransferases PimE as determined by the two-
hybrid study therefore support its involvement in regulation of LAM biosynthesis. 
Functional complementation between the LpqW fused to T25 domain at C-terminus and 
PimE fused to T18 domain at N-terminus as revealed in our study, provides a direct 
evidence for regulation of PimE by LpqW. Studies on LpqW in C. glutamicum  have 
functionally linked the enzyme to mannosyltransferase MptB (Rainczuk et al., 2012), 
but no evidence for the interaction was determined in our study with two-hybrid system. 
It is likely that the interaction between LpqW and MptB may occur in mycobacteria and 
be presented as a false negative by the two-hybrid system. The interactions responsible 
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for formation of these multi-enzyme complexes between the glycosyltransferases can 
serve as potential targets for anti-tubercular agents. Novel inhibitors against heterotypic 
interactions that prevent the metabolon formation would subsequently target two or 
more enzymes at the same time rendering it difficult for bacteria to develop resistance. 
Therefore, this ‘co-target’ approach offers a unique and an efficient alternative strategy 
for developing new and potent anti-TB compounds.  
 
Furthermore, the arabinosyltransferases AftD and EmbC which function along with 
AftC to synthesise the arabinan domain in LAM were also indentified to have a high 
degree of interaction between them. The enzyme EmbC catalyses the formation of linear 
arabinan chain comprising α(1→5) linked arabinose residues (Alcaide et al., 1997; 
Alderwick et al., 2011a; Birch et al., 2010; Shi et al., 2006). The branching is 
introduced in this linear chain by addition of α(1→3) units by AftD (Skovierova et al., 
2009). Our results are consistent with the already established functional relationship 
between EmbC and AftD. 
 
The two-hybrid approach based on reconstitution of AC is a powerful technique for 
analysis of protein-protein interactions that offers a few drawbacks when employed to 
study membrane proteins of mycobacteria. Since a positive interaction can only be 
obtained in a scenario where both the proteins of interest are sufficiently synthesised, 
correctly inserted into the membrane and not result in plasmid instability, the 
combinations tested negative for interactions may not be true negatives (Battesti and 
Bouveret, 2012; Karimova et al., 1998b; Karimova et al., 2000). These negative results 
may also result from non-expression of a fully functional protein, incorrect orientation 
in the membrane or mis-folding which results in cellular toxicity and plasmid instability 
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(Battesti and Bouveret, 2012; Karimova et al., 1998b; Karimova et al., 2000). Since the 
system is based on E. coli, expression of mycobacterial proteins in full is mostly a 
failure which increases the amount of false negatives generated (Battesti and Bouveret, 
2012). Therefore, a western blotting procedure to detect a full expression of the protein 
and secondary techniques such as co-immunoprecipitation, BN-PAGE, or more specific 
systems such as mycobacterial two hybrid system or yeast two hybrid system can be 
employed to reconfirm the interactions. In addition, a few protein interactions may 
occur only in presence of an accessory protein and go undetected by this system. In the 
reverse situation where functional complementation due to a non-specific interaction 
initiated by endogenous protein that acts as a tethering agent can also result in false 
positives. Therefore, a three hybrid approach or use of mycobacteria based two hybrid 
systems can help identify the potential membrane protein complexes especially between 
LpqW, MptB and MptC and between EmbA, EmbB and EmbC which could not be 













5 Tetrafluorinated galactofuranoside compounds as inhibitors of GlfT1 and 
GlfT2 in Mycobacterium smegmatis 
 
5.1 Introduction 
The mAGP complex is the target of many first line drugs including EMB with the 
target residing in the embCAB locus (Belanger et al., 1996) and INH that targets the 
enoyl-ACP reductase, InhA (Banerjee et al., 1994). Biosynthesis of the 
monosaccharides such as Rha, Galf and Araf which are the major constituents of the 
mycobacterial cell wall, that are lacking in humans and other mammals, constitute 
potential drug targets. The arabinan domain consists of approximately 30 Araf residues 
with the majority of the residues being α(1→5) linked and branching introduced by 
3,5-α-D-Araf residues (Daffe et al., 1990; Mcneil et al., 1991). The synthesis of the 
arabinan domain requires several ArafTs of the GT-C superfamily with a distinct DDX 
motif (Berg et al., 2007), which employ DPA as the arabinose donor (Liu and 
Mushegian, 2003; Wolucka et al., 1994). A recently, solved crystal structure of the C-
terminus of EmbC, an ArafT, revealed the presence of ligand binding sites (Alderwick 
et al., 2011a). The GlfTs, utilise UDP-Galf as the galactofuranose donor for building 
the galactan core of AG (De Arruda et al., 1989). The substrate UDP-Galf is 
synthesised from UDP-Glc via an epimerisation step to yield UDP-Galp that is 
subsequently converted to UDP-Galf by an essential flavoenzyme UDP-Galp mutase 
(UGM) (Pan et al., 2001). The galactan core is assembled by 
galactofuranosyltransferases, GlfT1 and GlfT2, which are encoded by Rv3782 and 
Rv3808c, respectively. GlfT2 is responsible for the synthesis of the bulk of galactan 
core, whilst GlfT1 initiates the synthesis by adding the first two sugar units. Both 
enzymes are recognised by the presence of a distinct DXD motif in the active site, 
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characteristic of the glycosyltransferases of the GT-A superfamily (Liu and Mushegian, 
2003). The enzyme GlfT1 is said to exhibit β-D-Galf (1→6) transferase activity 
(Alderwick et al., 2008) and catalyses the transfer of the two first Galf residues on to α-
L-Rhap-(1→3)-GlcNAc-phosphate peptidoglycan anchor. Experimental evidences 
suggest that GlfT2 exhibits both β-D-Galf (1→5) and β-D-Galf (1→6) transferase 
activity (Kremer et al., 2001; Wheatley et al., 2012), transferring both β-D-Galf (1→5) 
and β-D-Galf (1→6) to the polyprenol-bound oligosaccharide. A recent crystal 
structure of M. tuberculosis GlfT2 (Wheatley et al., 2012) has given much insight into 
the functioning of the catalytic core of the mycobacterial GlfTs. GlfT2 is a membrane 
bound protein with Asp256-Asp258 forming the DXD motif. GlfT2 binds Mn
2+
 in its 
active site, which probably functions as the co-factor for the enzyme. The possible 
explanation for dual activity of GlfT2 is provided by the ability of a narrow channel 
near loop 1 to accommodate trisaccharide substrates and the non-reducing ends of 
longer galactan substrates  
 
Additional insight into the functioning of these glycosyltransferases has been provided 
by in vitro glycosyltransferase assays using synthetic acceptors that act on substrate 
analogues (Alderwick et al., 2008; Lee et al., 1997; Pathak et al., 2001; Pathak et al., 
2007). These synthetic acceptor molecules have also been implicated in the design and 
evaluation of potential inhibitors of these enzymes (Cren et al., 2004; Pathak et al., 
2009; Subramaniam et al., 2005). At present, glycosyltransferase inhibitors are 
typically either donor or acceptor analogues with identical or lower Km values to the 
natural donors or acceptors (Pesnot et al., 2010). To design new inhibitors with higher 
binding affinities, a thorough insight into the protein-carbohydrate interactions is 
necessary. In this regard, a novel strategy of using “polar hydrophobicity” for 
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synthesising substrate analogues is lucrative and is currently being implemented to 
study protein-carbohydrate interactions (Ioannou et al., 2011). This strategy employs 
the use of donor and acceptor analogues with selectively replaced hydroxyl or 
hydrogen groups to highly electrophilic fluorine atoms for interaction with the enzyme. 
These fluorinated compounds have a higher affinity for the enzyme when compared to 
their non-fluorinated counterparts (Biffinger et al., 2004; Gao et al., 1995). The 
presence of fluorine atoms near the anomeric position in disaccharides significantly 
affects the activity of glycosyltransferases in various ways that aids in its inhibitory 
effect. These include inactivation of enzyme by means of chemical reactions, inhibition 
of enzyme activity or slow reactivity of the enzyme with the substrate. Modified 
disaccharides with 2ꞌ deoxy-2ꞌ fluoro and 5ꞌ-fluoro substitutions are very potent 
inhibitors of glycosyltransferases. For example, UDP-Gal-2F inhibitor that is 
synthesised by replacement of a hydroxyl group at position 2 in α-D-galactopyranose 
with a fluorine atom is a reversible inhibitor of α-1, 3-GalT with sufficiently high 
binding affinity. The compound functions as a competitive inhibitor as it generates no 
reaction product (Jamaluddin et al., 2007; Persson et al., 2001). Similarly, compounds 
such as UDP-(5F)-GlcNAc shows marked competitive inhibition against the substrate 
UDP-GlcNAc for GalTs such as UDP-GlcNAc:GlcNAc-P-P-Dol N-
acetylglucosaminyl transferase, chitobiosyl-P-P-lipid synthase and N-acetyllactosamine 
synthase and can be employed to study glycosyl transfer reactions at C-3 or C-6 
position (Hartman et al., 2007). In addition, these fluoride based inhibitors have found 
their use in determining the structure of glycosyl-enzyme intermediates by means of 
NMR spectroscopy or X-ray crystallography. For example, 2-acetamido-2-deoxy-β-D-
glucopyranosyl-(1→4)-2-deoxy-2-fluoro-β-D-glucopyranosyl fluoride, an inhibitor of 
hen egg white lysozyme was used to determine the structure of glycosyl-enzyme 
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intermediate from X-ray crystallography (Vocadlo et al., 2001) for both α- and β- 
glycosyltransferases (Davies et al., 2003; Lovering et al., 2005). These mechanistic 
studies reveal the transition state mechanisms of the fluorine based compounds that 
assist in designing of highly selective inhibitors with improved binding affinities 
(Gloster et al., 2007). 
In order to determine the residues essential for activity of GlfTs in the disaccharides for 
generation of the arabinan and galactan core, we tested a series of tetrafluorinated 
substrate analogues, synthesised by the Linclau group, University of Southampton, for 
their potential as acceptors or inhibitors. Table 5.1 summarises the structure and 
IUPAC names of the compounds utilised in the study. These synthetic compounds are 
designed to have a high degree of similarity with the natural substrates of GalTs and 
AraTs in mycobacteria and thus function as substrate analogues. The presence of 
fluorine atom in these compounds confers high electronegativity to the molecule and 
thus aids in their function as an acceptor. GlfTs and AraTs mediate a 
transglycosylation reaction by transfering Gal and Ara residues from the natural sugar 





Araf-acceptor product respectively. Both GalTs and AraTs are inverting enzymes that 
utilize carboxylate groups from Asp residues in the DXD motif in the active site. The 
synthetic acceptors initiate a nucleophilic attack at anomeric carbon of the sugar donor 
to afford a glycosyl enzyme intermediate that forms a glycosidic linkage with inversion 
of anomeric stereochemistry. In addition, the reaction regenerates the carriers UDP and 
decaprenyl phosphate (DP).The fluorine atoms in the substrate analogues can also 
engage in covalent binding with the enzyme. In this situation, inhibition of enzyme 
activity occurs due to loss of fluorine at or near the enzyme active site. The proposed 
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reaction scheme of the tested compounds along with the respective synthetic substrates 
is illustrated in Figure 5.1.  
The compounds were tested for their acceptor and inhibitor activity using membrane 
and cell wall extracts from M. smegmatis by mixing the compounds with 0.4 mM Gal 
(1→5) (SRI20668) and Gal (1→6) (SRI20669) gal-gal disaccharide probes, which are 
known to exhibit excellent acceptor activities (Pathak et al., 2007). Similarly, to test 
competitive inhibition of ArafTs, the test compound was mixed with 0.4 mM α-D-Araf-
(1→5)-α-D-Araf-l-O-C8H17 neoglycolipid acceptor with an established acceptor 
activity (Lee et al., 1998; Pathak et al., 2002).  
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Table 5.1: Tetra-fluorinated compound tested for their acceptor and inhibitor 
activity in M. smegmatis 
Compound 
# 













































Figure 5.1: Proposed mechanism for transglycosylation reactions catalysed by A. 
GalTs for compounds 48 and 83, B. GalTs for compounds 84 and 85 and C. AraTs for 





5.2 Materials and Methods 
5.2.1 GalT assay 
The acceptor activity of all four compounds 48, 83-85 (20 mM stock, stored in 
ethanol) was performed using a step-wise concentration gradient of 0.1-2.0 mM. The 
required concentration of the compound and 0.25 µCi of [U-
14
C]-UDP-Galp 
(American Radiolabeled Chemicals Inc., 250-300 mCi/mmol) were dried under a 
stream of argon in a microcentrifuge tube (1.5 mL) to remove any solvent. The dried 
mixture was resuspended in buffer containing 50 mM MOPS (adjusted to pH 8 with 
KOH), 10 mM MgCl2 and 1% IgePal (8 µL) and mixed with the remaining 
components of the assay; 1mM ATP (10 µL) and 100 mM NADH (8µL). The reaction 
was initiated by the addition of membranes (500 µg) and P60 fraction (200µg) 
resulting in a final reaction volume of 80 µL. The reaction mixtures were then 
incubated at 37
o
C for 1 hour and stopped using chloroform:methanol (1:1, 533 µL). 
The contents of the tubes were centrifuged at 18, 000 x g and supernatant was 
recovered and dried under a stream of argon. The dried constituents were re-
suspended in ethanol:water (1:1, 1 mL) and loaded onto a pre-equilibrated 
(ethanol:water [1:1]) 1 mL Whatman Strong Anion Exchange (SAX) cartridge washed 
with 3 mL of ethanol. The eluate was dried and the contents were partitioned between 
the aqueous and organic phase resulting from a mixture of n-butanol (2 mL) and H20 
(2 mL). The contents were centrifuged at 3,500 x g and the organic phase recovered. 
The remaining aqueous phase was re-extracted with 2 mL of n-butanol saturated water 
and the extracts pooled. The organic fraction of pooled extracts were back-washed 
twice with water saturated with n-butanol (2 mL). The n-butanol-saturated water 
fraction (4 mL) was then dried and re-suspended in 200 µL of n-butanol. The total 
cpm of radiolabeled material in n-butanol fraction was measured by scintillation 
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counting using 50% of the labeled material and 10 mL of EcoScintA (National 
Diagnostics, Atlanta). The counts present in control assays (reaction components 
lacking the test compound) were subtracted from the test samples to estimate the 
incorporation of [
14
C]-Galf. The remaining 50 % of the labeled material was subjected 
to thin-layer chromatography (TLC) in chloroform/methanol/ammonium 
hydroxide/water (65:25:0.5:3.6) on aluminium backed Silica Gel 60 F254 plates (E. 
Merck, Darmstadt, Germany). Autoradiograms were obtained by exposing TLC’s to 
X-ray film (Kodak X-Omat) for 5 days. To estimate the inhibitor activity of the 
compounds, a step-wise gradient 0.1-2 mM was mixed alongside [U-
14
C]-UDP-Galp 
(0.25 µCi) with 0.4 mM SRI20668 and 0.4 mM SRI20669 acceptor (20 mM stock 
stored in ethanol), depending upon the activity to be assayed Gal (1→5) or Gal(1→6) 
and dried under the stream of argon in a microcentrifuge tube (1.5 mL).  
 
5.2.2 AraT assay 
The acceptor activity of compound 87 (20 mM stock, stored in ethanol) was estimated 
by using a step-wise concentration gradient of 0.1-2.0 mM. Compound 87 was dried 
under a stream of argon in a microcentrifuge tube (1.5 mL) and placed in a vacuum 
desiccator for 15 minutes to remove any residual solvent. The dried compound was 
resuspended in buffer containing 50 mM MOPS (adjusted to pH 8 with KOH), 10 mM 
MgCl2, 10 mM ATP, 10 mM NADP, 10 mM NAD, 10 mM FAD. To initiate the 
reaction, p[
14
C]RPP (140,000 cpm, stored in 1 M sodium acetate), membranes (250 µg) 
and P60 fraction (250 µg) extracts prepared from M. smegmatis using previously 
described protocols (Lee et al., 1996) elaborated in General Materials and Methods, 
Section 7.4.6 were added to a final reaction volume of 80 µL. The reaction mixtures 
were then incubated at 37
o
C for 2 hours and stopped using chloroform:methanol (1:1, 
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533 µL). The contents of the tubes were centrifuged at 18,000 x g and supernatant was 
recovered and dried under a stream of argon. The dried constituents were re-suspended 
in ethanol:water (1:1, 1 mL) and loaded onto a pre-equilibrated (ethanol:water, 1:1) 1 
mL Whatman Strong Anion Exchange (SAX) cartridge and washed with 3 mL of 
absolute ethanol. The elute was dried and the contents were partitioned between 
aqueous and organic phase resulting from a mixture of n-butanol (2 mL) and water (2 
mL). The contents were centrifuged at 3,500 x g and organic phase was recovered. The 
remaining aqueous phase was re-extracted with 2 mL of n-butanol saturated water and 
the extracts were pooled. The organic fraction of pooled extracts was back-washed 
twice with water saturated with n-butanol (2 mL). The n-butanol-saturated water 
fraction (4 mL) was then dried and re-suspended in 200 µL of n-butanol. The total cpm 
of radiolabeled material in n-butanol was measured by scintillation counting using 50% 
of the labeled material and 10 mL of EcoScintA (National Diagnostics, Atlanta). The 
counts present in control assays (reaction components lacking compound 87) were 
subtracted from the test samples to estimate the incorporation of [
14
C]-Araf. The 
remaining 50% of the labeled material was dried, resuspended in butanol and equal 
counts were loaded on aluminium backed Silica Gel 60 F254 plates (E. Merck, 
Darmstadt, Germany) and subjected to thin-layer chromatography (TLC) in 
chloroform/methanol/ammonium hydroxide/water (65:25:0.5:3.6). Autoradiograms 
were obtained by exposing TLC’s to X-ray film (Kodak X-Omat) for 5 days. To 
estimate the inhibitor activity of the Compound 87, a step-wise gradient of 0.1-2 mM 
was mixed with 0.4 mM Ara (α1→5) acceptor (20 mM stock stored in ethanol) and 
dried under the stream of argon in a microcentrifuge tube (1.5 mL) and placed in a 
vacuum desiccator for 15 minutes to remove any residual solvent. The assay was 
performed as mentioned above. The total cpm of radiolabeled material in n-butanol 
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was measured by scintillation counting using 50% of the labeled material and 10 mL of 
EcoScintA (National Diagnostics, Atlanta). The counts present in control assays 
(reaction components lacking compound 87) were subtracted from the test samples to 
estimate the incorporation of [
14
C]-Araf. The remaining 50% of the labeled material 
was dried, resuspended in butanol and equal counts were loaded on aluminium backed 
Silica Gel 60 F254 plates (E. Merck, Darmstadt, Germany) and subjected to thin-layer 
chromatography (TLC) in chloroform/methanol/ammonium hydroxide/water 
(65:25:0.5:3.6). Phophor-imaging was performed by exposing TLCs to phosphor-
screen (Bio-Rad) for 2 days.   
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5.3 Results  
The tetrafluorinated compounds were evaluated for their acceptor and inhibitor activity 
using a cell free assay system comprising of membrane extracts and the cell wall 
enzymatic fraction P60 prepared from M. smegmatis. The compounds were analysed 
for their galactosyltransferase and arabinosyltransferase acceptor and inhibitor activity 
in a range of concentrations from 0.1 mM to 2.0 mM.  
 
5.3.1 Acceptor activity analysis for galactofuranosyltransferases using M. 
smegmatis membrane extracts for compounds 48, 83, 84 and 85. 
All compounds were analysed for their acceptor activity measured by the amount of 
radioactivity recovered. The radioactive counts recovered from the parent 
disaccharides were considered as one hundred percent and was used as a reference to 
estimate the percent recovery for the test compounds. The parent disaccharides 
Gal(β1→5)Gal (SRI20668) and Gal(β1→6)Gal (SRI20669) showed excellent 
incorporation of [
14
C]-Galf however, none of the compounds tested exhibited any 
significant acceptor activity, as very low amounts of radioactivity was recovered in the 
organic phase i.e. 1-9% (Table 5.2) when compared to the disaccharide analogues 
SRI20668 and SRI20669. The products were not analysed on TLC plates due to very 
low amounts of radioactivity recovered.  
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Table 5.2: Percent acceptor activity and radioactivity recovered for compounds 













0.4mM   
SRI20668 
0.4 12017 100 
0.1mM 48 0.1 1141 9.49 
0.25mM 48 0.25 596 4.96 
0.5mM 48 0.5 570 4.74 
0.75mM 48 0.75 670 5.58 
1.0mM 48 1 761 6.33 
2mM 48 2 718 5.97 
 
0.4mM   
SRI20668 
0.4 12017 100 
0.1mM 83 0.1 159 1.32 
0.25mM 83 0.25 192 1.60 
0.5mM 83 0.5 221 1.84 
0.75mM 83 0.75 252 2.10 
1.0mM 83 1 298 2.48 
2.0mM 83 2 197 1.64 
 
0.4mM   
SRI20669 
0.4 15299 100 
0.1mM 84 0.1 234 1.53 
0.25mM 84 0.25 704 4.60 
0.5mM 84 0.5 1397 9.13 
0.75mM 84 0.75 1327 8.67 
1.0mM 84 1 1856 12.13 
2mM 84 2 870 5.69 
 
0.4mM   
SRI20669 
0.4 15299 100 
0.1mM 85 0.1 207 1.35 
0.25mM 85 0.25 506 3.31 
0.5mM 85 0.5 359 2.35 
0.75mM 85 0.75 475 3.10 
1.0mM 85 1 634 4.14 
2.0mM 85 2 823 5.38 
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5.3.2 Inhibitor activity analysis galactofuranosyltransferases using M. 
smegmatis membrane extracts for compounds 48, 83, 84 and 85. 
Since the compounds showed poor acceptor activity, they were also tested as inhibitors 
and the activity was measured by the amount of radioactivity recovered when mixed 
with the disaccharide analogues SRI20668 (Gal-β(1→5)Gal) and SRI20669 (Gal-
β(1→6)Gal). The inhibitor activity was estimated using densitometry analysis of the 
autoradiograms. The radioactive counts recovered from the parent disaccharides were 
considered as one hundred percent and was used as a reference to estimate the percent 
recovery for the test compounds. The TLC/autoradiography demonstrated the inhibitor 
activity of compounds 48 and 83 (Figure 5.2 and 5.3) with maximum inhibition of 
82.26 and 74.25% respectively (Table 5.3), at a concentration of 2 mM, as a gradual 
decrease in conversion of Galf (1→5) disaccharide to the corresponding trisaccharide 
and tetrasaccharide product. However, only moderate inhibition, 47.42 and 67.26% 
was observed for compounds 84 and 85, respectively (Table 5.3), at a concentration of 
2 mM, rendering them less suitable as substrate analogues for enzyme inhibition 
studies. The TLC/autoradiography for compounds 84 and 85 (Figure 5.4 and 5.5) did 
not demonstrate a gradual decrease in conversion of Galf (β1→6) disaccharide to the 
corresponding trisaccharide or tetrasaccharide product except at the highest 
concentration of 2 mM where a moderate decrease was observed. In addition, all 
compounds at their inhibitory concentrations showed an overall reduction in 
trisaccharide and tetrasaccharide product formation. The inhibitor activity for all the 





Table 5.3: Percent inhibitor activity and radioactivity recovered for compounds 48, 













0.4mM  SRI20668 0.4 2471 36.82 0 
0.1mM 48 0.1 2475 39.71 ~ 0 
0.25mM 48 0.25 2202 33.37 9.37 
0.5mM 48 0.5 1852 34.16 7.22 
1.0mM 48 1 2027 31.01 15.78 
2mM 48 2 317 6.53 82.26 
     
0.4mM  SRI20668 0.4 2471 38.53 0 
0.1mM 83 0.1 4378 77.24 -100 
0.25mM 83 0.25 1679 27.96 27.43 
0.5mM 83 0.5 813 18.42 52.19 
1.0mM 83 1 738 13.89 63.95 
2.0mM 83 2 385 9.92 74.25 
     
0.4mM  SRI20669 0.4 34497.5 124.43 0 
0.1mM 84 0.1 28904 118.68 5.17 
0.25mM 84 0.25 32956 124.48 0 
0.5mM 84 0.5 33298 117.64 5.46 
1.0mM 84 1 30381 101.28 18.6 
2mM 84 2 20105 65.42 47.42 
     
0.4mM  Gal 
SRI20669 
0.4 34497.5 114.1 0 
0.1mM 85 0.1 29281 88.13 22.76 
0.25mM 85 0.25 33570 103.43 9.59 
0.5mM 85 0.5 24790 72.8 36.19 
1.0mM 85 1 28313 70.86 37.9 

























Figure 5.2: Autoradiogram for inhibitory activity of compound 48 with Gal-β(1→5)Gal 
acceptor.  The assays were supplemented with 0.25 µCi [
14
C-U]-UDP-Gal, 0.4 mM Gal-
β(1→5)Gal acceptor (SRI20668) along with concentrations 0.1, 0.25, 0.5, 1.0 and 2.0 mM of 
compound 48 to check its inhibitory effect. The reactions supplemented with only 0.4 mM 
SRI20668 acceptor generated corresponding tri- and tetrasaccharide products. Addition of 
compound 48 at concentrations 0.1, 0.25. 05, 1.0 and 2.0 mM to reaction mixture with 0.4 
mM SRI20688 led to a gradual decrease in synthesis of tri- and tetrasaccharide products. The 
compound was found to be a highly effective inhibitor at the concentration of 2.0 mM as an 
overall reduction by 82% in the tri- and tetrasaccharides was observed. The compound 48 
reacted with [
14
C-U]-UDP-Gal donor and generated [
14




































Figure 5.3: Autoradiogram for inhibitory activity of compound 83. The assays were 
supplemented with 0.25 µCi [
14
C-U]-UDP-Gal, 0.4 mM Gal-β(1→5)Gal acceptor 
(SRI20668) along with concentrations 0.1, 0.25, 0.5, 1.0 and 2.0 mM of compound 83 to 
check its inhibitory effect. The reactions supplemented with only 0.4 mM SRI20688 acceptor 
generated corresponding tri- and tetrasaccharide products. Addition of compound 83 at 
concentrations 0.1, 0.25. 05, 1.0 and 2.0 mM to reaction mixture with 0.4 mM SRI20688 led 
to a gradual decrease in synthesis of tri and tetrasaccharide products. The compound was 
found to be an effective inhibitor at the concentrations of 0.5-2.0 mM with an overall 
reduction in the tri and tetrasaccharides due to a reduction in the activity of disaccharide 






































Figure 5.4: Autoradiogram for inhibitory activity of compound 84. The assays were 
supplemented with 0.25 µCi [
14
C-U]-UDP-Gal, 0.4 mM Gal-β(1→6)Gal acceptor (SRI20669) 
along with concentrations 0.1, 0.25, 0.5, 1.0 and 2.0 mM of compound 84 to check its 
inhibitory effect. The reactions supplemented with only 0.4 mM SRI20669 acceptor generated 
corresponding tri- and tetrasaccharide products. Addition of compound 84 at concentrations 
0.1, 0.25. 05, 1.0 and 2.0 mM to reaction mixture with 0.4 mM SRI20688 led to no significant 
reduction in synthesis of tri- and tetrasaccharide products. Modest amount of reduction i.e. 
42.4% in radioactivity was observed for the compound at the concentration of 2.0 mM. The 
compound 84 reacted with [
14
C-U]-UDP-Gal to generate [
14



































Figure 5.5: Autoradiogram for inhibitory activity of compound 85. The assays were 
supplemented with 0.25 µCi [
14
C-U]-UDP-Gal, 0.4 mM Gal-β(1→6)Gal acceptor (SRI20669) 
along with concentrations 0.1, 0.25, 0.5, 1.0 and 2.0 mM of compound 85 to check its 
inhibitory effect. The reactions supplemented with only 0.4 mM SRI20669 acceptor generated 
corresponding tri- and tetrasaccharide products. Addition of compound 85 at concentrations 
0.1, 0.25. 05, 1.0 and 2.0 mM to reaction mixture with 0.4 mM SRI20688 led to no significant 
reduction in synthesis of tri- and tetrasaccharide products. At a concentration of 2.0 mM, 67% 
radioactivity was recovered for compound 85 with an overall reduction in products formed. 
The compound 85 reacted with [
14
C-U]-UDP-Gal and generated [
14






5.3.3 Acceptor and inhibitor activity analysis for 
arabinofuranosyltransferases using M. smegmatis membrane extracts for 
compound 87. 
Compound 87 was analysed either as an acceptor and/or inhibitor of DP[
14
C]A and 
activity was measured by the amount of radioactivity recovered in organic extracts. 
The parent disaccharide Ara-α(1→5)Ara showed excellent incorporation of [
14
C]-Araf 
from the donor DP[
14
C]A when assays were exogenously supplemented with 
p[
14
C]RPP (Figure 5.6 & 5.7) as evident from the trisaccharide produced. However, 
compound 87 when tested as an acceptor in assays supplemented with p[
14
C]RPP and 
compound 87 (0.1 mM-2 mM) yielded [
14
C]-Araf-(1→?)-87 and an unidentified 
product in very low quanities as evident from the autoradiogram (Figure 5.6). 
 





C]RPP into Araf-α(1→5)-Araf acceptor at a concentration of 2 mM (Figure 
5.7). Since the reaction supplemented with 0.4 mM Araf-α(1→5)-Araf and 2 mM 87 
generated the trisaccaharide product, the compound was ineffective as an inhibitor. In 
addition, the radioactivity recovered from reactions containing 0.4 mM disaccharide 
acceptor supplemented with compound 87 was higher (7472 cpm) than the assays 
supplemented with 0.4 mM disaccharide acceptor alone (5274 cpm) implying its role 











Figure 5.6: Autoradiogram for acceptor activity of compound 87. The assays were 
supplemented with 140,000 cpm of p[
14
C]RPP, 0.4 mM Araf-α(1→5)Araf acceptor and 
compound 87 (0.1, 0.25, 0.5, 1.0 and 2.0 mM) to check its acceptor activity. The reactions 
supplemented with only 0.4 mM Araf-α(1→5)Araf acceptor generated corresponding 
trisaccharide product. Addition of compound 87 at concentrations 0.1, 0.25. 05, 0.75, 1.0 and 
2.0 mM to reaction mixture with 140,000 cpm of p[
14
C]RPP led to synthesis of [
14
C]-Araf –
(1→?)-87 as a reaction product. The weak acceptor activity was evident for compound 87 as an 





































Figure 5.7: Phosphor-imaging scan for inhibitor activity of compound 87. The assays were 
supplemented with 140,000 cpm of p[
14
C]RPP, 0.2 mM and 0.4 mM Araf-α(1→5)Araf 
acceptor, 0.4 mM Araf-α(1→5)Araf acceptor with 2 mM compound 87 to check its inhibitory 
activity. All the reactions supplemented with Araf-α(1→5)Araf acceptor generated 
corresponding trisaccharide product. Addition of compound 87 at 2.0 mM concentration to 
reaction mixture with 140,000 cpm of p[
14
C]RPP and 0.4 mM Araf-α(1→5)Araf acceptor led 
to synthesis of corresponding trisaccharide and [
14
C]-Araf –(1→?)-87 as a reaction product 






The analysis of the crystal structure of galactofuranosyltransferases have suggested 
three vital strategies for generation of GlfT inhibitors (Wheatley et al., 2012). These 
include: modification of uridine base in substrate analogues with increased binding 
affinity to the enzyme in comparison to the natural substrate (Pesnot et al., 2010); 
allosteric inhibition of the enzyme by donor substrates with bulky functional groups 
and higher affinity to the ribose binding pocket in the enzyme resulting in stearic 
hindrance in neighbouring pockets (Qasba et al., 2005), and inhibitors that bind to the 
hydrophobic residues in the cytoplasmic face of the enzyme and prevent its interaction 
with the membrane, thus disallowing the catalysis to proceed adequately (Wheatley et 
al., 2012). New inhibitors for arabinofuranosyl transferases can be developed based on 
similar strategies. Inhibition of ArafTs can be achieved by synthetic DPA analogs that 
either inhibit arabinan synthesis or interfere in its interaction with plasma membrane 
and its components. Since, the activity of these enzymes is crucial for mAGP complex 
formation, substrate analogs which compete with the natural disaccharides for binding 
with the galactosyltransferases and arabinofuranosyltransferases can give insights into 
the mechanism of function of these enzymes and also help generate drug-like 
molecules that inhibit transferase activity.  
 
The four tetrafluorinated substrate analogues of naturally occurring disaccharides used 
in this study were found to be inhibitors for the galactosyltransferases GlfT1 and 
GlfT2, as they all showed some reduced incorporation of [
14
C]-Galf from the [U-
14
C]-
UDP-Galp donor when mixed with the respective disaccharide analogues SRI20668 
and SRI20669. The compounds 48; 1-O-Octyl-5-O-(β-galactofuranosyl)-2,3-dideoxy-
2,2,3,3-tetrafluoro-β-galactofuranose and 83; 1-O-Octyl-5-O-(β-galactofuranosyl)-2,3-
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dideoxy-2,2,3,3-tetrafluoro-α-galactofuranose, effectively inhibited the conversion of 
disaccharide analogue SRI20668 by 87 and 84% respectively at a concentration of 2 
mM. The IC50 value of 1.0 mM, as approximated from the graph was found to be 
lowest for compound 83. Therefore, compound 83 can be used for inhibitory studies 
for the enzymes GlfT1 and GlfT2.  
The compound 87; 1-O-Octyl-5-O-(α-arabinofuranosyl)-2,3-dideoxy-2,2,3,3-
tetrafluoro-arabinofuranose; readily accepts Araf residues to generate corresponding 
radioactive product and an unknown product. However, when tested as an inhibitor for 
Araf-α(1→5)Araf acceptor activity, compound 87 aided in [
14
C]-Araf uptake by the 
disaccharide acceptor, thus acting as a detergent. Therefore, compound 87 can be used 
in arabinofuranosyltransferase assays to enhance the efficiency of the reaction.  
The selective replacement of a hydrogen atom or hydroxyl group in a biologically 
active molecule with small and highly electrophilic fluorine atoms can alter its 
stereochemistry to suit development of pharmacologically active compounds (Liu et 
al., 2008). New drug candidates for therapy can be generated based on these fluoro-
analogues (Peek et al., 2001; Reyes and Heidelberger, 1965; Umeda and Heidelberger, 
1969). The fluorine atom offers a selective advantage over other modifications as its 
small size atom doesn’t distort the chemistry of the compound, imparts polar 
hydrophobicity and stability to the molecule, thus facilitating synthetic acceptor studies 
especially in case of glycosyltransferases where stability and weak binding of the 
synthetic acceptor to the enzyme is a persistent problem. These fluorinated analogues 
of Galf and Araf based disaccharides, substrates for GalfTs and ArafTs can not only be 
used to study enzyme function, metabolic pathways but can also be developed into 











6 Discussion and Future work  
The problem of emergence of drug resistant forms of M. tuberculosis poses a huge 
threat in controlling its spread. Repeated misuse of drugs in DOTS therapy have 
contributed to mutations in several of the target genes leading to the rise of MDR and 
XDR strains that are resistant to currently available first and second line anti-TB drugs. 
Consequently, considerable emphasis is being placed on developing potent therapeutics 
that are unaffected by current resistance mechanisms. The extremely hydrophobic and 
unusual cell wall of mycobacteria functions as the first line of defence against the 
chemotherapeutic agents and the pathway for the biogenesis of cell wall components, 
such as PG, AG, PI-based lipoglycans, their precursors and regulators offer excellent 
target systems for generating new antimycobacterial drugs. In this regard, the recently 
discovered cell wall inhibitors BTZs represent a promising drug candidate. Its 
mechanism of action was further investigated in this work. BTZs target the FAD 
dependent oxidoreductase DprE1 that functions in concert with DprE2 to catalyse 
epimerisation of DPR into DPA (Makarov et al., 2009). The end product DPA, is a 
prenyl based arabinose donor employed in the synthesis of the arabinan component in 
AG and LAM. In the presence of BTZ, the cell is unable to synthesise DPA which 
impairs the assembly of arabinan domains in AG and LAM, thus disrupting the cell 
wall (Makarov et al., 2009). The enzyme DprE1 is established as an essential enzyme 
in M. smegmatis and C. glutamicum (Crellin et al., 2011; Meniche et al., 2008). These 
experiments indicate that generation of DPA and its utilisation in arabinan synthesis is 
important for the formation of a complete cell wall in both mycobacteria and 
corynebacteria. The pathway for DPA biogenesis is initiated by transfer of a ribose 
residue to decaprenyl diphosphate carrier and is catalysed by UbiA, a prenyl 
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transferase (Alderwick et al., 2006a). Interestingly, inactivation of UbiA in C. 
glutamicum produced a viable mutant indicating that formation of DPA is not an 
essential reaction (Alderwick et al., 2005).  
The results reported in this thesis have explored the possible cause of death resulting 
from BTZ treatment of C. glutamicum. The effect of BTZ lead compound BTZ043 was 
examined on growth of C. glutamicum wild type and C. glutamicum::ubiA strains. 
Whilst the lethal effect of BTZ043 was evident in case of wild type, Cg-ubiA was 
resistant to the compound. Biochemical assays on membrane extracts from Cg-ubiA 
using DP[
14
C]R as a substrate established that the strain retains a functional copy of 
DprE1 which is effectively inhibited by BTZ043. Ineffectiveness of BTZ in case of 
Cg-ubiA mutant hinted towards existence of a secondary mechanism responsible for 
cellular toxicity and lysis. To deduce the alternative basis of lethality, C. glutamicum 
Z-decaprenyl diphosphate synthase (NCgl2203), was over-expressed in C. glutamicum 
and the inhibitory effect of BTZ on cell wall arabinan biosynthesis was examined. 
Interestingly, over expression of NCgl2203 in presence of BTZ, increased the tolerance 
of C. glutamicum wild type and restored arabinan biosynthesis in this strain. These 
results imply that the lethal effect of BTZ043 in corynebacteria and mycobacteria is a 
consequence of abated recycling of decaprenyl phosphate.  
Whilst a dearth of knowledge cannot be available in terms of cell wall biosynthesis, the 
regulatory networks for its synthesis are still poorly understood. In this work, we have 
identified a novel Lac-I based transcriptional regulator named IpsA that functions as an 
inositol-dependent transcriptional activator of the myo-inositol-phosphate synthase, 
ino1. A series of deletion mutants constructed in C. glutamicum were analysed for their 
cell morphology. Significantly altered cell morphology displayed by the Cg-ipsA 
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mutant highlighted a possible defect in its cell wall biosynthesis. The growth defects 
displayed by Cg-ipsA mutant when cultured in glucose media could be overcome when 
the media was supplemented with inositol as the carbon source. Inositol was then 
established as an effector of IpsA by EMSA studies. The microarray analysis of Cg-
ipsA revealed several downstream effectors including inositol-1-phosphate synthase 
Ino1 that was confirmed as a target from genetic complementation studies. Further 
analysis of cell wall lipids revealed complete absence of inositol-derived lipids 
including PI, PIMs and LAM and established IpsA to be a transcriptional activator, that 
facilitates transcription of ino1 which generates inostiol-1-phosphate from glucose-6-
phosphate.  
The gycosyltransferases in AG biosynthesis pathway are very attractive targets for 
developing anti-TB compounds. Several synthetic donor or acceptor analogues have 
been tested as inhibitors of the transferase activity of these enzymes. Lower binding 
affinities of these compounds have rendered them as weak inhibitors (Cren et al., 2004; 
Pathak et al., 2009; Pesnot et al., 2010; Subramaniam et al., 2005). In this regard, a 
novel strategy of using “polar hydrophobicity” for synthesising substrate analogues 
with increased binding affinities offers a reliable solution (Ioannou et al., 2011). Here 
in, we attempted to identify potential inhibitors of GlfTs by using tetrafluorinated 
substrate analogues. The four substrate analogues of naturally occurring disaccharides 
were deduced as inhibitors of the galactosyltransferases GlfT1 and GlfT2 with 
compound:1-O-Octyl-5-O-(β-galactofuranosyl)-2,3-dideoxy-2,2,3,3-tetrafluoro-α-
galactofuranose as the most promising candidate for pharmacological studies. In 
addition, the protein-protein interactions between glycosyltransferases of LAM 
biosynthesis pathway was employed to assess the druggablity of the interacting 
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partners. The significant homotypic and heterotypic interactions between the 
glycosyltransferases and accessory proteins were identified using a Bacterial Two 
Hybrid system based on reassembly of cAMP signaling pathway (Karimova et al., 
1998b). This approach recognised four possible interaction pairs that include; self-
associating PimA, heterotypic interactions between LpqW and the PimE and a 
significant association between EmbC and AftD. Whilst self-association of PimA 
implicated a novel process of dimerisation of a glycosyltransferase facilitated by PI 
ligand, the heterotypic associations of LpqW with the mannosyltransferases PimE 
strengthened the role of LpqW as a regulatory protein in LAM biosynthesis. The 
essential homotypic and heterotypic interactions as deduced offer a valuable target 
resource. Furthermore, the interacting partners as revealed by this study may also serve 
as ‘co-targets’ rendering it difficult for bacteria to develop resistance to inhibitors that 
prevent these interactions.  
It is predicted that the studies reported herein could further be explored in future 
experiments concerning: i) effect of DPR toxicity in cells upon BTZ action, ii) 
developing drug candidates against the MTB UppS and IpsA, iii) pharmacodynamic 
studies on tera-fluorinated inhibitors iv) development of a high throughput screen 













7 General materials and methods 
 
7.1 Culture media 
 
7.1.1 Luria-Bertani (LB) Broth   
25 g of LB powder (5 g/L sodium chloride; 10 g/L tryptone and 5 g/L yeast extract) 
was dissolved in 1 L of deionised water and sterilised by autoclaving at 121˚C for 15 
minutes. 
 
7.1.2 LB Agar  
37 g of LB-agar powder (15 g/L agar, 10 g/L tryptone, 5 g/L yeast extract, 5 g/L 
sodium chloride) was dissolved in 1 L of deionised water and sterilised by autoclaving 
at 121˚C for 15 minutes. 
 
7.1.3 MacConkey Agar  
40 g of MacConkey agar powder (17 g/L pancreatic digest of gelatine, 3 g/L peptones 
(meat and casein), 10 g/L lactose, 1.5 g/L bile salts no. 3, 5 g/L sodium chloride, 13.5 
g/L agar, 0.03 g/L neutral red, 1 mg/L crystal violet) was dissolved by boiling for 1 
minute in 1 L deionised water. The media was sterilised by autoclaving at 121ºC for 15 
minutes. MacConkey agar was purchased from Difco Laboratories. 
 
7.1.4 M63 minimal media  
15.6 g of M63 medium broth powder (2 g/L ammonium sulphate, 13.6 g/L potassium 
phosphate, monobasic, 0.5 mg/L ferrous sulphate heptahydrate) was dissolved in 1 L of 




121ºC for 15 minutes. The solution was allowed to cool to 50ºC and supplemented 





carbon source just before use. M63 medium broth powder was purchased from 
Amresco. 
 
7.1.5 M63 minimal agar 
15.6g M63 medium broth powder (2 g/L ammonium sulphate, 13.6 g/L potassium 
phosphate, monobasic, 0.5 mg/L ferrous sulphate heptahydrate) was dissolved in 1 L of 
deionised water and adjusted to pH 7.0 using potassium hydroxide. 15 g/L of agar was 
added to the salts mix and contents autoclaved at 121ºC for 15 minutes. The solution 
was allowed to cool to 50ºC and supplemented with 1 mL vitamin B1 (50 mg in 10 mL 




desired carbon source just before use. M63 
medium broth powder was purchased from Amresco. 
 
7.1.6 Tryptic Soy Broth (TSB) 
30 g of TSB broth (17 g/L pancreatic digest of casein, 3 g/L papaic digest of soybean, 
2.5 g/L dextrose, 5 g/L sodium chloride, 2.5 g/L dipotassium phosphate) was dissolved 
in 1 L of deionised water and sterilised by autoclaving at 121˚C for 15 minutes.  
 
7.1.7 Tryptic Soy Agar 
40 g of Tryptic Soy Agar (15 g/L pancreatic digest of casein, 5 g/L enzymatic digest of 
soybean meal, 5 g/L sodium chloride, 15 g/L agar) was dissolved in 1 L of deionised 





7.1.8 Brain Heart Infusion (BHI) Broth  
37 g of BHI broth (12.5 g/L calf brains, 5 g/L beef heart, 10 g/L peptone, 5 g/L sodium 
chloride, 2 g/L glucose, 2.5 g/L disodium hydrogen phosphate) was dissolved in 1 L of 
deionised water and sterilised by autoclaving at 121˚C for 15 minutes.  
 
7.1.9 Brain Heart Infusion (BHI) Agar 
37 g of BHI broth (12.5 g/L calf brains, 5 g/L beef heart, 10 g/L peptone, 5 g/L sodium 
chloride, 2 g/L glucose, 2.5 g/L disodium hydrogen phosphate) was dissolved in 1 L of 
deionised water. 15 g/L of agar was added to the mix and contents were sterilised by 
autoclaving at 121˚C for 15 minutes. 
 
7.1.10 Brain Heart Infusion Sorbitol (BHIS) Broth 
37 g of BHI broth (12.5 g/L calf brains, 5 g/L beef heart, 10 g/L peptone, 5 g/L sodium 
chloride, 2 g/L glucose, 2.5 g/L disodium hydrogen phosphate) was dissolved in 800 
mL of deionised water. 91 g sorbitol was added to the prepared BHI and volume was 
adjusted to 1 L. The contents were sterilised by autoclaving at 121˚C for 15 minutes.  
 
7.1.11 Brain Heart Infusion Sorbitol (BHIS) Agar 
37 g of BHI broth (12.5 g/L calf brains, 5 g/L beef heart, 10 g/L peptone, 5 g/L sodium 
chloride, 2 g/L glucose, 2.5 g/L disodium hydrogen phosphate) was dissolved in 800 
mL of deionised water. 91 g of sorbitol, 15 g/L of agar were added to the prepared BHI 





7.1.12 CGXII minimal media  
CGXII salts media was prepared by mixing 20 g ammonium sulphate, 5 g urea, 1 g 
potassium dihydrogen phosphate, 1 g dipotassium hydrogen phosphate, 0.25 g 
magnesium sulphate hepta hydrate, 42 g MOPS (3-[N-Morpholino] propanesulfonic 
acid) in 800 mL deionised water.  
 
The prepared salt mix was mixed with 1 mL of trace elements solution (1 g ferric 
sulphate heptahydrate, 1 g manganese sulphate monohydrate, 0.1 g zinc sulphate 
heptahydrate, 0.02 g copper sulphate, 0.002 g nickel chloride hexahydrate prepared in 
90 mL deionised water, adjusted to pH 1 using concentrated hydrochloric acid and 
filter sterilised), 1 mL calcium chloride solution (1 g in 100 mL deionised water, filter 
sterilised), 50 µL biotin solution (10 mg in 100 mL deionised water, filter sterilised),  8 
mL protocatechuate (0.3 g in 8 mL deionised water, dissolved by addition of 1 mL 10 
N sodium hydroxide, filter sterilised). The pH of the mixture was adjusted to 7 with 1 
N sodium hydroxide and final volume was adjusted to 920 mL and filter sterilised. The 





7.2 Antibiotic and Supplements 
 
Table 7.1: Antibiotics and supplements used and their preparation 
Accompaniments Stock Concentration Storage 
Kanamycin 50 mg/mL -20ºC, in water 
Ampicillin 100 mg/mL -20ºC, in water 
Streptomycin 100 mg/mL -20ºC, in water 
Tetracycline 10 mg/mL 
-20ºC, in 70% 
ethanol 
BTZ043 10 mg/mL -20ºC, in DMSO 
Isopropyl β-D-1-
thiogalactopyranoside (IPTG) 
1 M/mL -20ºC, in water 
5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) 
40 mg/mL -20ºC, in DMSO 
Inositol 50 % w/v 4ºC, in water 
Glucose 50 % w/v 4ºC, in water 
Maltose 50 % w/v 4ºC, in water 
 
7.3 Molecular biology techniques 
  
7.3.1 Plasmid extraction 
Plasmid DNA was purified using QIAGEN plasmid mini-prep kits. Overnight cultures 
of bacterial strains harbouring the required plasmids were pelleted and resuspended in 
RNase containing P1 resuspension buffer. The cells were lysed using sodium dodecyl 
sulphate based P2 lysis buffer, which aids in removal of proteins. The contents were 
mixed and treated with acetate-guanidine hydrocholoride containing neutralisation 
buffer N3 to separate chromosomal DNA from plasmid DNA. The plasmid DNA is 
recovered in soluble state by centrifuging the suspension. The supernatant is applied to 




proteins. The purified plasmid DNA is eluted in deionised water or in 10 mM Tris-HCl 
(pH 8.5).  
 
7.3.2 Polymerase Chain Reaction (PCR) 
A standard PCR mix was set up and amplified at a temperature gradient to deduce best 
amplification conditions for each gene. 
 
Table 7.2: PCR reaction mix conditions. 
Components Mix A Mix B Mix C Mix D 
100 pmol/µL 5ꞌ cloning 
primer 
0.08 µL 0.08 µL 0.08 µL 0.08 µL 
100 pmol/µL 3ꞌ cloning 
primer 
0.08 µL 0.08 µL 0.08 µL 0.08 µL 
5X GC buffer 4 µL 4 µL 4 µL 4 µL 
10 mM dNTP mix 0.4 µL 0.4 µL 0.4 µL 0.4 µL 
Template DNA 0.4 µL 0.4 µL 0.4 µL 0.4 µL 
10 U/mL Phusion 
polymerase 
0.2 µL 0.2 µL 0.2 µL 0.2 µL 
DMSO - 1.0 µL - 1.0 µL 
50 mM Magnesium 
chloride 
- - 0.4 µL 0.4 µL 
deionised water 14.84 µL 13.84 µL 14.44 µL 13.44 µL 
 
7.3.2.1  Two step PCR programme for gene amplification 
 
Initial denaturation at 98ºC for 30 seconds  
Denaturation at 98ºC for 10 seconds 
Annealing at 72ºC ± 8ºC for 1 minute 
Final extension at 72ºC for 10 minutes  
Hold at 4ºC for 10 minutes  




7.3.2.2  Three step PCR programme for gene amplification 
 
Initial denaturation  at 98ºC for 1.5 minutes  
Denaturation at 98ºC for 10 seconds 
Annealing at 66ºC ± 10ºC for 30 seconds 
Extension at 72ºC for 2 minutes  
Final extension at 72ºC for 10 minutes  
Hold at 4ºC for 10 minutes 
 
7.3.3 Gel Electrophoresis  
 
7.3.3.1  Agarose gel elctrophoresis 
To separate the different fragments of DNA, 0.8-1% agarose gel was prepared by 
dissolving agarose (Bioline) in 1X TAE buffer (50X stock: 242 g Tris-base, 57.1 mL 
acetate, 100 mL 0.5 M EDTA). The DNA samples to be analysed were loaded into the 
wells using 1X DNA loading dye (6X stock: 30% glycerol, 0.25% bromophenol blue in 
water) and electrophoresed at 100-120V. DNA was visualised by staining the gels with 
ethidium bromide and analysed under UV light using BioRad Gel Doc XR System. 
 
7.3.3.2  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)  
The levels of UppS were assessed in membrane and cytosolic fractions of C. 
glutamicum and C. glutamicum harbouring pVWEx2_uppS construct by 12% SDS 
PAGE. The LAM samples were also analysed by 15% SDS PAGE.  The gels were 
prepared using the following components:  




For resolving gel: 
3.7 5 mL 4X Resolving gel buffer (1.5 M Tris-HCI, 0.4% SDS pH 8.8), 11.25 mL 
acrylamide/bis/water mix (30% 37.5:1 acylamide/bis-acrylamide:water, proportions 
were adjusted according to the percentage of acrylamide in the gel, 6 mL acrylamide-
bis mix for 12%, 7.5 mL acrylamide-bis mix for 15%), 30 µL TEMED (N,N,N´,N´-
tetramethylethylenediamine), 75 µL 10% ammonium persulphate  were mixed in a 50 
mL Falcon tube and poured immediately in the gel cast. The gels were allowed to set 
for 15-20 minutes at room temperature.  
 
For stacking gel: 
1.25 mL 4X stacking gel buffer (0.5 M Tris-HCI, 0.4% SDS pH 6.8), 0.65 mL 
acrylamide/bis mix, 3.05 mL water, 15 µL TEMED, 75 µL 10% ammonium 
persulphate solution were mixed in a 15 mL Falcon tube and poured over the resolving 
gel. The gels were allowed to set for 15-20 minutes at room temperature.  
The protein samples to be analysed were mixed with 5X SDS loading buffer (360 mM 
Tris-HCI, pH 8.8, 9% (w/v) SDS, 0.9% (w/v) bromophenol blue, 15% (w/v) β-
mercaptoethanol and 30% glycerol) and boiled for 5 minutes. The gels were run at 
300V, 25 mA/gel until completion in running buffer (25 mM Tris, 190 mM Glycine, 4 
mM SDS). The gels were stained with Instant Blue stain (Expedeon) for proteins and 
with ProQ emerald glycoprotein stain (Invitrogen) for lipoglycans according to 
manufacturer’s instructions. 
 
7.3.4  Restriction digestion 
The plasmid DNA and PCR products were single or double digested based on required 




10X digestion buffer (as recommended by manufacturer), 2 µL of 10X BSA (if 
required by the enzyme), 50 units of enzyme and volume was adjusted to 20 µL with 
deionised water. The reaction mixture was incubated at 37°C for 2 hours. Following 
digestion, the enzymes were heat inactivated by incubating the reaction mixtures at 
65°C for 20 minutes. The products were analysed on Agarose gels if required. 
  
7.3.5  Ligation 
The digested PCR products were ligated into the linearised vectors using T4 DNA 
ligase. For this purpose, the vector and the amplicon were mixed in a molar ratio of 1:3 
with 2 µL of 10X Ligation buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 
mM DTT), 2000 units of T4 DNA ligase and volume was adjusted to 20 µL with 
deionised water. The mixture was incubated at 16°C for 30-60 minutes. 
 
7.3.6 Preparation of competent E. coli cells  
The plasmid construct pVWEx2_uppS was propagated in TOP10 E. coli cells. The 
plasmid constructs for two-hybrid system were propagated in E. coli XL-1 blue cells. 
For analysis of fusion proteins, the plasmids were tested in Cya
-
 BTH101 cells. A 
single colony of relevant strains was used to inoculate 5 mL of LB broth and incubated 
at 37°C, 200 rpm for overnight. The cultures were supplemented with a suitable 
antibiotic marker if required. The overnight cultures were then used to inoculate 250 
mL LB in 1 L erlenmeyer flask and incubated at 37°C, 200 rpm until 0.4-0.6 OD600. 
The cells were harvested by centrifugation (3129 x g, 10 minutes, 4°C) and 
resuspended in 1/4
th
 volume of ice-cold TFB1 buffer (30 mM potassium acetate, 100 
mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 15% glycerol, filter sterilised, stored at 




centrifugation (3129 x g, 10 minutes, 4°C). The supernatant was discarded and the 
pellet was resuspended in 1/25
th
 volume of ice-cold TFB2 (10 mM MOPS pH 6.5, 10 
mM RbCl2, 75 mM CaCl2, 15% glycerol, filter sterilised, stored at 4°C). The 
suspension was incubated on ice for 1 hour. Aliquots of 200 µL were prepared, flash 
frozen and stored at -80°C for several days.  
 
7.3.7 Transformation of chemically competent E. coli cells 
Prepared competent cells of required E. coli strain were thawed on ice and mixed with 
2 µL of the ligation mix. The mixture was further incubated on ice for 15 minutes. For 
heat shock, the cold mixture was incubated at 42°C for 45-60 seconds and immediately 
transferred to ice and incubated on ice for further 10 minutes. The transformation 
mixture was added to 1 mL LB broth and transferred to 37°C, 200 rpm for 45 minutes. 
This allows plasmid to settle and propagate in the freshly transformed cells. The 
required transfomants were obtained by plating 75 µL of the culture on suitable 
selection plates.  
 
7.3.8 Preparation of electrocompetent C. glutamicum cells 
Fresh C. glutamicum colonies were streaked out on BHI agar plates and incubated at 
30°C overnight. A pre-culture was set up by inoculating a single colony from BHI 
plates in 50 mL BHIS in 500 mL Erlenmeyer flask and incubated overnight at 30°C, 
200 rpm. On day 2, 2 mL of pre-culture was used to inoculate 100 mL BHIS medium 
in 500 mL Erlenmeyer flask and transferred to 30°C, 200 rpm until OD600 was 1.75 
(approximately 2-4 hours). The cells were harvested by centrifugation at 3129 x g, 20 
minutes, 4°C. The supernatant was discarded and pellet was resuspended in 2 mL ice 




deionised water; filter sterilised and stored at 4°C. The cell suspension was transferred 
into a 50 mL Falcon tube and centrifuged as before. This step was repeated and cells 
were maintained on ice throughout. After a wash with TG buffer, the pellet was 
resuspended in 2 mL of 10% glycerol (60 mL 87% glycerol in 500 mL deionised 
water, filter sterilised, stored at 4°C) and centrifuged as before. The pellet thus 
obtained was resuspended in 1 mL of 10% glycerol and dispensed into 150 µL 
aliquots, flash frozen and stored at -80°C until further use.  
 
7.3.9 Electroporation of plasmids into C. glutamicum cells 
The pVWEx2_UppS plasmid construct was electroporated into C. glutamicum to 
generate C. glutamicum pVWEx2_UppS strain. For this purpose, an aliquot of 
prepared electrocompetent cells was thawed on ice and mixed with 2 µL of plasmid 
DNA (max. conc. 10 µg). The mixture was transferred into a 2 mm electroporation 
cuvette and carefully layered with 0.8 mL ice cold 10% glycerol. The cuvette was 
placed in the electroporator and electroporated at 25 μF, 200 Ω, 2,500 V and 
immediately transferred into 4 mL pre-warmed BHIS broth and incubated at 46°C for 6 
minutes. The cells were now allowed to regenerate at 30°C, 200 rpm for 1 hour. The 
culture was harvested, resuspended in 75 µL BHIS and plated on BHIS plates with 5 
µg/mL tetracycline. The plates were incubated at 30°C for 2 days. 
 
7.4 Biochemical techniques  
 
7.4.1 Thin layer chromatography 
The samples for TLC analysis are applied onto the silica plates and developed in 




specific solvent systems as described below.  System A, B, C and D are used for 
separation of non-polar lipids. System D and E are utilised in separation of polar lipids. 
The TLCs are thoroughly dried after each run. 
 
Table 7.3: Solvent systems for 1D and 2D TLC analysis of lipid extracts 
System Direction Solvent Proportions 
No. of 
runs 
A 1 petroleum ether 60-80°C/ethyl acetate 98:2 (v/v) 3 
A 2 petroleum ether 60-80°C/acetone 92:8 (v/v) 1 
B 1 petroleum ether 60-80°C/acetone 92:8 (v/v) 3 
B 2 toluene/acetone 95:5 (v/v) 1 
C 1 chloroform/methanol 96:4 (v/v) 1 
C 2 toluene/acetone 80:20 (v/v) 1 

















7.4.2 Non polar and polar lipid extraction 
Non-polar and polar lipid extracts were prepared from C. glutamicum cells and 
analysed by 2D TLC. For this purpose, cells from required cultures were harvested by 
centrifugation (3129 x g, 10 minutes) and resuspended in 2 mL of methanol/0.3% NaCl 
(100:10, v/v) and 2 mL of petroleum ether (60-80°C) and mixed on a rotator for 30 
minutes. Addition of petroleum ether results in partitioning of the extracts into an 
upper organic and a lower aqueous phase. The mixture was centrifuged (3129 x g, 3 
minutes) and the upper layer of petroleum ether was transferred into a separate tube. 
The lower layer with the cell debris was again treated with 2 mL of petroleum ether 




before and the upper layer was combined with the previously collected supernatant. 
The petroleum ether extracts thus obtained contained non-polar lipids, which were 
dried under nitrogen and analysed on TLC using appropriate systems.  
 
The lower aqueous layer was then treated with 2.3 mL of chloroform/methanol/0.3 % 
NaCl (90:100:30, v/v/v) and the suspension was mixed on a rotator for 1 hour. The 
mixture was centrifuged as before and the supernatant was transferred into a fresh tube. 
The pellet was further treated with 0.75 mL of chloroform/methanol/0·3% NaCl 
(50:100:40, v/v/v) and mixed on a rotator for 30 minutes. The suspension was then 
centrifuged as before and the supernatant was pooled with the previously collected 
fraction. This step was repeated. The pellets were retained for further analysis and the 
combined supernatant fractions were processed with 1.3 mL of chloroform and 1.3 mL 
of 0.3 % NaCl. The suspension was mixed on a rotator for 10 minutes and centrifuged 
as before. The lower phase containing the polar lipids was recovered and dried under 
nitrogen. The extracts were analysed using appropriate TLC systems. 
 
 Thin layer chromatography (TLC) analysis for lipids for cold samples, 50-100 µg of 
extracts were loaded onto the TLC for analysis. In case of radiolabelled extacts, 
10,000-50,000 cpm of each sample was used for lipid analysis using chromatography. 
The cold samples were stained with phosphomolybdic acid (MPA, 5% in ethanol) for 
lipids or Molisch reagent (6 g α-napthol in 25 mL H2SO4 and 450 mL ethanol) for 
carbohydrates and charred using a heat gun to reveal lipids on the TLC plates. To 
analyse phospholipids, Dittmer and Lester reagent was prepared by mixing solution A 
(40 g molybdenum VI oxide dissolved in 1 L of boiling sulfuric acid), solution B (1.7 g 




used to stain the TLC plates. The stained plates were left at room temperature and the 
presence of blue spots on TLC corresponding to phospholipids was noted. 
Autoradiography was performed for radiolabelled lipid extracts.  
 
7.4.3 Preparation of mAGP from C. glutamicum  
The required cultures of C. glutamicum were cultivated as per the experimental 
conditions and cells were harvested by centrifugation at 3129 x g, 10 minutes. The 
pellet was extracted thrice with 50% ethanol at 85°C for 6 hours (in oil bath) to remove 
lipoarabinomannan. Following the hot ethanol extraction, cell pellets were resuspended 
in phosphate buffered saline with 20% Triton X-100 (pH 7.2) and treated with 
Proteinase K at 55°C for 3-4 hours. The debris were centrifuged at 3129 x g for 10 
minutes and the pellet was resuspended in 2% SDS solution (prepared in PBS). The 
samples were incubated at 95°C for 1 hour to remove any residual proteins. This 
extraction step was repeated twice. De-proteinated pellet was washed with water to 
remove any residues. The pellet was further washed with 90% acetone (v/v, prepared in 
water) and dehydrated completely by washing with 100% acetone. The pellet was dried 
under a stream of nitrogen to yield a highly purified mAGP preparation 
 
7.4.4 Acid hydrolysis of mAGP for carbohydrate analysis 
The mAGP preparations were hydrolysed using 400 μl of 2 M trifluoroacetic acid 
(TFA) at 120°C for 3 hours. The acid was completely removed by drying the 
preparation under a stream of nitrogen. The carbohydrate residues were resuspended in 
2 mL water. The suspension was partitioned into an aqueous and an organic phase by 
addition of 2 mL chloroform and mixed on the rotator for 10 minutes. The mixture was 




under a stream of nitrogen. The samples were loaded on HP-Cellulose TLC (Merck) 
and developed thrice in pyridine/ethyl acetate/glacial acetic acid/water (5:5:1:3 
v/v/v/v). The radiolabelled extracts were visualised by autoradiography and the cold 
samples were analysed using α-naphthol staining as described in section 4.2. 
 
7.4.5 Preparation of cell wall lipoglycans from C. glutamicum 
The cell cultures were grown as per the experimental conditions and analysed for their 
lipoglycans using hot ethanol extraction method. For this purpose, the cells were 
harvested from cultures by centrifugation (3129 x g, 10 minutes) and pellet was 
washed with 2 mL phosphate buffered saline. The washed pellet was resuspended in 2 
mL 50% ethanol (prepared in water) and the mixture was refluxed at 85°C in hot-oil 
bath for 5-6 hours. Following the hot-ethanol treatment, the mixture was centrifuged as 
before and the supernatant was collected in a fresh tube. The remaining pellet was 
further extracted 3-4 times using the same procedure. The pooled supernatant was dried 
under a stream of nitrogen and the resulting pellet containg proteins, lipoglycans, 
neutral glycans was resuspended in 1.5 mL water by brief sonication. The suspension 
was treated with 95% phenol (w/v prepared in PBS) at 65°C for 1 hour. The mixture 
was cooled to room temperature and tubes were centrifuged at 3129 x g for 1 hour to 
obtain a clear bi-phase. The upper aqueous layer was recovered and transferred to a 1.5 
inch low molecular weight cut off dialysis tubing, (Spectra/Por membrane 6, MWCO 
3,500 kDA, Spectrum Labs) and dialysed overnight against water. The dialysed sample 
was recovered and dried under a stream of nitrogen. The extracts were resuspended in 
required volume of water and analysed using SDS-PAGE and visualised with ProQ 





7.4.6 Preparation of enzymatically active membranes and cell envelope 
The required strains of C. glutamicum and M. smegmatis were grown to 1 L and the 
cells were harvested  by centrifugation (4˚C, 7000 x g, 10 minutes). The pellet was 
washed twice with phosphate buffered saline (4˚C, 7000 x g, 10 minutes) and 
resuspended in 35 mL BufferA (50 mM MOPS pH 7.9, 5 mM β-mercaptoethanol, 5 
mM MgCl2) and sonicated (60s on, 90s off, 10 cycles) on ice. The cell debris was 
pelleted (30,000 x g, 20 minutes, 4˚C) and the supernatant was used for membrane 
preparations. The pellet was resuspended in 24 mL BufferA and equally divided into 
two 40 mL centrifuge tubes. To each tube, 18 mL of cold Percoll solution was added 
and centrifuged (30,000 x g, 60 minutes, 4˚C). The particulate upper diffused band, 
containing both cell wall and cell membranes was collected and washed thrice in 
Buffer A. The pellet was resuspended in 1mL Buffer A and protein concentration was 
determined using BCA method (Pierce BCA Protein Assay Kit, Thermo Scientific) as 
per manufracturer’s instructions. The supernatant collected previously was subjected to 
ultracentrifugation (100,000 x g, 90 minutes, 4˚C) and the pellet (containing the 
enzymatically active membranes) was resuspended in 400 µL BufferA. The protein 
concentration was determined using the BCA method (BCA Protein Assay Kit, 
Thermo Scientific) as per manufracturer’s instructions.  
 
7.4.7 Synthesis of pRPP 
To characterise the effect of BTZ043 on C. glutamicum, the substrates pRPP and DPR 
were exogenously prepared and supplemented in the final assay. The recombinant Mt-
PrsA was expressed in Escherichia coli C41 cells and the subsequently purified by 
IMAC at a concentration of 2 mg/mL. To synthesise pRPP in vitro, [
14
C]-U-D-glucose 




KH2PO4, 5 mM MgCl2) and the first three enzymic reactions of the pentose phosphate 
pathway were performed using commercially available enzymes (Roche and Sigma). 
To the radiolabelled glucose, 20 µL ATP (100 mM) and 50µL Hexokinse/Glucose-6-
Phosphate Dehydrogenase mix (3 mg/mL) were added and the reaction was incubated 
at 37˚C for 20 minutes. To the mix, 10 µL ATP and 20 µL NADP (100 mM) were 
added and mixture was incubated at 37˚C for 10 minutes followed by addition of 50 µL 
6-phosphogluconic dehydrogenase and incubation at 37˚C for 20 minutes. In the third 
step, 50 µL phosphoriboisomerase was added to the mix along with 20 µL NADP and 
incubated at 37˚C for 15 minutes. This resulted in purified [
14
C]-U-α-D-Ribose-5-
Phosphate as a substrate for p[
14
C]Rpp synthetase, Mt-PrsA. In the last step, 0.2 mL 
purified Mt-PrsA was added twice in a step wise manner along with 20 µL ATP and 
each reaction was incubated at 37˚C for 30 minutes. The mixture was then transferred 
to protein concentrator to remove the enzymes. The flow-through was loaded on LC-
SAX ion exchange columns and washed twice with water. The pure p[
14
C]Rpp was 
eluted using a step gradient of sodium acetate (100 mM-2 M) and radioactivity was 
determined using the scintialltion counter for all the fractions. The fractions with 
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